



(72) LEVINE, ARNOLD J., US
(72) PENNICA, DIANE, US
(71) GENENTECH, INC., US
(51) Int.Cl.⁶ C12N 15/12, C12N 15/62, C07K 14/47, C07K 16/18
(30) 1997/10/29 (60/063,704) US
(30) 1998/02/04 (60/073,612) US
(54) **GENES INDUCTIBLES WNT-1**
(54) **WNT-1 INDUCIBLE GENES**

mouse.cl.65 1 **MA PQGRPALPARCEPPA APPVPPRRERGGGARGPGVS GGRGRAGGAEG**
human.cl.65 1 **MP PQGRDPAFPDRCE - - APPVPPRRERGGGARGPGEP GGRGRAGGAEG**

mouse.cl.65 51 **RGVKCVLVGDGAVGKTSLVVSYTTNGYPT EYIPTAFDNFSAYVSVGGRPV**
human.cl.65 49 **RGVKCVLVGDGAVGKTSLVVSYTTNGYPT EYIPTAFDNFSAYVSVGGRPV**

mouse.cl.65 101 **RLQLCDTAGQDEFDKLRPLCYTNTDIFLLCF SVVSP T SFQNVG EKWP E I**
human.cl.65 98 **RLQLCDTAGQDEFDKLRPLCYTNTDIFLLCF SVVSP S SFQNVG EKWP E I**

mouse.cl.65 151 **RRHCPKAPIILVGTQSDLR EDVKVLI ELDKCKEKPVP EEA AKLCAEEV KA**
human.cl.65 148 **RCHCPKAPIILVGTQSDLR EDVKVLI ELDKCKEKPVP EEA AKLCAEEI KA**

mouse.cl.65 201 **VSYIECSALTQKNLKEVFDA AIVAGION S DS QL QPKKSKSRTPOKVRDLS**
human.cl.65 198 **AS YIECSALTQKNLKEVFDA AIVAGIQY S DT Q QPKKSKSRTPOKMKNLS**

mouse.cl.65 251 **KSWWRKYCCLA**
human.cl.65 248 **KSWWKKYCGFY**

(57) La présente invention concerne de l'ADN dont les gènes sont induits au moins par le Wnt-1. L'invention concerne également des molécules d'acide nucléique codant ces polypeptides, ainsi que des vecteurs et des cellules hôtes comprenant ces séquences d'acide nucléique. L'invention concerne en outre des molécules de polypeptides chimériques comprenant ces polypeptides fusionnés à des séquences de polypeptides hétérologues, des anticorps qui se lient à ces polypeptides, et des procédés de production de ces polypeptides.

(57) DNAs are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides, and methods for producing the polypeptides.



PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, C07K 14/47, C12N 15/62, C07K 16/18	A2	(11) International Publication Number: WO 99/21999 (43) International Publication Date: 6 May 1999 (06.05.99)
---	-----------	---

(21) International Application Number: PCT/US98/22992 (22) International Filing Date: 29 October 1998 (29.10.98) (30) Priority Data: 60/063,704 29 October 1997 (29.10.97) US 60/073,612 4 February 1998 (04.02.98) US (71) Applicant: GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US). (72) Inventors: LEVINE, Arnold, J.; 138 FitzRandolph Road, Princeton, NJ 08540 (US). PENNICA, Diane; 2417 Hale Drive, Burlingame, CA 94010 (US). (74) Agents: HASAK, Janet, E. et al.; Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080-4990 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
--	--

(54) Title: POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME

mouse.cl.65 human.cl.65	1 1	MAPQGRPALPARCEPPAAPPVPPRRERGGRGARGPGVSGGRRAGGAEG MPQGRDPAFDRCE...APPVPPRRERGGRGARGPGEPGGRRAGGAEG
mouse.cl.65 human.cl.65	51 49	RGVKCVLVGGGAVGKTSLVVSYTTNGYPT EYIPTAFDNFSAVVSVDGRPV RGVKCVLVGGGAVGKTSLVVSYTTNGYPT EYIPTAFDNFSAVVSVDGRPV
mouse.cl.65 human.cl.65	101 98	RLQLCDTAGQDEFDKLRPLCYTNTDIFLLCF8VVSPT8FQNV8EKWVPEI RLQLCDTAGQDEFDKLRPLCYTNTDIFLLCF8VVSPT8FQNV8EKWVPEI
mouse.cl.65 human.cl.65	151 148	RHCPKAPIILVGTQSDLRDVKVLIELDKCKEKPVP EEA AKLCAEEVKA RHCPKAPIILVGTQSDLRDVKVLIELDKCKEKPVP EEA AKLCAEEIKA
mouse.cl.65 human.cl.65	201 198	VSYIECSALTQKNLKEVFDA AIVAGIQHSDSOLQPKKSKSRTPDKVRDL8 ASYIECSALTQKNLKEVFDA AIVAGIQYSDTQQPKKSKSRTPDKMKNL8
mouse.cl.65 human.cl.65	251 248	KSWWRKYCCLA KSWWKKYCCFV

(57) Abstract

DNAs are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides, and methods for producing the polypeptides.

WO 99/21999

PCT/US98/22992

POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME

This invention was made with government support under grant no. 5PO1 CA41086, awarded by the National Institutes of Health, National Cancer Institute. The government has certain rights in the invention.

FIELD OF THE INVENTION

5 The present invention relates generally to the identification and isolation of novel DNA and to the recombinant production of novel polypeptides useful in the management of malignancies.

BACKGROUND OF THE INVENTION

Wnts are encoded by a large gene family whose members have been found in round worms, insects, cartilaginous fish, and vertebrates. Holland *et al.*, Dev. Suppl., 125-133 (1994). Wnts are thought to function in a variety of developmental and physiological processes since many diverse species have multiple conserved *Wnt* genes. McMahon, Trends Genet., 8: 236-242 (1992); Nusse and Varmus, Cell, 69: 1073-1087 (1992). *Wnt* genes encode secreted glycoproteins that are thought to function as paracrine or autocrine signals active in several primitive cell types. McMahon, *supra*; Nusse and Varmus, *supra*. The *Wnt* growth factor family includes more than ten genes identified in the mouse (*Wnt*-1, -2, -3A, -3B, -4, -5A, -5B, -6, -7A, -7B, -8A, -8B, -10B, -11, -12, and -13) (see, *e.g.*, Gavin *et al.*, Genes Dev., 4: 2319-2332 (1990); Lee *et al.*, Proc. Natl. Acad. Sci. USA, 92: 2268-2272 (1995); Christiansen *et al.*, Mech. Dev., 51: 341-350 (1995)) and at least nine genes identified in the human (*Wnt*-1, -2, -3, -5A, -7A, -7B, -8B, -10B, and -11) by cDNA cloning. See, *e.g.*, Vant Veer *et al.*, Mol. Cell. Biol., 4: 2532-2534 (1984).

The *Wnt-1* proto-oncogene (*int-1*) was originally identified from mammary tumors induced by mouse mammary tumor virus (MMTV) due to an insertion of viral DNA sequence. Nusse and Varmus, Cell, 31: 99-109 (1982). In adult mice, the expression level of *Wnt-1* mRNA is detected only in the testis during later stages of sperm development. *Wnt-1* protein is about 42 KDa and contains an amino-terminal hydrophobic region, which may function as a signal sequence for secretion. Nusse and Varmus, *supra*, 1992. The expression of *Wnt-2/irp* is detected in mouse fetal and adult tissues and its distribution does not overlap with the expression pattern for *Wnt-1*. *Wnt-3* is associated with mouse mammary tumorigenesis. The expression of *Wnt-3* in mouse embryos is detected in the neural tubes and in the limb buds. *Wnt-5a* transcripts are detected in the developing fore- and hind limbs at 9.5 through 14.5 days and highest levels are concentrated in apical ectoderm at the distal tip of limbs. Nusse and Varmus, *supra* (1992). Recently, a *Wnt* growth factor, termed *Wnt-x*, was described (WO95/17416) along with the detection of *Wnt-x* expression in bone tissues and in bone-derived cells. Also described was the role of *Wnt-x* in the maintenance of mature osteoblasts and the use of the *Wnt-x* growth factor as a therapeutic agent or in the development of other therapeutic agents to treat bone-related diseases.

Wnts may play a role in local cell signaling. Biochemical studies have shown that much of the secreted *Wnt* protein can be found associated with the cell surface or extracellular matrix rather than freely diffusible in the medium. Papkoff and Schryver, Mol. Cell. Biol., 10: 2723-2730 (1990); Bradley and Brown, EMBO J., 9: 1569-1575 (1990).

Studies of mutations in *Wnt* genes have indicated a role for *Wnts* in growth control and tissue patterning. In *Drosophila*, *wingless* (*wg*) encodes a *Wnt*-related gene (Rijsewicz *et al.*, Cell, 50: 649-657 (1987)) and *wg* mutations alter the pattern of embryonic ectoderm, neurogenesis, and imaginal disc outgrowth. Morata and Lawrence, Dev. Biol., 56: 227-240 (1977); Baker, Dev. Biol., 125: 96-108 (1988); Klingensmith and Nusse, Dev.

WO 99/21999

PCT/US98/22992

Biol., **166**: 396-414 (1994). In *Caenorhabditis elegans*, *lin-44* encodes a Wnt homolog which is required for asymmetric cell divisions. Herman and Horvitz, *Development*, **120**: 1035-1047 (1994). Knock-out mutations in mice have shown Wnts to be essential for brain development (McMahon and Bradley, *Cell*, **62**: 1073-1085 (1990); Thomas and Cappechi, *Nature*, **346**: 847-850 (1990)), and the outgrowth of embryonic primordia for kidney (Stark *et al.*, *Nature*, **372**: 679-683 (1994)), tail bud (Takada *et al.*, *Genes Dev.*, **8**: 174-189 (1994)), and limb bud. Parr and McMahon, *Nature*, **374**: 350-353 (1995). Overexpression of *Wnts* in the mammary gland can result in mammary hyperplasia (McMahon, *supra* (1992); Nusse and Varmus, *supra* (1992)), and precocious alveolar development. Bradbury *et al.*, *Dev. Biol.*, **170**: 553-563 (1995).

Wnt-5a and *Wnt-5b* are expressed in the posterior and lateral mesoderm and the extraembryonic mesoderm of the day 7-8 murine embryo. Gavin *et al.*, *supra*. These embryonic domains contribute to the AGM region and yolk sac tissues from which multipotent hematopoietic precursors and HSCs are derived. Dzierzak and Medvinsky, *Trends Genet.*, **11**: 359-366 (1995); Zon *et al.*, in Gluckman and Coulombel, ed., Colloque, *INSERM*, **235**: 17-22 (1995), presented at the Joint International Workshop on Foetal and Neonatal Hematopoiesis and Mechanism of Bone Marrow Failure, Paris France, April 3-6, 1995; Kanatsu and Nishikawa, *Development*, **122**: 823-830 (1996). *Wnt-5a*, *Wnt-10b*, and other *Wnts* have been detected in limb buds, indicating possible roles in the development and patterning of the early bone microenvironment as shown for *Wnt-7b*. Gavin *et al.*, *supra*; Christiansen *et al.*, *Mech. Devel.*, **51**: 341-350 (1995); Parr and McMahon, *supra*.

The Wnt/Wg signal transduction pathway plays an important role in the biological development of the organism and has been implicated in several human cancers. This pathway also includes the tumor suppressor gene, APC. Mutations in the APC gene are associated with the development of sporadic and inherited forms of human colorectal cancer. The Wnt/Wg signal leads to the accumulation of beta-catenin/Armadillo in the cell, resulting in the formation of a bipartite transcription complex consisting of beta-catenin and a member of the lymphoid enhancer binding factor/T cell factor (LEF/TCF)HMG box transcription factor family. This complex translocates to the nucleus where it can activate expression of genes downstream of the Wnt/Wg signal, such as the engrailed and Ultrabithorax genes in *Drosophila*. The downstream target genes of Wnt-1 signaling in vertebrates that presumably function in tumorigenesis, however, are currently unknown.

For a most recent review on Wnt, see Cadigan and Nusse, *Genes & Dev.*, **11**: 3286-3305 (1997).

Another family of proteins, the Rho and Rac subfamilies of Ras proteins, have been implicated in transformation by oncogenic ras. Thus far, activation of the pathways governed by three members of the Rho family of GTP-binding proteins, CDC42, Rac, and Rho, has been found to be necessary for Ras transformation. Activating Ras mutations occur in about 30% of all human tumors, indicating that elements of the CDC42, Rac, and Rho signaling pathways are drug targets for cancer therapy. These three members play a central role in the organization of the actin cytoskeleton and regulate transcription. Like Ras, the Rho proteins interact directly with protein kinases, which are likely to serve as downstream effector targets of the activated GTPase. The roles of the different Rho proteins in Ras transformation appear to be distinct: CDC42 specifically controls anchorage-independent growth, whereas Rac controls Rac-induced mitogenicity. The small G proteins Rac1, Rac2, and Rac3 are highly related GTPases. Didsbury *et al.*, *J. Biol. Chem.*, **264**: 16378-16382 (1989); Moll *et al.*, *Oncogene*, **6**: 863-866 (1991); Shirsat *et al.*, *Oncogene*, **5**: 769-772 (1990); Haataja *et al.*, *J. Biol. Chem.*, **272**: 20384-20388 (1997). *RAC3* is located at chromosome 17q23-25, a region frequently deleted in breast cancer. Cropp *et al.*, *Proc. Natl. Acad. Sci.*

WO 99/21999

PCT/US98/22992

USA, 87: 7737-7741 (1990); Cornelis *et al.*, *Oncogene*, 8: 781-785 (1993). Recent data have provided evidence that constitutive activity of the Rho-family GTPases is associated with cytoskeletal rearrangement and disorganized growth, motility, and invasiveness of cells, all hallmarks of neoplasia.

There is a need to elucidate the further members of the above families, including cell-surface molecules that may be tumor-specific antigens or proteins that serve a regulatory function in initiating the Wnt pathway of tumorigenesis. These would also include downstream components of the Wnt signaling pathway that are important to the transformed phenotype and the development of cancer. There is also a need to identify other proteins that, perhaps in conjunction with beta-catenin, regulate Wnt-1 downstream genes, as well as GTPases.

SUMMARY OF THE INVENTION

Several putative Wnt-1-induced genes have been identified at the mRNA level in a high-throughput cDNA subtraction experiment. Thus, applicants have identified novel cDNA clones (clone 65 and clone 320) that encode novel polypeptides that are Wnt induced, designated as clone 65 and clone 320, respectively. The clone 65 molecules have homology to the Rac and Rho subfamily noted above.

In one embodiment, this invention provides isolated nucleic acid comprising DNA having at least about 800 nucleotides and at least about a 70% sequence identity to (a) a DNA molecule encoding a human clone 65 polypeptide comprising the sequence of amino acids 1 to 258 of Figures 5A and 5B (SEQ ID NO:3), or (b) the complement of the DNA molecule of (a). Preferably, this nucleic acid has at least one clone 65 or 320 biological activity.

In another aspect, the invention provides isolated nucleic acid comprising DNA having at least about 700 nucleotides and at least about a 95% sequence identity to (a) a DNA molecule encoding a human clone 65 polypeptide comprising the sequence of amino acids 1 to 258 of Figures 5A and 5B (SEQ ID NO:3), or (b) the complement of the DNA molecule of (a). Preferably, this nucleic acid comprises DNA encoding a human clone 65 polypeptide having amino acid residues 1 to 258 of Figures 5A and 5B (SEQ ID NO:3), or the complement thereof.

In a still further aspect, the invention provides isolated nucleic acid comprising DNA having at least about 800 nucleotides and at least about a 70% sequence identity to (a) a DNA molecule encoding a mouse clone 65 polypeptide comprising the sequence of amino acids 1 to 261 of Figures 1A and 1B (SEQ ID NO:6), or (b) the complement of the DNA molecule of (a). Preferably, this nucleic acid comprises DNA having at least about a 85% sequence identity to (a) a DNA molecule encoding a mouse clone 65 polypeptide comprising the sequence of amino acids 1 to 261 of Figures 1A and 1B (SEQ ID NO:6), or (b) the complement of the DNA molecule of (a). Preferably, this nucleic acid comprises DNA encoding a mouse clone 65 polypeptide having amino acid residues 1 to 261 of Figures 1A and 1B (SEQ ID NO:6), or the complement thereof.

In a still further embodiment, the invention provides an isolated nucleic acid comprising DNA having at least about 800 nucleotides and at least about a 70% sequence identity to (a) a DNA molecule encoding the same full-length polypeptide encoded by the human clone 65 polypeptide cDNA in ATCC Deposit No. 209536 (pRK5E.h.WIG-3.65.4A), or (b) the complement of the DNA molecule of (a). Preferably, this nucleic acid comprises DNA having at least about a 95% sequence identity to (a) a DNA molecule encoding the same full-length polypeptide encoded by the human clone 65 polypeptide cDNA in ATCC Deposit No.209536 (pRK5E.h.WIG-3.65.4A), or (b) the complement of the DNA molecule of (a).

WO 99/21999

PCT/US98/22992

In another embodiment, the invention provides isolated nucleic acid comprising SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 18, or 19, and an isolated clone 65 polypeptide encoded by such a nucleic acid.

A still further aspect of the invention involves a process for producing a clone 65 polypeptide comprising culturing a host cell comprising clone 65-encoding nucleic acid under conditions suitable for expression of the clone
5 65 polypeptide and recovering the clone 65 polypeptide from the cell culture.

Further provided is an isolated clone 65 polypeptide encoded by the clone 65-encoding nucleic acid. Preferably, this polypeptide is human clone 65 or mouse clone 65.

In another embodiment, the invention provides an isolated nucleic acid having at least about 800 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding
10 a human clone 65 polypeptide comprising the sequence of amino acids 1 to 258 of Figures 5A and 5B (SEQ ID NO:3), or (b) the complement of the DNA molecule of (a), and, if the test DNA molecule has at least about a 70% sequence identity to (a) or (b), isolating the test DNA molecule.

Also provided is a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human clone 65 polypeptide comprising the sequence of amino acids 1 to 258
15 of Figures 5A and 5B (SEQ ID NO:3), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about a 70% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.

Also provided by the invention is isolated nucleic acid encoding mouse clone 320 comprising DNA having
20 at least about 500 nucleotides and having at least about a 97% sequence identity to (a) a DNA molecule comprising the sequence of nucleotides 1 to 2822 of Figure 2 (SEQ ID NO:7), or (b) the complement of the DNA molecule of (a). Further provided is isolated nucleic acid encoding mouse clone 320 comprising DNA having at least about 700 nucleotides and having at least about a 70% sequence identity, more preferably at least about an 80% sequence identity, more preferably still at least about a 90% sequence identity, and yet more preferably at least about a 95%
25 sequence identity, and more preferably at least about a 100% sequence identity, to (a) a DNA molecule comprising the sequence of nucleotides 1 to 727 of Figure 3 (SEQ ID NO:8), or (b) the complement of the DNA molecule of (a).

Also provided is isolated nucleic acid encoding mouse clone 320 comprising DNA having at least about 700 nucleotides and having at least 75% sequence identity to (a) a DNA molecule comprising the sequence of
30 nucleotides 1 - 2526 of Figures 4A and 4B (SEQ ID NO:9), or (b) the complement of the DNA molecule of (a). More preferably, this nucleic has at least about 90% sequence identity to (a) or (b).

Also provided by the invention is isolated nucleic acid encoding mouse clone 320 comprising DNA having at least about 500 nucleotides and having at least about a 97% sequence identity to (a) a DNA molecule comprising the sequence of nucleotides 1 to 2822 of Figure 2 (SEQ ID NO:7), or (b) the complement of the DNA molecule of
35 (a) and comprising DNA having at least about 700 nucleotides and having at least about a 70% sequence identity, more preferably at least about an 80% sequence identity, more preferably still at least about a 90% sequence identity, and yet more preferably at least about a 95% sequence identity, and more preferably at least about a 100% sequence identity, to (c) a DNA molecule comprising the sequence of nucleotides 1 to 727 of Figure 3 (SEQ ID NO:8), or (d) the complement of the DNA molecule of (c).

WO 99/21999

PCT/US98/22992

Further provided is isolated nucleic acid encoding mouse clone 320 comprising DNA having at least about 500 nucleotides and having at least about a 97% sequence identity to (a) a DNA molecule comprising the sequence of nucleotides 1 to 2822 of Figure 2 (SEQ ID NO:7), or (b) the complement of the DNA molecule of (a) and comprising DNA having at least about 700 nucleotides and having at least a 75% sequence identity to (c) a DNA molecule comprising the sequence of nucleotides 1 to 2526 of Figures 4A and 4B (SEQ ID NO: 9), or (d) the complement of the DNA molecule of (c).

Additionally provided is isolated nucleic acid encoding mouse clone 320 comprising DNA having at least about 700 nucleotides and having at least about a 70% sequence identity to (a) a DNA molecule comprising the sequence of nucleotides 1 to 727 of Figure 3 (SEQ ID NO:8), or (b) the complement of the DNA molecule of (a) and comprising DNA having at least about 700 nucleotides and having at least a 75% sequence identity to (c) a DNA molecule comprising the sequence of nucleotides 1 to 2526 of Figures 4A and 4B (SEQ ID NO: 9), or (d) the complement of the DNA molecule of (c).

Still further provided is isolated nucleic acid encoding mouse clone 320 comprising DNA having at least about 500 nucleotides and having at least about a 97% sequence identity to (a) a DNA molecule comprising the sequence of nucleotides 1 to 2822 of Figure 2 (SEQ ID NO:7), or (b) the complement of the DNA molecule of (a) and comprising DNA having at least about 700 nucleotides and having at least a 75% sequence identity to (c) a DNA molecule comprising the sequence of nucleotides 1 to 2526 of Figures 4A and 4B (SEQ ID NO: 9), or (d) the complement of the DNA molecule of (c) and comprising DNA having at least about 700 nucleotides and having at least about a 70% sequence identity to (e) a DNA molecule comprising the sequence of nucleotides 1-727 of Figure 3 (SEQ ID NO:8), or (f) the complement of the DNA molecule of (e).

Also provided by the invention is isolated nucleic acid encoding mouse clone 320 comprising DNA having at least about 500 nucleotides and having at least about a 95% sequence identity to (a) a DNA molecule encoding the same polypeptide encoded by the mouse clone 320 polypeptide cDNA in ATCC Deposit No. 209534 (pRK5E.m.WIG-4.320.9), or (b) the complement of the DNA molecule of (a). Preferably, the nucleic acid is about 3 kilobases in length.

More preferably, the nucleic acid comprises DNA that encodes the same polypeptide encoded by the mouse clone 320 polypeptide cDNA in ATCC Deposit No. 209534 (pRK5E.m.WIG-4.320.9).

In another aspect, the invention provides a polypeptide encoded by the clone 320 nucleic acid above.

Further provided is an isolated nucleic acid having at least about 500 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding the same polypeptide encoded by the mouse clone 320 polypeptide cDNA in ATCC Deposit No. 209534 (pRK5E.m.WIG-4.320.9), or (b) the complement of the DNA molecule of (a), and, if the test DNA molecule has at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.

In a still further embodiment, the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding the same polypeptide encoded by the mouse clone 320 polypeptide cDNA in ATCC Deposit No. 209534 (pRK5E.m.WIG-4.320.9), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about a 95% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.

WO 99/21999

PCT/US98/22992

Preferably the complements of the DNA molecules herein remain stably bound to the primary sequence under at least moderate, and optionally, under high stringency conditions.

Also provided are vectors comprising the above nucleic acids, host cells comprising the vector, preferably wherein the cell is a Chinese hamster ovary (CHO) cell, an *E. coli* cell, a baculovirus-infected cell, or a yeast cell.

5 Additionally provided are a chimeric molecule comprising one of the above polypeptides or an inactivated variant thereof, fused to a heterologous amino acid sequence, wherein the heterologous amino acid sequence may be, for example, an epitope tag sequence or an Fc region of an immunoglobulin. Also provided is an antibody which specifically binds to one of the above polypeptides, wherein the antibody can be a monoclonal antibody.

Further provided are a composition comprising one of the above polypeptides and a carrier therefor, and 10 a composition comprising an antagonist to one of the polypeptides and a carrier therefor. Preferably, these compositions may also comprise a chemotherapeutic agent or growth-inhibitory agent.

In another embodiment, the invention provides a method for treating a clone 65- or 320-related disorder in a mammal comprising administering to the mammal an effective amount of any of the above compositions. Preferably, the disorder is a malignant disorder or arteriosclerosis. More preferably, the malignant disorder is breast 15 cancer, ovarian cancer, colon cancer, or melanoma.

Also provided herein is a kit comprising one of the above clone 65 or 320 polypeptides or clone 65 or 320 antagonists, such as anti-clone 65 antibodies or anti-clone 320 antibodies, and instructions for using the antibody to detect a cancer induced by Wnt.

Also provided is a method for inducing cell death comprising exposing a cell which is induced by Wnt to 20 an effective amount of one of the above clone 65 or 320 polypeptides or clone 65 or 320 antagonists, such as anti-clone 65 or anti-clone 320 antibodies. Preferably, such cell is a cancer cell. More preferably, the cell is in a mammal, more preferably a human. Optionally, an effective amount of another chemotherapeutic antibody is also exposed to the cell, such as an anti-ErbB2 antibody. Further, optionally the method comprises exposing the cell to a chemotherapeutic agent, a growth-inhibitory agent, or radiation. Optionally, the cell is exposed to the growth- 25 inhibitory agent prior to exposure to the anti-clone 65 or anti-clone 320 antibody.

In a further aspect, the invention provides an article of manufacture, comprising:

a container;

a label on the container; and

a composition comprising an active agent contained within the container; wherein the composition is 30 effective for inducing cell death, the label on the container indicates that the composition can be used for treating conditions characterized by overinduction of Wnt, and the active agent in the composition is one of the polypeptides noted above, or an antagonist to one of the polypeptides such as an antibody.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B show the derived amino acid sequence of a native-sequence mouse clone 65 protein from 35 amino acids 1 to 261 (SEQ ID NO:6) and the nucleotide sequence (and complementary sequence) encoding the protein (SEQ ID NOS:4 and 5, respectively). This is from the mouse clone 65.11.3. A histidine sequence was fused to the heat-stable antigen. The heat-stable antigen sequence has been removed. There is 465 bp of 3' untranslated region and 86 bp of the coding region. The first 139 bp of the sequence has 89% GC content. This is the added region compared to other family members. A potential glycosylation site is at amino acid 88 through 91. A potential

WO 99/21999

PCT/US98/22992

protein kinase C phosphorylation site is at amino acids 210 through 212. Potential casein kinase II phosphorylation sites are at amino acids 84 through 87, 122 through 125, 164 through 167, and 202 through 205. Potential N-myristoylation sites are at amino acids 29 through 34, 37 through 42, 46 through 51, and 225 through 240. A potential prenyl group binding site is at amino acids 258 through 261. A potential ATP/GTP-binding site motif A (P-loop) is at amino acids 59 through 66.

Figure 2 shows a nucleotide sequence (SEQ ID NO:7) contained within the mouse clone 320 polypeptide cDNA in ATCC deposit no. 209534.

Figure 3 shows another nucleotide sequence (SEQ ID NO:8) contained within the mouse clone 320 polypeptide cDNA in ATCC deposit no. 209534.

Figures 4A and 4B show yet another nucleotide sequence (and the complement thereof) (SEQ ID NOS:9 and 10, respectively) contained within the mouse clone 320 polypeptide cDNA in ATCC deposit no. 209534.

Figures 5A and 5B show the derived amino acid sequence of a native-sequence human clone 65 protein from amino acids 1 to 258 (SEQ ID NO:3) and the consensus nucleotide sequence (and complementary sequence) encoding the protein (SEQ ID NOS:1 and 2, respectively), which is derived from three human clones from a human fetal liver library. There are 2955 bp of 3' untranslated region and 777 bp of coding region in the sequence. Potential N-glycosylation sites are from amino acids 85 through 88, amino acids 138 through 141, and amino acids 245 through 248. Potential protein kinase C phosphorylation sites are at amino acids 140 through 142 and 207 through 209. Potential casein kinase II phosphorylation sites are at amino acids 81 through 84, 119 through 122, 161 through 164, and 199 through 202. Potential N-myristoylation sites are at amino acids 26 through 31, 43 through 48, and 222 through 227. A potential ATP/GTP-binding site motif A (P-loop) is at amino acids 56 through 63.

Figure 6 shows an alignment of the full-length amino acid sequences of the human and mouse clone 65 (SEQ ID NOS:3 and 6, respectively).

Figure 7 shows a map of the vector pBabe puro (5.1 kb) used to transform cells for purposes of differential expression. The vector includes both unique restriction sites and multiple restriction sites. It is shown here in modified form for Wnt-1 cloning wherein the *HindIII* site after the SV40 promoter in the original pBabe puro vector has been removed and a *HindIII* site added to the multiple cloning site of the original pBabe puro vector. Wnt-1 is cloned from *EcoRI-HindIII* in the multiple cloning site. Constructs derived from this vector are selected in ampicillin (100 µg/ml) and the cells infected in culture are selected in 1.0-2.5 µg/ml puromycin.

Figure 8 shows the sequences of the PCR-Select® cDNA synthesis primer (SEQ ID NO:20), adaptors 1 and 2 (SEQ ID NOS:21 and 22, respectively) and complementary sequences for the adaptors (SEQ ID NOS:23 and 24, respectively), PCR primer 1 (SEQ ID NO:25), PCR primer 2 (SEQ ID NO:26), nested PCR primer 1 (SEQ ID NO:27), nested PCR primer 2 (SEQ ID NO:28), control primer G3PDH 5' primer (SEQ ID NO:29), and control primer G3PDH 3' primer (SEQ ID NO:30) used for suppression subtractive hybridization for identifying clones 65 and 320. When the adaptors are ligated to *RsaI*-digested cDNA, the *RsaI* site is restored.

Figure 9 shows the cloning site region of the plasmid pGEM-T used to clone all of the clone 65 and 320 sequences herein (SEQ ID NOS:31 and 32 for 5' and 3' sequences, respectively).

Figure 10 shows the sequence (SEQ ID NO:12) of a clone 65.11 obtained by screening with a probe derived from clone 65, which is the initial clone isolated in the process to obtain full-length mouse clone 65 DNA.

WO 99/21999

PCT/US98/22992

Figure 11 shows the sequence (SEQ ID NO:13) of a clone 65.9 obtained by screening with a probe derived from clone 65.

Figure 12 shows the sequence (SEQ ID NO:14) of a clone 65.11.1 obtained by screening with a probe derived from the CDC-42 homologous region of clone 65.11.

5 Figures 13A and 13B show the sequence (SEQ ID NO:15) of a clone 65.11.3 obtained by screening with a probe derived from the CDC-42 homologous region of clone 65.11.

Figure 14 shows the sequence (SEQ ID NO:16) of a clone 65.11.6 obtained by screening with a probe derived from the CDC-42 homologous region of clone 65.11.

10 Figure 15 shows the sequence (SEQ ID NO:17) of clone 65.1 obtained by screening with a probe derived from clone 65.

Figure 16 shows the sequence (SEQ ID NO:18) of clone 65.6 obtained by screening with a probe derived from clone 65.

Figure 17 shows the sequence (SEQ ID NO:19) of clone 65.13 obtained by screening with a probe derived from clone 65.

15 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

I. Definitions

The terms "clone 65 polypeptide", "clone 65 homologue" and grammatical variants thereof, as used herein, encompass native- sequence protein derived from clone 65 and variants thereof (which are further defined herein). The clone 65 polypeptide may be isolated from a variety of sources, such as from human tissue types or from another
20 source, or prepared by recombinant or synthetic methods, or by any combination of these and similar techniques.

The terms "clone 320 polypeptide", "clone 320 homologue", and grammatical variants thereof, as used herein, encompass native-sequence protein derived from clone 320 and variants thereof (which are further defined herein). The clone 320 polypeptide may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods, or by any combination of these and similar
25 techniques.

A "native-sequence clone 65 polypeptide" comprises a polypeptide having the same amino acid sequence as a clone 65 polypeptide derived from nature. Such native-sequence clone 65 polypeptides can be isolated from nature or can be produced by recombinant or synthetic means. The term "native-sequence clone 65 polypeptide" specifically encompasses naturally-occurring truncated or other forms of a clone 65 polypeptide disclosed herein,
30 naturally-occurring variant forms (*e.g.*, alternatively-spliced forms or splice variants), and naturally-occurring allelic variants of a clone 65 polypeptide. In one embodiment of the invention, the native-sequence clone 65 polypeptide is a full-length, native-sequence human clone 65 polypeptide comprising amino acids 1 to 258 of Figures 5A and 5B (SEQ ID NO:3), with or without the N-terminal methionine. In another embodiment of the invention, the native-sequence clone 65 polypeptide is a full-length native-sequence mouse clone 65 polypeptide comprising amino acids
35 1 to 261 of Figures 1A and 1B (SEQ ID NO:6), with or without the N-terminal methionine.

In another embodiment of the invention, the native-sequence clone 65 polypeptide is one which is encoded by a nucleotide sequence comprising one of the mouse clone 65 splice or other native-sequence variants, including SEQ ID NOS:11, 12, 13, 14, 15, 16, 17, 18, or 19, with or without an N-terminal methionine.

WO 99/21999

PCT/US98/22992

A "native-sequence clone 320 polypeptide" comprises a polypeptide having the same amino acid sequence as a clone 320 polypeptide derived from nature. Such native-sequence clone 320 polypeptides can be isolated from nature or can be produced by recombinant or synthetic means. The term "native-sequence clone 320 polypeptide" specifically encompasses naturally-occurring truncated or secreted forms of a clone 320 polypeptide disclosed herein, naturally-occurring variant forms (*e.g.*, alternatively spliced forms or splice variants), and naturally-occurring allelic variants of a clone 320 polypeptide. In one embodiment of the invention, the native-sequence clone 320 polypeptide is a mature or full-length, native-sequence mouse clone 320 polypeptide comprising the insert of about 3 kilobases from pRK5E.m.WIG-4.320.9 (deposited with the ATCC as accession no. 209534), with or without any signal sequence, and with or without an N-terminal methionine.

The term "clone 65 variant" means an active clone 65 polypeptide as defined below having at least about 80%, preferably at least about 85%, more preferably at least about 90%, most preferably at least about 95% amino acid sequence identity with human clone 65 having the deduced amino acid sequence shown in Figs. 5A and 5B (SEQ ID NO:3) and/or with mouse clone 65 having the deduced amino acid sequence shown in Figs. 1A and 1B (SEQ ID NO:6). Such variants include, for instance, clone 65 polypeptides wherein one or more amino acid residues are added to, or deleted from, the N- or C-terminus of the full-length sequences of Figures 5A-B and 1A-B (SEQ ID NOS:3 and 6, respectively), including variants from other species, but excludes a native-sequence clone 65 polypeptide.

The term "clone 320 variant" means an active clone 320 polypeptide as defined below having at least about 80%, preferably at least about 85%, more preferably at least about 90%, most preferably at least about 95% amino acid sequence identity with mouse clone 320 derived from the clone deposited with the ATCC under ATCC no. 209534. Such variants include, for instance, clone 320 polypeptides wherein one or more amino acid residues are added to, or deleted from, the N- or C-terminus of the sequence encoding mouse clone 320 contained within the about 3-kb insert of pRK5E.m.WIG-4.320.9 deposited with the ATCC under accession no. 209534, including variants from other species, but excludes a native-sequence clone 320 polypeptide.

"Percent (%) amino acid sequence identity" with respect to the clone 65 and 320 sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in a clone 65 or 320 polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.

"Percent (%) nucleic acid sequence identity" with respect to the coding region of the clone 65 and 320 sequences identified herein is defined as the percentage of nucleotides in a candidate sequence that are identical with the nucleotides in the coding region of the clone 65 or clone 320 sequence of interest, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, ALIGN, or Megalign (DNASTAR™).

WO 99/21999

PCT/US98/22992

software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.

"Stringent conditions" are those that (1) employ low ionic strength and high temperature for washing, for example, 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C; (2) employ during
 5 hybridization a denaturing agent, such as formamide, for example, 50% (vol/vol) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42°C; (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC and 0.1%
 10 SDS; or (4) employ a buffer of 10% dextran sulfate, 2 x SSC (sodium chloride/sodium citrate), and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C.

"Moderately stringent conditions" are described in Sambrook *et al.*, Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), and include the use of a washing solution and hybridization conditions (*e.g.*, temperature, ionic strength, and percent SDS) less stringent than described above.
 15 An example of moderately stringent conditions is a condition such as overnight incubation at 37°C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 mg/mL denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C. The skilled artisan will recognize how to adjust the temperature, ionic strength, *etc.*, as necessary to accommodate factors such as probe length and the like.

20 "Isolated," when used to describe the various polypeptides disclosed herein, means polypeptide that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In preferred embodiments, the polypeptide will be purified (1) to a degree sufficient to obtain at least 15 residues of
 25 N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stain. Isolated polypeptide includes polypeptide *in situ* within recombinant cells, since at least one component of the natural environment of clone 65 or 320 polypeptide will not be present. Ordinarily, however, isolated polypeptide will be prepared by at least one purification step.

30 An "isolated" nucleic acid encoding a clone 65 or 320 polypeptide is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the respective nucleic acid. An isolated clone 65-encoding or clone 320-encoding nucleic acid molecule is other than in the form or setting in which it is found in nature. An isolated clone 65-encoding or clone 320-encoding nucleic acid molecule therefore is distinguished from the clone 65-encoding or clone 320-
 35 encoding nucleic acid molecule as it exists in natural cells. However, an isolated clone 65-encoding or clone 320-encoding nucleic acid molecule includes a nucleic acid molecule contained in cells that ordinarily express clone 65-encoding and clone 320-encoding DNA, where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells.

WO 99/21999

PCT/US98/22992

The term "control sequences" refers to DNA sequences necessary for the expression of an operably-linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

5 Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that
10 the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

The term "antibody" is used in the broadest sense and specifically covers single anti-clone 65 or anti-clone
15 320 monoclonal antibodies (including agonist, antagonist, and neutralizing antibodies), and anti-clone 65 or anti-clone 320 antibodies, and antibody compositions with polypeptopic specificity. The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, *i.e.*, the individual antibodies comprising the population are identical except for possible naturally- occurring mutations that may be present in minor amounts.

20 "Active" or "activity" or "biological activity", for purposes herein, describes the activity of form(s) of a clone 65 or 320 polypeptide, including its variants, or its antagonists, which retain the biologic and/or immunologic activities of a native or naturally-occurring (native-sequence) clone 65 or 320 polypeptide or its antagonist. Preferred "activities" for a clone 65 or 320 polypeptide or its antagonist include the ability to inhibit proliferation of tumor cells or to stimulate proliferation of normal cells and to treat arteriosclerosis, including atherosclerosis, as well as to induce
25 wound repair and hematopoiesis, prevent desmoplasia, prevent fibrotic lesions associated with skin disorders such as scleroderma, keloid, eosinophilic fasciitis, nodular fasciitis, and Dupuytren's contracture, to treat bone-related diseases such as osteoporosis, to regulate anabolism including promotion of growth, to treat immune disorders, to treat Wilms' tumor and kidney-related disorders, to treat testis-related disorders, to treat lung-related disorders, and to treat cardiac disorders.

30 An "antagonist" of a clone 65 or 320 polypeptide is a molecule that inhibits an activity of a clone 65 or 320 polypeptide. Preferred antagonists are those which interfere with or block an undesirable biological activity of a clone 65 or 320 polypeptide, such as where a clone 65 or 320 polypeptide might act to stimulate cancer cells and the antagonist would serve to inhibit the growth of those cells. Such molecules include antibodies and small molecules that have such inhibitory capability, as well as polypeptide variants of, and receptors for, a clone 65 or 320
35 polypeptide (if available) or portions thereof that bind to clone 65 or 320 polypeptide. Thus, the receptor can be expression cloned from the family; then a soluble form of the receptor is made by identifying the extracellular domain and excising the transmembrane domain therefrom. The soluble form of the receptor can then be used as an antagonist, or the receptor can be used to screen for small molecules that would antagonize clone 65 or 320 polypeptide activity.

WO 99/21999

PCT/US98/22992

Alternatively, using the murine nucleotide sequences shown in Figures 1-4 (SEQ ID NOS:4, 7, 8, or 9, respectively), or the murine amino acid sequence shown in Figure 1 (SEQ ID NO:6) or the human nucleotide and amino acid sequences shown in Figures 5A-5B (SEQ ID NOS:1 and 3), variants of native clone 65 or clone 320 are made that act as antagonists.

5 Antagonist activity can be determined by several means, including standard assays for induction of cell death such as that described herein, *e.g.*, ³H-thymidine proliferation assays, or other mitogenic assays, such as an assay measuring the capability of the candidate antagonist of inducing EGF-potentiated anchorage independent growth of target cell lines (Volckaert *et al.*, Gene, 15:215-223 (1981)) and/or growth inhibition of neoplastic cell lines. Roberts *et al.*, Proc. Natl. Acad. Sci. USA, 82:119-123 (1985). Anchorage-independent growth refers to the
10 ability of clone 65 polypeptide-treated or clone 320 polypeptide-treated, or TGF- β -treated and EGF-treated non-neoplastic target cells to form colonies in soft agar, a characteristic ascribed to transformation of the cells. In this assay, the candidate is incubated together with an equimolar amount of a clone 65 or 320 polypeptide otherwise detectable in the EGF-potentiated anchorage-independent target cell growth assay, and the culture observed for failure to induce anchorage-independent growth.

15 "Treatment" refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those already with the disorder or condition as well as those in which the disorder or condition is to be prevented.

"Mammal" for purposes of treatment refers to any animal classified as a mammal, including humans, domestic, and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, sheep, pigs, cows, *etc.*
20 Preferably, the mammal is human.

A "clone 65-related or clone 320-related disorder" is any condition that would benefit from treatment with the clone 65 or 320 polypeptides or clone 65 or 320 antagonists herein. This includes chronic and acute disorders, as well as those pathological conditions which predispose the mammal to the disorder in question. Non-limiting examples of disorders to be treated herein include benign and malignant tumors; leukemias and lymphoid
25 malignancies; neuronal, glial, astrocytal, hypothalamic and other glandular, macrophagal, epithelial, stromal, and blastocoelic disorders; hematopoiesis-related disorders; tissue-growth disorders; skin disorders; desmoplasia, fibrotic lesions; kidney disorders; bone-related disorders; trauma such as burns, incisions, and other wounds; catabolic states; testicular-related disorders; and inflammatory, angiogenic, and immunologic disorders, including arteriosclerosis. A "Wnt-related disorder" is one caused at least by the upregulation of the Wnt gene pathway, including Wnt-1 and
30 Wnt-4, but preferably Wnt-1, and may include cancer.

The terms "cancer", "cancerous", and "malignant" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include but are not limited to, carcinoma including adenocarcinoma, lymphoma, blastoma, melanoma, sarcoma, and leukemia. More particular examples of such cancers include squamous cell cancer, small-cell lung cancer, non-small cell lung cancer,
35 gastrointestinal cancer, Hodgkin's and non-Hodgkin's lymphoma, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer such as hepatic carcinoma and hepatoma, bladder cancer, breast cancer, colon cancer, colorectal cancer, endometrial carcinoma, salivary gland carcinoma, kidney cancer such as renal cell carcinoma and Wilms' tumors, basal cell carcinoma, melanoma, prostate cancer, vulval cancer, thyroid cancer, testicular cancer,

WO 99/21999

PCT/US98/22992

esophageal cancer, and various types of head and neck cancer. The preferred cancers for treatment herein are breast, colon, lung, and melanoma.

The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells. The term is intended to include radioactive isotopes (*e.g.*, ^{131}I , ^{125}I , ^{90}Y , and ^{186}Re), chemotherapeutic agents, and toxins such as enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof.

A "chemotherapeutic agent" is a chemical compound useful in the treatment of cancer. Examples of chemotherapeutic agents include Adriamycin, Doxorubicin, 5-Fluorouracil, Cytosine arabinoside ("Ara-C"), Cyclophosphamide, Thiotepa, Busulfan, Cytosine, Taxol, Toxotere, Methotrexate, Cisplatin, Melphalan, Vinblastine, Bleomycin, Etoposide, Ifosfamide, Mitomycin C, Mitoxantrone, Vincristine, Vinorelbine, Carboplatin, Teniposide, Daunomycin, Carminomycin, Aminopterin, Dactinomycin, Mitomycins, Esperamicins (see U.S. Pat. No. 4,675,187), Melphalan, and other related nitrogen mustards. Also included in this definition are hormonal agents that act to regulate or inhibit hormone action on tumors, such as tamoxifen and onapristone.

A "growth-inhibitory agent" when used herein refers to a compound or composition which inhibits growth of a cell, such as an Wnt-overexpressing cancer cell, either *in vitro* or *in vivo*. Thus, the growth-inhibitory agent is one which significantly reduces the percentage of malignant cells in S phase. Examples of growth-inhibitory agents include agents that block cell cycle progression (at a place other than S phase), such as agents that induce G1 arrest and M-phase arrest. Classical M-phase blockers include the vincas (vincristine and vinblastine), taxol, and topo II inhibitors such as doxorubicin, daunorubicin, etoposide, and bleomycin. Those agents that arrest G1 also spill over into S-phase arrest, for example, DNA alkylating agents such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C. Further information can be found in The Molecular Basis of Cancer, Mendelsohn and Israel, eds., Chapter 1, entitled "Cell cycle regulation, oncogenes, and antineoplastic drugs" by Murakami *et al.* (WB Saunders: Philadelphia, 1995), especially p. 13. The 4D5 antibody (and functional equivalents thereof) can also be employed for this purpose if the cancer involves ErbB2-overexpressing cancer cells. See, *e.g.*, WO 92/22653.

"Northern analysis" or "Northern blot" is a method used to identify RNA sequences that hybridize to a known probe such as an oligonucleotide, DNA fragment, cDNA or fragment thereof, or RNA fragment. The probe is labeled with a radioisotope such as ^{32}P , or by biotinylation, or with an enzyme. The RNA to be analyzed is usually electrophoretically separated on an agarose or polyacrylamide gel, transferred to nitrocellulose, nylon, or other suitable membrane, and hybridized with the probe, using standard techniques well known in the art such as those described in sections 7.39-7.52 of Sambrook *et al.*, *supra*.

The technique of "polymerase chain reaction," or "PCR," as used herein generally refers to a procedure wherein minute amounts of a specific piece of nucleic acid, RNA and/or DNA, are amplified as described in U.S. Pat. No. 4,683,195 issued 28 July 1987. Generally, sequence information from the ends of the region of interest or beyond needs to be available, such that oligonucleotide primers can be designed; these primers will be identical or similar in sequence to opposite strands of the template to be amplified. The 5' terminal nucleotides of the two primers may coincide with the ends of the amplified material. PCR can be used to amplify specific RNA sequences, specific DNA sequences from total genomic DNA, and cDNA transcribed from total cellular RNA, bacteriophage, or plasmid sequences, *etc.* See generally Mullis *et al.*, Cold Spring Harbor Symp. Quant. Biol., 51: 263 (1987);

WO 99/21999

PCT/US98/22992

Erlich, ed., PCR Technology, (Stockton Press, NY, 1989). As used herein, PCR is considered to be one, but not the only, example of a nucleic acid polymerase reaction method for amplifying a nucleic acid test sample comprising the use of a known nucleic acid as a primer and a nucleic acid polymerase to amplify or generate a specific piece of nucleic acid.

5 II. Compositions and Methods of the Invention

A. Full-length Clone 65 or 320 Polypeptide

The present invention provides newly identified and isolated nucleotide sequences encoding a polypeptide referred to in the present application as a clone 65 or clone 320 polypeptide. In particular, cDNAs have been identified and isolated encoding novel murine and human clone 65 polypeptides as well as murine clone 320 as
10 disclosed in further detail in the Examples below.

Using BLAST and FastA sequence alignment computer programs, it was found that the coding sequences of mouse and human clone 65, as well as the three sequences for mouse clone 320 disclosed herein, show significant homology to DNA sequences disclosed in the GenBank database, including those published by Adams *et al.*, Nature,
15 377: 3-174 (1995).

Using BLAST and FastA sequence alignment computer programs, it was found that mouse and human clone 65 show significant homology to members of the Rho family of small GTPases (mouse and human clone 65 are 58-59% and 59% homologous, respectively, to human G25k gtp-binding protein, placental and brain isoforms, and 59% homologous to canine CDC42 GTP-binding protein). Accordingly, it is presently believed that the clone 65 polypeptides disclosed in the present application possess activity relating to the treatment of various cancers with
20 which Ras is associated, as well as to arteriosclerosis, such as atherosclerosis.

B. Clone 65 and 320 Polypeptide Variants

In addition to the full-length native-sequence clone 65 and 320 polypeptides described herein, it is contemplated that variants of these sequences can be prepared. Clone 65 and 320 variants can be prepared by introducing appropriate nucleotide changes into the clone 65-encoding and clone 320-encoding DNA, or by synthesis
25 of the desired variant clone 65 and 320 polypeptides. Those skilled in the art will appreciate that amino acid changes may alter post-translational processes of the clone 65 and 320 polypeptides, such as changing the number or position of glycosylation sites or altering the membrane-anchoring characteristics, if the native clone 65 or 320 polypeptide is membrane bound.

Variations in the native full-length clone 65 and 320 sequences, or in various domains of the clone 65 and
30 320 polypeptides described herein, can be made, for example, using any of the techniques and guidelines for conservative and non-conservative mutations set forth, for instance, in U.S. Patent No. 5,364,934. Variations may be a substitution, deletion, or insertion of one or more codons encoding the clone 65 and 320 polypeptide that results in a change in the amino acid sequence as compared with the native-sequence clone 65 and 320 polypeptide. Optionally the variation is by substitution of at least one amino acid with any other amino acid in any portion of the
35 clone 65 and 320 polypeptide. Guidance in determining which amino acid residue may be inserted, substituted, or deleted without adversely affecting the desired activity may be found by comparing the sequence of the clone 65 and 320 polypeptide with that of homologous known Rac or Rho protein molecules, in the case of clone 65, and minimizing the number of amino acid sequence changes made in regions of high homology. Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural and/or

WO 99/21999

PCT/US98/22992

chemical properties, such as the replacement of a leucine with a serine, i.e., conservative amino acid replacements. Insertions or deletions may optionally be in the range of 1 to about 5 amino acids. The variation allowed may be determined by systematically making insertions, deletions, or substitutions of amino acids in the sequence and testing the resulting variants for activity in *in vitro* assays for gene upregulation or downregulation and in transgenic or
 5 knock-out animals.

The variations can be made on the cloned DNA to produce variant DNA using methods known in the art such as oligonucleotide-mediated (site-directed) mutagenesis (Carter *et al.*, Nucl. Acids Res., 13:4331 (1986); Zoller *et al.*, Nucl. Acids Res., 10:6487 (1987)), cassette mutagenesis (Wells *et al.*, Gene, 34:315 (1985)), alanine scanning, PCR mutagenesis, restriction selection mutagenesis (Wells *et al.*, Philos. Trans. R. Soc. London SerA, 317:415
 10 (1986)), or other known techniques.

Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous sequence. Among the preferred scanning amino acids are relatively small, neutral amino acids. Such amino acids include alanine, glycine, serine, and cysteine. Alanine is typically a preferred scanning amino acid among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main-chain conformation
 15 of the variant. Alanine is also typically preferred because it is the most common amino acid. Further, it is frequently found in both buried and exposed positions. T.E. Creighton, Proteins: Structure and Molecular Properties (W.H. Freeman & Co., San Francisco, 1983); Chothia, J. Mol. Biol., 150:1 (1976). If alanine substitution does not yield adequate amounts of variant, an isoteric amino acid can be used.

Further deletional variants of the full-length clone 65 and 320 polypeptides include variants from which
 20 the N-terminal signal peptide, if any, and/or the initiating methionine has been deleted.

C. Modifications of the Clone 65 and 320 Polypeptides

Covalent modifications of the clone 65 and 320 polypeptides are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a clone 65 or 320 polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C- terminal
 25 residues. Derivatization with bifunctional agents is useful, for instance, for crosslinking a clone 65 or 320 polypeptide to a water-insoluble support matrix or surface for use in the method for purifying anti-clone 65 antibodies and anti-clone 320 antibodies, and vice-versa. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azido-salicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidyl-
 30 propionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane, and agents such as methyl-3-((p-azidophenyl)dithio)propioimide.

Other modifications include deamidation of glutamyl and asparagyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the α -amino groups of lysine, arginine, and histidine side chains
 35 (Creighton, *supra*, pp. 79-86), acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of the clone 65 or 320 polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in the native sequence (either by deleting the underlying glycosylation site or by removing the glycosylation moieties by chemical

WO 99/21999

PCT/US98/22992

and/or enzymatic means) and/or adding one or more glycosylation sites that are not present in the native sequence. In addition, the phrase includes qualitative changes in the glycosylation of the native proteins, involving a change in the nature and proportion of the various sugar residues present.

Addition of glycosylation sites to the clone 65 or 320 polypeptide herein may be accomplished by altering the amino acid sequence. The alteration may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues to the native sequence (for O-linked glycosylation sites). The amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the clone 65 or 320 polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids. The DNA mutation(s) may be made using methods described above.

Another means of increasing the number of carbohydrate moieties on the clone 65 or 320 polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, *e.g.*, in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981).

Removal of carbohydrate moieties present on the clone 65 or 320 polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, *et al.*, Arch. Biochem. Biophys., 259:52 (1987) and by Edge *et al.*, Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura *et al.*, Meth. Enzymol., 138:350 (1987).

Another type of covalent modification comprises linking the clone 65 or 320 polypeptide to one of a variety of nonproteinaceous polymers, *e.g.*, polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth, *e.g.*, in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

The clone 65 or 320 polypeptide of the present invention may also be modified in a way to form a chimeric molecule comprising a clone 65 or 320 polypeptide, or a fragment thereof, fused to a heterologous polypeptide or amino acid sequence. In one embodiment, such a chimeric molecule comprises a fusion of the clone 65 or 320 polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino- or carboxyl-terminus of a native or variant clone 65 or 320 molecule. The presence of such epitope-tagged forms can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the clone 65 or 320 polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In an alternative embodiment, the chimeric molecule may comprise a fusion of the clone 65 or 320 polypeptide, or fragments thereof, with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule, such a fusion could be to the Fc region of an Ig, such as an IgG molecule.

Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; the flu HA tag polypeptide and its antibody 12CA5 (Field *et al.*, Mol. Cell. Biol., 8:2159-2165 (1988)); the c-myc tag and the 8F9, 3C7, 6E10, G4, B7, and 9E10 antibodies thereto (Evan *et al.*, Molecular and Cellular Biology, 5:3610-3616 (1985)); and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody. Paborsky *et al.*, Protein Engineering, 3(6):547-553 (1990). Other tag polypeptides include the Flag-peptide (Hopp *et al.*, BioTechnology, 6:1204-1210 (1988)); the KT3 epitope peptide

WO 99/21999

PCT/US98/22992

(Martin *et al.*, Science, **255**:192-194 (1992)); an α -tubulin epitope peptide (Skinner *et al.*, J. Biol. Chem., **266**:15163-15166 (1991)); and the T7 gene 10 protein peptide tag. Lutz-Freyermuth *et al.*, Proc. Natl. Acad. Sci. USA, **87**:6393-6397 (1990).

D. Preparation of Clone 65 and 320 Polypeptides

5 The description below relates primarily to production of clone 65 and 320 polypeptides by culturing cells transformed or transfected with a vector containing at least DNA encoding the mature or full-length sequences of human or mouse clone 65 (SEQ ID NOS:3 or 6, respectively), or containing at least mouse clone 320 DNA (deposited at the ATCC as accession no. 209534 and comprising SEQ ID NOS:7, 8, and/or 9).

It is, of course, contemplated that alternative methods, which are well known in the art, may be employed
10 to prepare clone 65 and 320 polypeptides. For instance, the clone 65 or 320 polypeptide sequence, or portions thereof, may be produced by direct peptide synthesis using solid-phase techniques. See, e.g., Stewart *et al.*, Solid-Phase Peptide Synthesis (W.H. Freeman Co.: San Francisco, CA, 1969); Merrifield, J. Am. Chem. Soc., **85**:2149-2154 (1963). *In vitro* protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be accomplished, for instance, using an Applied Biosystems peptide synthesizer (Foster City, CA) in
15 accordance with manufacturer's instructions. Various portions of clone 65 and 320 polypeptides may be chemically synthesized separately and combined using chemical or enzymatic methods to produce a full-length clone 65 or 320 polypeptide.

1. Isolation of DNA Encoding Clone 65 and 320 Polypeptides

DNA encoding a clone 65 or 320 polypeptide may be obtained from a cDNA library prepared from tissue
20 believed to possess the mRNA for clone 65 or 320 polypeptide and to express it at a detectable level. Accordingly, DNA encoding human clone 65 or 320 polypeptide can be conveniently obtained from a cDNA library prepared from human tissue, such as a human fetal liver library or as otherwise described in the Examples. The genes encoding clone 65 and 320 polypeptides may also be obtained from a genomic library or by oligonucleotide synthesis.

A still alternative method of cloning clone 65 or 320 polypeptide is suppressive subtractive hybridization,
25 which is a method for generating differentially regulated or tissue-specific cDNA probes and libraries. This is described, for example, in Diatchenko *et al.*, Proc. Natl. Acad. Sci. USA, **93**: 6025-6030 (1996). The procedure is based primarily on a technique called suppression PCR and combines normalization and subtraction in a single procedure. The normalization step equalizes the abundance of cDNAs within the target population and the subtraction step excludes the common sequences between the target and driver populations.

30 Libraries can be screened with probes (such as antibodies to a clone 65 or 320 polypeptide or oligonucleotides of at least about 20-80 bases) designed to identify the gene of interest or the protein encoded by it. Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures, such as described in Sambrook *et al.*, *supra*. An alternative means to isolate the gene encoding clone 65 or 320 polypeptide is to use PCR methodology. Sambrook *et al.*, *supra*; Dieffenbach *et al.*, PCR Primer: A Laboratory
35 Manual (New York: Cold Spring Harbor Laboratory Press, 1995).

The Examples below describe techniques for screening a cDNA library. The oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized. The oligonucleotide is preferably labeled such that it can be detected upon hybridization to DNA in the library being screened. Methods of labeling are well known in the art, and include the use of radiolabels like ³²P-labeled ATP,

WO 99/21999

PCT/US98/22992

biotinylation, or enzyme labeling. Hybridization conditions, including moderate stringency and high stringency, are provided in Sambrook *et al.*, *supra*.

Sequences identified in such library screening methods can be compared and aligned to other known sequences deposited and available in public databases such as GenBank or other private sequence databases.

- 5 Sequence identity (at either the amino acid or nucleotide level) within defined regions of the molecule or across the full-length sequence can be determined through sequence alignment using computer software programs such as ALIGN, DNASTar, and INHERIT which employ various algorithms to measure homology.

- Nucleic acid having polypeptide-coding sequence may be obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequences disclosed herein for the first time, and, if necessary, using
10 conventional primer extension procedures as described in Sambrook *et al.*, *supra*, to detect precursors and processing intermediates of mRNA that may not have been reverse-transcribed into cDNA.

2. Selection and Transformation of Host Cells

- Host cells are transfected or transformed with expression or cloning vectors described herein for clone 65 or 320 polypeptide production and cultured in conventional nutrient media modified as appropriate for inducing
15 promoters, selecting transformants, or amplifying the genes encoding the desired sequences. The culture conditions, such as media, temperature, pH, and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in Mammalian Cell Biotechnology: a Practical Approach, M. Butler, ed. (IRL Press, 1991) and Sambrook *et al.*, *supra*.

- 20 Methods of transfection are known to the ordinarily skilled artisan, for example, CaPO_4 and electroporation. Depending on the host cell used, transformation is performed using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in Sambrook *et al.*, *supra*, or electroporation is generally used for prokaryotes or other cells that contain substantial cell-wall barriers. Infection with *Agrobacterium tumefaciens* is used for transformation of certain plant cells, as described by Shaw *et al.*, Gene, 23:315 (1983) and
25 WO 89/05859 published 29 June 1989. For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, Virology, 52:456-457 (1978) can be employed. General aspects of mammalian cell host system transformations have been described in U.S. Patent No. 4,399,216. Transformations into yeast are typically carried out according to the method of Van Solingen *et al.*, J. Bact., 130:946 (1977) and Hsiao *et al.*, Proc. Natl. Acad. Sci. (USA), 76:3829 (1979). However, other methods for introducing DNA into cells, such
30 as by nuclear microinjection, electroporation, bacterial protoplast fusion with intact cells, or polycations, *e.g.*, polybrene or polyornithine, may also be used. For various techniques for transforming mammalian cells, see Keown *et al.*, Methods in Enzymology, 185:527-537 (1990) and Mansour *et al.*, Nature, 336:348-352 (1988).

- Suitable host cells for cloning or expressing the DNA in the vectors herein include prokaryote, yeast, or higher eukaryote cells. Suitable prokaryotes include but are not limited to eubacteria, such as Gram-negative or
35 Gram-positive organisms, for example, *Enterobacteriaceae* such as *Escherichia*, *e.g.*, *E. coli*, *Enterobacter*, *Erwinia*, *Klebsiella*, *Proteus*, *Salmonella*, *e.g.*, *Salmonella typhimurium*, *Serratia*, *e.g.*, *Serratia marcescans*, and *Shigella*, as well as *Bacilli* such as *B. subtilis* and *B. licheniformis* (*e.g.*, *B. licheniformis* 41P disclosed in DD 266,710 published 12 April 1989), *Pseudomonas* such as *P. aeruginosa*, and *Streptomyces*. Various *E. coli* strains are publicly available, such as *E. coli* K12 strain MM294 (ATCC 31,446); *E. coli* X1776 (ATCC 31,537); *E. coli* strain W3110

WO 99/21999

PCT/US98/22992

(ATCC 27,325); and K5 772 (ATCC 53,635). These examples are illustrative rather than limiting. Strain W3110 is one particularly preferred host or parent host because it is a common host strain for recombinant DNA product fermentations. Preferably, the host cell secretes minimal amounts of proteolytic enzymes. For example, strain W3110 may be modified to effect a genetic mutation in the genes encoding proteins endogenous to the host, with
 5 examples of such hosts including *E. coli* W3110 strain 1A2, which has the complete genotype *tonA*; *E. coli* W3110 strain 9E4, which has the complete genotype *tonA ptr3*; *E. coli* W3110 strain 27C7 (ATCC 55,244), which has the complete genotype *tonA ptr3 phoA E15 (argF-lac)169 degP ompT kar^r*; *E. coli* W3110 strain 37D6, which has the complete genotype *tonA ptr3 phoA E15 (argF-lac)169 degP ompT rbs7 ilvG kar^r*; *E. coli* W3110 strain 40B4, which is strain 37D6 with a non-kanamycin resistant *degP* deletion mutation; and an *E. coli* strain having mutant
 10 periplasmic protease disclosed in U.S. Patent No. 4,946,783 issued 7 August 1990. Alternatively, *in vitro* methods of cloning, *e.g.*, PCR or other nucleic acid polymerase reactions, are suitable.

In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for vectors containing nucleic acid encoding clone 65 or 320 polypeptide. *Saccharomyces cerevisiae* is a commonly used lower eukaryotic host microorganism. However, a number of other genera, species,
 15 and strains are commonly available and useful herein, such as *Schizosaccharomyces pombe* (Beach and Nurse, Nature, 290: 140 (1981); EP 139,383 published 2 May 1985); *Kluyveromyces* hosts (U.S. Patent No. 4,943,529; Fleer *et al.*, Bio/Technology, 9: 968-975 (1991)) such as, *e.g.*, *K. lactis* (MW98-8C, CBS683, CBS4574; Louvencourt *et al.*, J. Bacteriol., 737 (1983)), *K. fragilis* (ATCC 12,424), *K. bulgaricus* (ATCC 16,045), *K. wickerhamii* (ATCC 24,178), *K. waltii* (ATCC 56,500), *K. drosophilum* (ATCC 36,906; Van den Berg *et al.*, Bio/Technology, 8: 135
 20 (1990)), *K. thermotolerans*, and *K. marxianus*; *yarrowia* (EP 402,226); *Pichia pastoris* (EP 183,070; Sreekrishna *et al.*, J. Basic Microbiol., 28: 265-278 (1988)); *Candida*; *Trichoderma reesia* (EP 244,234); *Neurospora crassa* (Case *et al.*, Proc. Natl. Acad. Sci. USA, 76: 5259-5263 (1979)); *Schwanniomyces* such as *Schwanniomyces occidentalis* (EP 394,538 published 31 October 1990); and filamentous fungi such as, *e.g.*, *Neurospora*, *Penicillium*, *Tolypocladium* (WO 91/00357 published 10 January 1991), and *Aspergillus* hosts such as *A. nidulans* (Ballance *et al.*, Biochem. Biophys. Res. Commun., 112: 284-289 (1983); Tilburn *et al.*, Gene, 26: 205-221 (1983); Yelton *et al.*, Proc. Natl. Acad. Sci. USA, 81: 1470-1474 (1984)) and *A. niger* Kelly and Hynes, EMBO J., 4: 475-479 (1985).
 Methylophilic yeasts are suitable herein and include, but are not limited to, yeast capable of growth on methanol selected from the genera consisting of *Hansenula*, *Candida*, *Kloeckera*, *Pichia*, *Saccharomyces*, *Torulopsis*, and *Rhodotorula*. A list of specific species that are exemplary of this class of yeasts may be found in C. Anthony, The
 30 Biochemistry of Methylophilic Yeasts, 269 (1982).

Suitable host cells for the expression of glycosylated clone 65 or 320 polypeptide are derived from multicellular organisms. Examples of invertebrate cells include insect cells such as *Drosophila* S2 and *Spodoptera* Sf9, as well as plant cells. Examples of useful mammalian host cell lines include Chinese hamster ovary (CHO) and COS cells. More specific examples include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL
 35 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture (Graham *et al.*, J. Gen. Virol., 36:59 (1977)); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77:4216 (1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod., 23:243-251 (1980)); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); and mouse mammary tumor (MMT 060562, ATCC CCL51). The selection of the appropriate host cell is deemed to be within the skill in the art.

3. Selection and Use of a Replicable Vector

The nucleic acid (*e.g.*, cDNA or genomic DNA) encoding the desired clone 65 or 320 polypeptide may be inserted into a replicable vector for cloning (amplification of the DNA) or for expression. Various vectors are publicly available. The vector may, for example, be in the form of a plasmid, cosmid, viral particle, or phage. The appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease site(s) using techniques known in the art. Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard ligation techniques which are known to the skilled artisan.

The desired clone 65 or 320 polypeptide may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence, if the clone 65 or 320 polypeptide is conducive to being secreted, or other polypeptide having a specific cleavage site at the N-terminus of the mature or full-length protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a part of the DNA encoding the clone 65 or 320 polypeptide that is inserted into the vector. The signal sequence may be a prokaryotic signal sequence such as, for example, the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders. For yeast secretion the signal sequence may be, *e.g.*, the yeast invertase leader, alpha factor leader (including *Saccharomyces* and *Kluyveromyces* α -factor leaders, the latter described in U.S. Patent No. 5,010,182), or acid phosphatase leader, the *C. albicans* glucoamylase leader (EP 362,179 published 4 April 1990), or the signal described in WO 90/13646 published 15 November 1990. In mammalian cell expression, mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders, and including signals from clone 65 or 320 polypeptide.

Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 μ plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV, or BPV) are useful for cloning vectors in mammalian cells.

Expression and cloning vectors will typically contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, *e.g.*, ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, *e.g.*, the gene encoding D-alanine racemase for *Bacilli*.

An example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the nucleic acid encoding clone 65 or 320 polypeptide, such as DHFR or thymidine kinase. An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as described by Urlaub *et al.*, Proc. Natl. Acad. Sci. USA, 77:4216 (1980). A suitable selection gene for use in yeast is the *trp1* gene present in the yeast plasmid YRp7. Stinchcomb *et al.*, Nature, 282:39 (1979); Kingsman *et al.*, Gene, 7:141 (1979); Tschemper *et al.*, Gene, 10:157 (1980). The *trp1* gene provides a

WO 99/21999

PCT/US98/22992

selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1. Jones, Genetics, 85:12 (1977).

Expression and cloning vectors usually contain a promoter operably linked to the nucleic acid sequence encoding clone 65 or 320 polypeptide to direct mRNA synthesis. Promoters recognized by a variety of potential host
5 cells are well known. Promoters suitable for use with prokaryotic hosts include the β -lactamase and lactose promoter systems (Chang *et al.*, Nature, 275:615 (1978); Goeddel *et al.*, Nature, 281:544 (1979)), alkaline phosphatase, a tryptophan (trp) promoter system (Goeddel, Nucleic Acids Res., 8:4057 (1980); EP 36,776), and hybrid promoters such as the tac promoter. deBoer *et al.*, Proc. Natl. Acad. Sci. USA, 80:21-25 (1983). Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding the clone 65 or
10 320 polypeptide.

Examples of suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase (Hitzeman *et al.*, J. Biol. Chem., 255:2073 (1980)) or other glycolytic enzymes (Hess *et al.*, J. Adv. Enzyme Reg., 7:149 (1968); Holland, Biochemistry, 17:4900 (1978)), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate
15 isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.

Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters
20 for use in yeast expression are further described in EP 73,657.

Clone 65 or 320 transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus,
25 hepatitis-B virus, and Simian Virus 40 (SV40); from heterologous mammalian promoters, *e.g.*, the actin promoter or an immunoglobulin promoter; and from heat-shock promoters, provided such promoters are compatible with the host cell systems.

Transcription of a DNA encoding a clone 65 or 320 polypeptide by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10
30 to 300 bp, that act on a promoter to increase its transcription. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, α -fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. The enhancer may be spliced into the vector at a position 5' or 3' to the sequence
35 coding for a clone 65 or 320 polypeptide, but is preferably located at a site 5' from the promoter.

Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated

WO 99/21999

PCT/US98/22992

regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding clone 65 or 320 polypeptide.

Still other methods, vectors, and host cells suitable for adaptation to the synthesis of clone 65 and 320 polypeptides in recombinant vertebrate cell culture are described in Gething *et al.*, Nature, 293:620-625 (1981);
 5 Mantei *et al.*, Nature, 281:40-46 (1979); EP 117,060; and EP 117,058.

4. Detecting Gene Amplification/Expression

Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA (Thomas, Proc. Natl. Acad. Sci. USA, 77:5201-5205 (1980)), dot blotting (DNA analysis), or *in situ* hybridization, using an appropriately labeled probe,
 10 based on the sequences provided herein. Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.

Gene expression, alternatively, may be measured by immunological methods, such as immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene
 15 product. Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native-sequence clone 65 or 320 polypeptide or against a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to DNA encoding clone 65 or 320 polypeptide and encoding
 20 a specific antibody epitope.

5. Purification of Polypeptide

Forms of clone 65 or 320 polypeptide may be recovered from culture medium or from host cell lysates. If membrane-bound, it can be released from the membrane using a suitable detergent solution (*e.g.*, Triton-X 100) or by enzymatic cleavage. Cells employed in expression of clone 65 and 320 polypeptides can be disrupted by
 25 various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell lysing agents.

It may be desired to purify clone 65 or 320 polypeptide from recombinant cell proteins or polypeptides. The following procedures are exemplary of suitable purification procedures: by fractionation on an ion-exchange column; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such
 30 as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, SEPHADEXTM G-75; protein A SEPHAROSETM columns to remove contaminants such as IgG; and metal chelating columns to bind epitope-tagged forms of the clone 65 or 320 polypeptide. Various methods of protein purification may be employed, and such methods are known in the art and described, for example, in Deutscher, Methods in Enzymology, 182 (1990); and Scopes, Protein Purification: Principles and Practice (Springer-Verlag: New
 35 York, 1982).

In one specific example of purification, either a poly-HIS tag or the Fc portion of human IgG is added to the C-terminal coding region of the cDNA for clone 65 or clone 320 before expression. The conditioned media from the transfected cells are harvested by centrifugation to remove the cells and filtered. For the poly-HIS tagged constructs, the protein may be purified using a Ni-NTA column. After loading, the column may be washed with

WO 99/21999

PCT/US98/22992

additional equilibration buffer and the protein eluted with equilibration buffer containing 0.25 M imidazole. The highly purified protein may then be desalted into a storage buffer if desired.

Immunoadhesin (Fc-containing) constructs of the clone 65 or clone 320 polypeptides may be purified from the conditioned media by pumping them onto a 5-ml Protein A column that had been equilibrated in a phosphate buffer. After loading, the column may be washed extensively with equilibration buffer before elution with citric acid. The eluted protein may be immediately neutralized by collecting 1-ml fractions into tubes containing TRIS buffer. The highly purified protein may be subsequently desalted into storage buffer as described above for the poly-HIS tagged proteins. The homogeneity of the protein may be assessed by SDS polyacrylamide gels and by N-terminal amino acid sequencing by Edman degradation.

The purification step(s) selected will depend, for example, on the nature of the production process used and the particular clone 65 or 320 polypeptide produced.

E. Uses for Clone 65 and 320 Polypeptides and Their Nucleic Acid

Nucleotide sequences (or their complement) encoding clone 65 and 320 polypeptides have various applications in the art of molecular biology, including uses as hybridization probes, in chromosome and gene mapping, and in the generation of anti-sense RNA and DNA. Nucleic acid encoding clone 65 or 320 polypeptide will also be useful for the preparation of clone 65 or 320 polypeptide by the recombinant techniques described herein.

The full-length nucleotide sequences for mouse or human clone 65 (SEQ ID NOS:4 and 1, respectively), or portions thereof, or the sequences in Figures 2, 3, and 4 for mouse clone 320 (SEQ ID NOS:7, 8, and/or 9), or portions thereof, may be used as hybridization probes for a cDNA library to isolate or detect the full-length gene encoding the clone 65 or 320 polypeptide of interest or to isolate or detect still other genes (for instance, those encoding naturally occurring variants of clone 65 or 320 polypeptide, other clone 65 or 320 polypeptide family members, or clone 65 or 320 polypeptides from other species) which have a desired sequence identity to the clone 65 polypeptide sequences disclosed in Figures 1 and 5 (SEQ ID NOS:6 and 3, respectively). For example, such procedures as *in situ* hybridization, Northern and Southern blotting, and PCR analysis may be used to determine whether DNA and/or RNA encoding a different clone 65 or 320 polypeptide is present in the cell type(s) being evaluated. Optionally, the length of the probes will be about 20 to about 50 bases. For example, the hybridization probes may be derived from ESTs, cloned sequences, or genomic sequences including promoters, enhancer elements, and introns of DNA encoding native-sequence clone 65 or 320 polypeptide.

By way of example, a screening method will comprise isolating the coding region of the clone 65 or clone 320 gene using the known DNA sequence to synthesize a selected probe of about 40 bases. Hybridization probes may be labeled by a variety of labels, including radionucleotides such as ^{32}P or ^{35}S , or enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems. Labeled probes having a sequence complementary to that of any of the genes encoding clone 65 or 320 polypeptide of the present invention can be used to screen libraries of human cDNA, genomic DNA, or mRNA to determine to which members of such libraries the probe hybridizes. Hybridization techniques are described in further detail in the Examples below.

The probes may also be employed in PCR techniques to generate a pool of sequences for identification of closely-related clone 65 and 320 sequences.

Nucleotide sequences encoding a clone 65 or 320 polypeptide can also be used to construct hybridization probes for mapping the gene that encodes the particular clone 65 or 320 polypeptide and for the genetic analysis of

WO 99/21999

PCT/US98/22992

individuals with genetic disorders. The nucleotide sequences provided herein may be mapped to a chromosome and specific regions of a chromosome using known techniques, such as *in situ* hybridization, linkage analysis against known chromosomal markers, and hybridization screening with libraries.

Nucleic acid encoding a clone 65 or 320 polypeptide may be used as a diagnostic to determine the extent and rate of the expression of the DNA encoding a clone 65 or 320 polypeptide in the cells of a patient. To accomplish such an assay, a sample of a patient's cells is treated, via *in situ* hybridization, or by other suitable means, and analyzed to determine whether the sample contains mRNA molecules capable of hybridizing with the nucleic acid molecule.

Nucleic acids that encode clone 65 or 320 polypeptide or any of their modified forms can also be used to generate either transgenic animals or "knock-out" animals which, in turn, are useful in the development and screening of therapeutically useful reagents. A transgenic animal (*e.g.*, a mouse or rat) is an animal having cells that contain a transgene, which transgene was introduced into the animal or an ancestor of the animal at a prenatal, *e.g.*, an embryonic stage. A transgene is a DNA that is integrated into the genome of a cell from which a transgenic animal develops. In one embodiment, cDNA encoding a clone 65 or 320 polypeptide can be used to clone genomic DNA encoding the clone 65 or 320 polypeptide in accordance with established techniques and the genomic sequences used to generate transgenic animals that contain cells which express DNA encoding the clone 65 or 320 polypeptide.

Methods for generating transgenic animals, particularly animals such as mice or rats, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009 and WO 97/38086. Typically, particular cells would be targeted for clone 65 or 320 transgene incorporation with tissue-specific enhancers. Transgenic animals that include a copy of a transgene encoding the clone 65 or 320 polypeptide introduced into the germ line of the animal at an embryonic stage can be used to examine the effect of increased expression of DNA encoding the clone 65 or 320 polypeptide. Such animals can be used as tester animals for reagents thought to confer protection from, for example, pathological conditions associated with its overexpression. In accordance with this facet of the invention, an animal is treated with the reagent and a reduced incidence of the pathological condition, compared to untreated animals bearing the transgene, would indicate a potential therapeutic intervention for the pathological condition.

Alternatively, non-human homologues of clone 65 and 320 polypeptides can be used to construct a clone 65 or 320 polypeptide "knock-out" animal which has a defective or altered gene encoding a clone 65 or 320 polypeptide as a result of homologous recombination between the endogenous gene encoding the clone 65 or 320 polypeptide and altered genomic DNA encoding the clone 65 or 320 polypeptide introduced into an embryonic cell of the animal. For example, cDNA encoding the clone 65 or 320 polypeptide can be used to clone genomic DNA encoding the clone 65 or 320 polypeptide in accordance with established techniques. A portion of the genomic DNA encoding the clone 65 or 320 polypeptide can be deleted or replaced with another gene, such as a gene encoding a selectable marker which can be used to monitor integration. Typically, several kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector. See *e.g.*, Thomas and Capecchi, Cell, 51:503 (1987) for a description of homologous recombination vectors. The vector is introduced into an embryonic stem cell line (*e.g.*, by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are selected. See *e.g.*, Li et al., Cell, 69:915 (1992). The selected cells are then injected into a blastocyst of an animal (*e.g.*, a mouse or rat) to form aggregation chimeras. See *e.g.*, Bradley, in Teratocarcinomas and Embryonic

WO 99/21999

PCT/US98/22992

Stem Cells: A Practical Approach, E. J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term to create a "knock-out" animal. Progeny harboring the homologously recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombined DNA. Knock-out animals can be characterized, for instance, by their ability to defend against certain pathological conditions and by their development of pathological conditions due to absence of the clone 65 or 320 polypeptide.

In particular, assays in which the Rac and Rho family members are usually used are preferably performed with the clone 65 polypeptide. Further, an assay to determine whether TGF- β induces the clone 65 or 320 polypeptide, indicating a role in cancer, may be performed as known in the art, as well as assays involving induction of cell death and ^3H -thymidine proliferation assays. Mitogenic and tissue growth assays are also performed with the clone 65 or 320 polypeptide as set forth above. The results are applied accordingly.

The clone 65 or 320 polypeptides of the present invention may also be used to induce the formation of anti-clone 65 or anti-clone 320 polypeptide antibodies, which are identified by routine screening as detailed below.

For diagnostic purposes, the clone 65 or clone 320 polypeptide can be used in accordance with immunoassay technology. Examples of immunoassays are provided by Wide at pages 199-206 of Radioimmuno Assay Method, Kirkham and Huner, ed., E & S. Livingstone, Edinburgh, 1970.

Thus, in one embodiment, clone 65 or clone 320 polypeptides can be detectably labeled and incubated with a test sample containing the molecules of interest (such as biological fluids, *e.g.*, serum, sputum, urine, *etc.*), and the amount of clone 65 or clone 320 molecule bound to the sample ascertained.

Immobilization of reagents is required for certain assay methods. Immobilization entails separating the clone 65 or clone 320 polypeptide from any analyte that remains free in solution. This conventionally is accomplished by either insolubilizing the clone 65 or clone 320 polypeptide before the assay procedure, as by adsorption to a water-insoluble matrix or surface (Bennich *et al.*, U.S. 3,720,760), by covalent coupling (for example, using glutaraldehyde cross-linking), or by insolubilizing the molecule afterward, *e.g.*, by immunoprecipitation.

The foregoing are merely exemplary diagnostic assays. Other methods now or hereafter developed for the determination of these analytes are included within the scope hereof.

In addition, clone 65 and 320 polypeptides are useful for screening for compounds that bind to them as defined above. Preferably, these compounds are small molecules such as organic or peptide molecules that exhibit one or more of the desired activities. Screening assays of this kind are conventional in the art, and any such screening procedure may be employed, whereby the test sample is contacted with the clone 65 or 320 polypeptide herein and the extent of binding and biological activity of the bound molecule are determined.

Clone 65 and clone 320 polypeptides are additionally useful in affinity purification of a molecule that binds to clone 65 or clone 320 polypeptide and in purifying antibodies thereto. The clone 65 or clone 320 polypeptide is typically coupled to an immobilized resin such as Affi-Gel 10TM (Bio-Rad, Richmond, CA) or other such resins (support matrices) by means well known in the art. The resin is equilibrated in a buffer (such as one containing 150 mM NaCl, 20 mM HEPES, pH 7.4 supplemented to contain 20% glycerol and 0.5% NP-40) and the preparation to

WO 99/21999

PCT/US98/22992

be purified is placed in contact with the resin, whereby the molecules are selectively adsorbed to the clone 65 or clone 320 polypeptide on the resin.

The resin is then sequentially washed with suitable buffers to remove non-adsorbed material, including unwanted contaminants, from the mixture to be purified, using, *e.g.*, 150 mM NaCl, 20 mM HEPES, pH 7.4, containing 0.5% NP-40; 150 mM NaCl, 20 mM HEPES, pH 7.4 containing 0.5 M NaCl and 0.1% NP-40; 150 mM NaCl, 20 mM HEPES, pH 7.4 containing 0.1% deoxycholate; 150 mM NaCl, 20 mM HEPES, pH 7.4 containing 0.1% NP-40; and a solution of 0.1% NP-40, 20% glycerol and 50 mM glycine, pH 3. The resin is then treated so as to elute the binding molecule using a buffer that will break the bond between the binding molecule and clone 65 or clone 320 polypeptide (using, *e.g.*, 50 mM glycine, pH 3, 0.1% NP-40, 20% glycerol, and 100 mM NaCl).

It is contemplated that the clone 65 and 320 polypeptides of the present invention may be used to treat various conditions, including those characterized by overexpression and/or activation of at least the Wnt pathway. Further, they are useful in diagnosing cancer, for example, as a marker for increased susceptibility to cancer or for having cancer. Exemplary conditions or disorders to be treated with the clone 65 and 320 polypeptides include benign or malignant tumors (*e.g.*, renal, liver, kidney, bladder, testicular, breast, gastric, ovarian, colorectal, prostate, pancreatic, lung, esophageal, vulval, thyroid, hepatic carcinomas; sarcomas; glioblastomas; and various head and neck tumors); leukemias and lymphoid malignancies; other disorders such as neuronal, glial, astrocytal, hypothalamic, and other glandular, macrophagal, epithelial, stromal, and blastocoelic disorders; cardiac disorders; renal disorders; catabolic disorders; bone-related disorders such as osteoporosis; and inflammatory, angiogenic, and immunologic disorders, such as arteriosclerosis.

The clone 65 and 320 polypeptides of the invention are administered to a mammal, preferably a human, in accord with known methods, such as intravenous administration as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation routes. Intravenous or subcutaneous administration of the polypeptide is preferred.

Therapeutic formulations of the clone 65 or 320 polypeptide are prepared for storage by mixing the polypeptide having the desired degree of purity with optional pharmaceutically acceptable carriers, excipients, or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counter-ions such as sodium; metal complexes (*e.g.*, Zn-protein complexes); and/or non-ionic surfactants such as TWEEN™, PLURONIC™, or polyethylene glycol (PEG).

Other therapeutic regimens may be combined with the administration of the clone 65 and 320 polypeptides of the instant invention. For example, the patient to be treated with the polypeptides disclosed herein may also

WO 99/21999

PCT/US98/22992

receive radiation therapy if the disorder is cancer. Alternatively, or in addition, a chemotherapeutic agent may be administered to the patient with cancer. Preparation and dosing schedules for such chemotherapeutic agents may be used according to manufacturers' instructions or as determined empirically by the skilled practitioner. Preparation and dosing schedules for such chemotherapy are also described in Chemotherapy Service, Ed., M.C. Perry (Williams & Wilkins: Baltimore, MD, 1992). The chemotherapeutic agent may precede or follow administration of the polypeptide or may be given simultaneously therewith. The polypeptide may be combined with an anti-oestrogen compound such as tamoxifen or an anti-progesterone such as onapristone (see, EP 616812) in dosages known for such molecules.

It may be desirable also to co-administer with the clone 65 or 320 polypeptide (or anti-clone 65 or anti-clone 320 polypeptide antibodies) antibodies against other tumor-associated antigens, such as antibodies which bind to HER-2, EGFR, ErbB2, ErbB3, ErbB4, or vascular endothelial factor (VEGF). Alternatively, or in addition, two or more different anti-cancer antibodies, such as anti-ErbB2 antibodies, may be co-administered to the patient with the clone 65 or 320 polypeptide (or anti-clone 65 or anti-clone 320 polypeptide antibodies). Sometimes, it may be beneficial also to administer one or more cytokines to the patient.

In a preferred embodiment, the clone 65 or clone 320 polypeptide is co-administered with a growth-inhibitory agent to the cancer patient. For example, the growth-inhibitory agent may be administered first, followed by the clone 65 or 320 polypeptide. However, simultaneous administration or administration of the clone 65 or clone 320 polypeptide first is also contemplated. Suitable dosages for the growth-inhibitory agent are those presently used and may be lowered due to the combined action (synergy) of the growth-inhibitory agent and polypeptide. The antibodies, cytotoxic agents, cytokines, or growth-inhibitory agents are suitably present in combination in amounts that are effective for the purpose intended.

The active ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin microcapsules and poly(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. Ed. (1980), *supra*.

The formulations to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the polypeptide, which matrices are in the form of shaped articles, *e.g.*, films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and γ ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated polypeptides remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization

WO 99/21999

PCT/US98/22992

depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

5 For the prevention or treatment of disease or disorder, the appropriate dosage of clone 65 or 320 polypeptide will depend on the type of disorder to be treated, as defined above, the severity and course of the disorder, whether the polypeptide is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the polypeptide, the route of administration, the condition of the patient, and the discretion of the attending physician. The polypeptide is suitably administered to the patient at one time or over a series of treatments.

10 Depending on the type and severity of the disease, about 1 $\mu\text{g/kg}$ to 15 mg/kg (e.g., 0.1-20 mg/kg) of clone 65 or 320 polypeptide is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. A typical daily dosage might range from about 1 $\mu\text{g/kg}$ to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment is sustained until a desired suppression of symptoms of the
15 disorder occurs. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.

In another embodiment of the invention, an article of manufacture containing materials useful for the treatment of the disorders described above is provided. The article of manufacture comprises a container and a label. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The containers may be formed from
20 a variety of materials such as glass or plastic. The container holds a composition which is effective for treating the condition and may have a sterile access port (for example, the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The active agent in the composition is the clone 65 or 320 polypeptide. The label on, or associated with, the container indicates that the composition is used for treating the condition or disorder of choice. The article of manufacture may further comprise a second container comprising
25 a pharmaceutically acceptable buffer, such as phosphate-buffered saline, Ringer's solution, and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.

F. Anti-Clone 65 and 320 Polypeptide Antibodies

The present invention further provides anti-clone 65 and 320 polypeptide antibodies. Exemplary antibodies
30 include polyclonal, monoclonal, humanized, bispecific, and heteroconjugate antibodies.

1. Polyclonal Antibodies

The anti-clone 65 and 320 polypeptide antibodies of the present invention may comprise polyclonal antibodies. Methods of preparing polyclonal antibodies are known to the skilled artisan. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant.
35 Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include the clone 65 or 320 polypeptide or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may

WO 99/21999

PCT/US98/22992

be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without undue experimentation.

2. Monoclonal Antibodies

- 5 The anti-clone 65 or 320 polypeptide antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized *in vitro*.
- 10 The immunizing agent will typically include the clone 65 or 320 polypeptide or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as PEG, to form a hybridoma cell. Goding, Monoclonal Antibodies: Principles and Practice (Academic Press: New York, 1986) pp. 59-103. Immortalized cell lines are
- 15 usually transformed mammalian cells, particularly myeloma cells of rodent, bovine, and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine
- 20 ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high-level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California, and the American Type Culture Collection, Manassas,

25 Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies. Kozbor, J. Immunol., 133:3001 (1984); Brodeur *et al.*, Monoclonal Antibody Production Techniques and Applications (Marcel Dekker, Inc.: New York, 1987) pp. 51-63.

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against a clone 65 or 320 polypeptide. Preferably, the binding specificity of

30 monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980).

After the desired hybridoma cells are identified, the clones may be subcloned by limiting dilution

35 procedures and grown by standard methods. Goding, *supra*. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells may be grown *in vivo* as ascites in a mammal.

WO 99/21999

PCT/US98/22992

The monoclonal antibodies secreted by the subclones may be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, CHO cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison *et al.*, Proc. Natl. Acad. Sci. USA, **81**: 6851-6855 (1984)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

The antibodies may be monovalent antibodies. Methods for preparing monovalent antibodies are well known in the art. For example, one method involves recombinant expression of immunoglobulin light chain and modified heavy chain. The heavy chain is truncated generally at any point in the Fc region so as to prevent heavy-chain crosslinking. Alternatively, the relevant cysteine residues are substituted with another amino acid residue or are deleted so as to prevent crosslinking.

In vitro methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly Fab fragments, can be accomplished using routine techniques known in the art.

3. Humanized Antibodies

The anti-clone 65 and anti-clone 320 polypeptide antibodies of the invention may further comprise humanized antibodies or human antibodies. Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (such as Fv, Fab, Fab', F(ab')₂, or other antigen-binding subsequences of antibodies) that contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary-determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin, and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody preferably also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. Jones *et al.*, Nature, **321**:522-525 (1986); Riechmann *et al.*, Nature, **332**:323-329 (1988); Presta, Curr. Op. Struct. Biol., **2**:593-596 (1992).

WO 99/21999

PCT/US98/22992

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers (Jones *et al.*, Nature, 5 321:522-525 (1986); Riechmann *et al.*, Nature, 332:323-327 (1988); Verhoeyen *et al.*, Science, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly 10 some FR residues are substituted by residues from analogous sites in rodent antibodies.

Human antibodies can also be produced using various techniques known in the art, including phage-display libraries. Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks *et al.*, J. Mol. Biol., 222:581 (1991). The techniques of Cole *et al.* and Boerner *et al.* are also available for the preparation of human monoclonal antibodies. Cole *et al.*, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985); Boerner *et al.*, J. Immunol., 15 147(1):86-95 (1991).

4. Bispecific Antibodies

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for a clone 65 or 320 polypeptide; the other one is for any other antigen, and preferably for a cell-surface protein or receptor or 20 receptor subunit.

Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities. Milstein and Cuello, Nature, 305:537-539 (1983). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential 25 mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker *et al.*, EMBO J., 10:3655-3659 (1991).

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant-domain sequences. The fusion preferably is with an immunoglobulin heavy- 30 chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh *et al.*, Methods in Enzymology, 121:210 (1986).

35 5. Heteroconjugate Antibodies

Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection. WO 91/00360; WO 92/200373; EP 03089. It is contemplated that the antibodies may be prepared *in vitro* using known

WO 99/21999

PCT/US98/22992

methods in synthetic protein chemistry, including those involving cross-linking agents. For example, immunotoxins may be constructed using a disulfide-exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

5 G. Uses for anti-clone 65 and anti-clone 320 Polypeptide Antibodies

The antibodies of the invention may be used as affinity purification agents. In this process, the antibodies are immobilized on a solid phase such as SEPHADEXTM resin or filter paper, using methods well known in the art. The immobilized antibody is contacted with a sample containing the clone 65 or 320 polypeptide (or fragment thereof) to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all
10 the material in the sample except the clone 65 or 320 polypeptide, which is bound to the immobilized antibody. Finally, the support is washed with another suitable solvent, such as glycine buffer, pH 5.0, that will release the clone 65 or 320 polypeptide from the antibody.

Anti-clone 65 or 320 polypeptide antibodies may also be useful in diagnostic assays for clone 65 or 320 polypeptide, e.g., detecting its expression in specific cells, tissues, or serum. Thus, the antibodies may be used in the
15 diagnosis of human malignancies (see, for example, U.S. Pat. No. 5,183,884).

For diagnostic applications, the antibody typically will be labeled with a detectable moiety. Numerous labels are available which can be preferably grouped into the following categories:

(a) Radioisotopes, such as ³⁵S, ¹⁴C, ¹²⁵I, ³H, and ¹³¹I. The antibody can be labeled with the radioisotope using the techniques described in Current Protocols in Immunology, Volumes 1 and 2, Coligen *et al.*, Ed., (Wiley-
20 Interscience: New York, 1991), for example, and radioactivity can be measured using scintillation counting.

(b) Fluorescent labels such as rare earth chelates (europium chelates) or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, Lissamine, phycoerythrin, and Texas Red are available. The fluorescent labels can be conjugated to the antibody using the techniques disclosed in Current Protocols in Immunology, *supra*, Coligen, ed., for example. Fluorescence can be quantified using a fluorimeter.

(c) Various enzyme-substrate labels are available, and U.S. Patent No. 4,275,149 provides a review of some of these. The enzyme preferably catalyzes a chemical alteration of the chromogenic substrate which can be measured using various techniques. For example, the enzyme may catalyze a color change in a substrate, which can be measured spectrophotometrically. Alternatively, the enzyme may alter the fluorescence or chemiluminescence of the substrate. Techniques for quantifying a change in fluorescence are described above. The chemiluminescent
25 substrate becomes electronically excited by a chemical reaction and may then emit light which can be measured (using a chemiluminometer, for example) or donates energy to a fluorescent acceptor. Examples of enzymatic labels include luciferases (e.g., firefly luciferase and bacterial luciferase; U.S. Patent No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, malate dehydrogenase, urease, peroxidase such as horseradish peroxidase (HRPO), alkaline phosphatase, β -galactosidase, glucoamylase, lysozyme, saccharide oxidases (e.g., glucose oxidase, galactose
30 oxidase, and glucose-6-phosphate dehydrogenase), heterocyclic oxidases (such as uricase and xanthine oxidase), lactoperoxidase, microperoxidase, and the like. Techniques for conjugating enzymes to antibodies are described in O'Sullivan *et al.*, Methods for the Preparation of Enzyme-Antibody Conjugates for use in Enzyme Immunoassay, in Methods in Enzym., Vol. 73, Langone and Van Vunakis, eds. (New York: Academic Press, 1981), pp. 147-166.

Examples of enzyme-substrate combinations include:

(I) Horseradish peroxidase (HRPO) with hydrogen peroxide as a substrate, wherein the hydrogen peroxidase oxidizes a dye precursor (*e.g.*, orthophenylene diamine (OPD) or 3,3',5,5'-tetramethyl benzidine hydrochloride (TMB));

5 (ii) alkaline phosphatase (AP) with para-nitrophenyl phosphate as chromogenic substrate; and

(iii) β -D-galactosidase (β -D-Gal) with a chromogenic substrate (*e.g.*, p-nitrophenyl- β -D-galactosidase) or fluorogenic substrate (4-methylumbelliferyl- β -D-galactosidase).

Numerous other enzyme-substrate combinations are available to those skilled in the art. For a general review of these, see, for example, U.S. Patent Nos. 4,275,149 and 4,318,980.

10 Sometimes, the label is indirectly conjugated with the antibody. The skilled artisan will be aware of various techniques for achieving this. For example, the antibody can be conjugated with biotin and any of the three broad categories of labels mentioned above can be conjugated with avidin, or *vice versa*. Biotin binds selectively to avidin, and thus, the label can be conjugated with the antibody in this indirect manner. Alternatively, to achieve indirect conjugation of the label with the antibody, the antibody is conjugated with a small hapten (*e.g.*, digoxin) and one of
15 the different types of labels mentioned above is conjugated with an anti-hapten antibody (*e.g.*, anti-digoxin antibody). Thus, indirect conjugation of the label with the antibody can be achieved.

In another embodiment of the invention, the anti-clone 65 or 320 polypeptide antibody need not be labeled, and the presence thereof can be detected using a labeled antibody that binds to the anti-clone 65 or 320 polypeptide antibody.

20 The antibodies of the present invention may be employed in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays. Zola, Monoclonal Antibodies: A Manual of Techniques (New York: CRC Press, Inc., 1987), pp.147-158.

Competitive binding assays rely on the ability of a labeled standard to compete with the test sample analyte for binding with a limited amount of antibody. The amount of clone 65 or 320 polypeptide in the test sample is
25 inversely proportional to the amount of standard that becomes bound to the antibodies. To facilitate determining the amount of standard that becomes bound, the antibodies preferably are insolubilized before or after the competition, so that the standard and analyte that are bound to the antibodies may conveniently be separated from the standard and analyte which remain unbound.

Sandwich assays involve the use of two antibodies, each capable of binding to a different immunogenic
30 portion, or epitope, of the protein to be detected. In a sandwich assay, the test sample analyte is bound by a first antibody which is immobilized on a solid support, and thereafter a second antibody binds to the analyte, thus forming an insoluble three-part complex. See, *e.g.*, U.S. Pat No. 4,376,110. The second antibody may itself be labeled with a detectable moiety (direct sandwich assays) or may be measured using an anti-immunoglobulin antibody that is labeled with a detectable moiety (indirect sandwich assay). For example, one type of sandwich assay is an ELISA
35 assay, in which case the detectable moiety is an enzyme.

For immunohistochemistry, the tumor sample may be fresh or frozen or may be embedded in paraffin and fixed with a preservative such as formalin, for example.

WO 99/21999

PCT/US98/22992

The antibodies may also be used for *in vivo* diagnostic assays. Preferably, the antibody is labeled with a radionuclide (such as ^{111}In , ^{99}Tc , ^{14}C , ^{131}I , ^{125}I , ^3H , ^{32}P or ^{35}S) so that the tumor can be localized using immunoscintigraphy.

Additionally, anti-clone 65 or 320 polypeptide antibodies may be useful as antagonists to clone 65 or 320 polypeptide functions where clone 65 or 320 polypeptide is upregulated in cancer cells or stimulates their proliferation or is upregulated in atherosclerotic tissue. Hence, for example, the anti-clone 65 and 320 polypeptide antibodies may by themselves or with a chemotherapeutic agent or other cancer treatment or drug such as anti-HER-2 antibodies be effective in treating certain forms of cancer such as breast cancer, colon cancer, lung cancer, and melanoma. Further uses for the antibodies include inhibiting the binding of a clone 65 or 320 polypeptide to its receptor, if applicable, or to a protein that binds to the clone 65 or 320 polypeptide, if applicable. For therapeutic use, the antibodies can be used in the formulations, schedules, routes, and doses indicated above under uses for the clone 65 and 320 polypeptides. In addition, anti-clone 65 and 320 polypeptide antibodies may be administered into the lymph as well as the blood stream.

As a matter of convenience, the anti-clone 65 or 320 polypeptide antibody of the present invention can be provided in a kit format, *i.e.*, a packaged combination of reagents in predetermined amounts with instructions for performing the diagnostic assay. Where the antibody is labeled with an enzyme, the kit will include substrates and cofactors required by the enzyme (*e.g.*, a substrate precursor which provides the detectable chromophore or fluorophore). In addition, other additives may be included such as stabilizers, buffers (*e.g.*, a block buffer or lysis buffer), and the like. The relative amounts of the various reagents may be varied to provide for concentrations in solution of the reagents which substantially maximize the sensitivity of the assay. Particularly, the reagents may be provided as dry powders, usually lyophilized, including excipients which on dissolution will provide a reagent solution having the appropriate concentration.

The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.

EXAMPLES

Commercially available reagents referred to in the examples were used according to manufacturer's instructions unless otherwise indicated. The source of those cells identified in the following examples, and throughout the specification, by ATCC accession numbers is the American Type Culture Collection, 10801 University Blvd., Manassas, Virginia.

EXAMPLE 1: Isolation of cDNA Clones Encoding Mouse Clone 65

Several putative genes encoding clone 65 and 320 polypeptides have been identified at the mRNA level in a high throughput PCR-select cDNA subtraction experiment carried out using a mouse mammary cell line (C57MG), which has been transformed by a Wnt-1 retroviral vector and compared with the parental cell line. The clone 65 and 320 polypeptide family disclosed herein, including the mouse clone 65 gene, was induced only in the transformed cell line C57MGWnt-1.

WO 99/21999

PCT/US98/22992

1. Suppression Subtractive Hybridization

Mouse clone 65 was isolated independently by Wnt-1 differential screening using suppression subtractive hybridization (SSH), as described by Diatchenko *et al.*, *Proc. Natl. Acad. Sci. USA*, **93**: 6025-6030 (1996). SSH was carried out using the PCR-SELECT® cDNA Subtraction Kit (Clontech Laboratories, Inc.) according to the manufacturer's protocol. Driver double-stranded (ds) cDNA was synthesized from 2 micrograms of polyA+ RNA isolated from a mouse mammary cell line (C57MG), obtainable from a mouse breast cancer myoepithelial cell line. This cell line is described in Brown *et al.*, *Cell*, **46**: 1001-1009 (1986); Olson and Papkoff, *Cell Growth and Differentiation*, **5**: 197-206 (1994); Wong *et al.*, *Mol. Cell. Biol.*, **14**: 6278-6286 (1994); and Jue *et al.*, *Mol. Cell. Biol.*, **12**: 321-328 (1992), and is responsive to Wnt-1 but not to Wnt-4. Tester ds cDNA was synthesized from 2 micrograms of polyA+ RNA isolated from a transformed version of C57MG, called C57MG/wnt-1.

The C57MG/wnt-1 mouse mammary derivative cell line was prepared by first transforming the parent line with a Wnt-1 retroviral vector, pBabe Puro (5.1 kb). This vector has a 5' LTR, packaging elements, a multiple cloning site, the puromycin-resistance gene driven off the SV40 promoter, a 3' LTR, and the bacterial elements for replication and ampicillin selection. The vector was modified slightly for Wnt-1 cloning by removing the *HindIII* site after the SV40 promoter and adding a *HindIII* site to the multiple cloning site. Wnt-1 is cloned from *EcoRI-HindIII* in the multiple cloning site. Figure 7 shows a map of the vector.

The transformed derivative cells were grown up in a conventional fashion, and the final cell population was selected in DMEM + 10% FCS with 2.5 µg/ml puromycin to stabilize the expression vector. PCR was performed using the Clontech kit, including the cDNA synthesis primer (SEQ ID NO:20), adaptors 1 and 2 (SEQ ID NOS:21 and 22, respectively) and complementary sequences for the adaptors (SEQ ID NOS:23 and 24, respectively), PCR primer 1 (SEQ ID NO:25), PCR primer 2 (SEQ ID NO:26), nested PCR primer 1 (SEQ ID NO:27), nested PCR primer 2 (SEQ ID NO:28), control primer G3PDH5' primer (SEQ ID NO:29), and control primer G3PDH3' primer (SEQ ID NO:30), shown in Figure 8.

Products generated from the secondary PCR reaction were inserted into the cloning site region of pGEM-T vector (Promega), shown in Figure 9 (SEQ ID NOS:31 and 32 for 5' and 3' sequences, respectively). Plasmid DNAs were prepared using the Wizard Miniprep KitTM (Promega). DNA sequencing of the subcloned PCR fragments was performed manually by the chain termination reaction (Sequenase 2.0TM Kit, Pharmacia). Nucleic acid homology searches were performed using the BLAST program noted above.

A total of 1384 clones were sequenced out of greater than 5000 found. A total of 1996 DNA templates were prepared. A program was used to trim the vector off, and a different program used to cluster the clones into two or more identical clones or with an overlap of 50 bases the same. Then a BLAST was performed of a representative clone from the cluster. Primers were designed for RT-PCR to see if the clones were differentially expressed.

2. Semi-quantitative RT-PCR

The initial clone isolated, designated clone 65, had 212 bp and the sequence:

35 5' CAGAGGGTGGGTGGGAAAGAGTGAATTATTTAATTTTAAATGTTATAATAAAGCCAATGT
AGTTGAGACCAAGGAAATGAGCATTGAGAACACAACTTGAAGTCTGGTGCCAGGGTTGT
TGGACCTCACACCCTGTCTCTGAGCCACCCGGAAGTGACATAAAGGACGCTGT
GTGATCAAGTTCTGGACACTTTTCTGGGATG (SEQ ID NO:11).

WO 99/21999

PCT/US98/22992

RT-PCR primers were designed for confirming differential expression, pulling out additional clones, screening for full-length mouse clone, and screening for the human clone. The RT-PCR primers were designed as follows:

65.pcr.top1: 5'-CAGAGGGTGGGTGGGAAAGAGTGA (SEQ ID NO:33)

5 and

65.pcr.bot2: 3'-CCTTCACTGTATTTCTGCGACAC (SEQ ID NO:34)

For the RT-PCR procedure, cell lines were grown to subconfluence before extracting the RNA. Total RNA was extracted using Stat-60TM (Tel-TestTM B) per manufacturer's instructions. First-strand cDNA was prepared from 0.1 µg - 3 µg of total RNA with the SuperscriptTM RT kit (Gibco, BRL). PCR amplification of 5 µl of first-strand cDNA was performed in a 50-µl PCR reaction. The above primers were used to amplify first-strand cDNA. As controls, primers corresponding to nucleotide positions 707-729 (sense; 5'-GTGGCCCATGCTCTGGCAGAGGG (SEQ ID NO:35)) or 836-859 (sense; 5'-GACTGGAGCAAGGTCGTCCTCGCC (SEQ ID NO:36)) and 1048-1071 (anti-sense; 5'-GCACCACCCACAAGGAAGCCATCC (SEQ ID NO:37)) of human triosephosphate isomerase (huTPI) (Maquat *et al.*, *J. Biol. Chem.*, **260**: 3748-3753 (1985); Brown *et al.*, *Mol. Cell. Biol.*, **5**: 1694-1706 (1985)) were used to amplify first-strand cDNA. For mouse triosephosphate isomerase, primers corresponding to nucleotide positions 433-456 (sense; 5'-GACGAAAGGGAAGCCGGCATCACC (SEQ ID NO: 38)) or 457-480 bp (sense; 5'-GAGAAGGTCGTGTTTCGAGCAAACC (SEQ ID NO: 39)) and 577-600 bp (antisense; 5'-CTTCTCGTGTACTTCCTGTGCCTG (SEQ ID NO:40)) or 694-717 bp (antisense; 5'-CACGTCAGCTGGCGTTGCCAGCTC (SEQ ID NO:41)) were used for amplification.

Briefly, 4 µCi of (-³²P)CTP (3000 Ci/mmol) was added to each reaction with 2.5 U of TaKaRa Ex TaqTM (Panvera, Madison, WI) and 0.2 µM of each dNTP. The reactions were amplified in a 480 PCR thermocyclerTM (Perkin Elmer) using the following conditions: 94°C for 1 min., 62°C for 30 sec., 72°C for 1 min, for 18-25 cycles. 5 µl of PCR products were electrophoresed on a 6% polyacrylamide gel. The gel was exposed to film. Densitometry measurements were obtained using Alpha Ease Version 3.3aTM software (Alpha Innotech Corporation) to quantitate the clone 65-specific and clone 320-specific or TPI-specific gene products.

3. Northern Blot Analysis

Adult multiple-tissue Northern blots (Clontech) and the Northern blot of the C57MG parent and C57MG/Wnt-1 derivative polyA+RNA (2 µg/lane) were hybridized with a probe designated 65.50mer.2 of nucleotide bases 261-310 of Figures 1A and 1B:

5'-CAACTTCTCGGCCGTGGTGTCTGTAGATGGGCGGCCTGTGAGACTCCAGC

(SEQ ID NO:42) generated using the primers noted above. The membranes were washed in 0.1 X SSC at 55-65°C and exposed for autoradiography. Blots were rehybridized with a 75-bp synthetic probe from the human actin gene. See Godowski *et al.*, *Proc. Natl. Acad. Sci. USA*, **86**: 8083-8087 (1989) for a method for making a probe with overlapping oligos, which is how the actin probe was prepared.

4. cDNA Library Screening

Clones encoding the full-length mouse clone 65 polypeptide were isolated by screening RNA library 211: C57MG/Wnt-1 by colony hybridization with the above probe. The inserts of certain of these clones were subcloned into pBluescriptTM IISK+ and their DNA sequence determined by dideoxy DNA sequencing on both strands.

5. Results

WO 99/21999

PCT/US98/22992

The recently described technique of SSH combines a high subtraction efficiency with an equalized representation of differentially expressed sequences. This method is based on specific PCR reactions that permit exponential amplification of cDNAs which differ in abundance, whereas amplification of sequences of identical abundance in two populations is suppressed. The SSH technique was used herein to isolate genes expressed in a mouse mammary myoepithelial cell transformed with *Wnt-1* whose expression is reduced or absent in the parental myoepithelial cell. The polyA+RNA extracted from both types of cells was used to synthesize tester and driver cDNAs. The degree of subtraction efficiency was monitored by Southern blot analysis of unsubtracted and subtracted PCR products using a β -actin probe. No β -actin mRNA was apparent in the subtracted PCR products, confirming the efficiency of the subtraction.

After RT-PCR and Northern blot analysis were carried out on the initial clone to confirm differential expression, there was found about a 2-fold induction in the *Wnt-1* cell line by Northern blot and a 4.5-fold induction by RT-PCR. Upon screening of the library, the full-length mouse clone 65 was obtained, designated clone 65.11.3. The cDNA for mouse clone 65 encodes a novel intracellular protein that is strongly induced in the *Wnt-1*/C57mg cell line, but is absent, or at very low levels, in the parent/C57mg cells. This clone, 65.11.3, encodes a protein about 48-60% identical in sequence to members of the Rho family of small GTPases.

The nucleotide sequence and putative amino acid sequence of mouse clone 65 are shown in Figures 1A and 1B (SEQ ID NOS:4 and 6, respectively). The alignment of the human and mouse clone 65 amino acid sequences is shown in Figure 6 (SEQ ID NOS:3 and 6, respectively). The mouse clone was placed in pRK5E, described above, and deposited with the ATCC. Upon transformation into JM 109 cells, the plasmid renders the cells Amp resistant. Upon digestion with *HindIII* and *NotI*, the cells provide a mouse insert size of 786 base pairs from the Met codon to the stop codon. There are 1824 bp upstream of the *NotI* site encoding mouse heat-stable antigen (HSA) (CD24) fused to the clone 65 insert, which can be eliminated by digestion with *NotI*. Because the HSA sequence adjacent to the 5' end of the gene was removed electronically, there is no 5' sequence for clone 65 upstream of the Met in Figures 1A and 1B.

Without being limited to any one theory, the PCR/RT primers may fall in the 3' UTR of an alternatively spliced clone because the final clone 65.11.3 (mouse clone 65) does not have these sequences. A number of other clones were obtained by screening a C57mg/*Wnt-1* cDNA library using the specific probes described below.

Two subsequent clones, designated as 65.11 and 65.9 and having 2224 and 2004 bp respectively, were identified using a probe derived from the original 212 bp clone 65. Their sequences (SEQ ID NOS:12 and 13, respectively) are shown in Figures 10 and 11, respectively. Clones 65.11 and 65.9 have different 5' ends, virtually identical 3' ends, and CA repeats. The 5' end of clone 65.11 has a CDC-42-like region. The 5' end of clone 65.9 contains a region with homology to part of a 314-bp EST, AA462407 (isolated from a mouse mammary gland).

Three other clones were obtained from the same library by screening with a probe derived from the region homologous to CDC-42 of clone 65.11: clone 65.11.1 having 836 bp (SEQ ID NO:14; Fig. 12), the full-length mouse clone 65 clone 65.11.3 (SEQ ID NO:15; Figs. 13A-13B) having 2251 bp, described below and the coding region of which is disclosed in Figs. 1A-1B, and sharing a region in the 5' end with EST AA613604 (isolated from adult mouse placenta), and clone 65.11.6 having 847 bp (SEQ ID NO:16; Fig. 14).

WO 99/21999

PCT/US98/22992

Three other clones (65.1, 65.6, and 65.13) were also obtained from the primary screen (using a portion of the original clone 65 as a probe, one of which (clone 65.1) has a 5' end similar to that of clone 65.9. The sequences of these clones (SEQ ID NOS:17, 18, and 19, respectively) are shown in Figures 15, 16, and 17, respectively.

The subsequent clones, which may be splice variants, contain pieces of the 3' end of the initial clone, and/or contain an unusual 5' end, and/or contain a CDC-42-like end.

EXAMPLE 2: Isolation of a cDNA clone Encoding Mouse clone 320

The cDNA for mouse clone 320 was isolated independently by Wnt-1 differential screening using the procedure described in Example 1. The initial clone isolated was designated clone 320 and had 165 bp. There were two clones in this cluster. The clone was at least partially sequenced as described above and RT-PCR primers were designed as follows:

320.pcr.top1: (corresponding to bases 2319-2342 of Figs. 4A-4B)

5'-GCACACACGCATGGAGGCAAGCTC (SEQ ID NO:43)

and

320.pcr.bot1: (corresponding to bases 2423-2446 of Figs. 4A-4B)

3'-ACCACCTCGACATTTGTTCTACCG (SEQ ID NO:44)

RT-PCR and Northern blot procedures were carried out as described in Example 1 to confirm differential expression.

Then four clones encoding at least partial-length mouse clone 320 were isolated by screening RNA library 211: C57MG/Wnt-1 by colony hybridization with a probe designated 320.50.mer.1 of nucleotide bases 1997-2046 of Figures 4A-4B:

5'-CTCCTGACCTTTGGGGCTGCCACTTCCCAGGACGACCACTGCCTGCCCCAC
(SEQ ID NO:45).

The cDNA for mouse clone 320 encodes a novel protein that is strongly induced in the Wnt-1/C57mg cell line, but is absent in the parent/C57mg cells and may be useful in the regulation of cancer cells.

The nucleotide sequence of a consensus sequence made up of all three clones (SEQ ID NO:7) is shown in Figs. 4A and 4B. The nucleotide sequence of another clone of mouse clone 320 is shown in Figs. 5A and 5B (SEQ ID NO:8) and of yet another clone is shown in Figure 6 (SEQ ID NO:9). The consensus sequence is a mouse clone 320 sequence of 2822 bp having no obvious or apparent open reading frame, and is probably a partial clone. When RNA from tumors arising in mice in a colony established from two Wnt-1 male transgenic mice (provided by Harold Varmus at NCI) was subjected to RT-PCR using the above primers, clone 320 was strongly induced. A small section of only about 200 bp of the consensus sequence matches a region in the 3'UTR of human Wnt-5A.

The mouse clone was placed in pRK5E, described above, and deposited with the ATCC. Upon transformation into JM 109 cells, the plasmid renders the cells ampicillin resistant. Upon digestion with *Bam*HI and *Hind*III, this provides a mouse insert size of about 3 kilobase pairs.

EXAMPLE 3: Isolation of a cDNA clone Encoding Human Clone 65

To isolate the full-length human clone corresponding to 65.11.3 (mouse clone 65), a human fetal liver cDNA library (Clontech), treated with the SuperScriptTM kit using the pRK5E vector as described above, was screened with a probe (65.50.mer.2 (SEQ ID NO:42) noted above in Example 1) at low stringency (20% formamide, 1 X SSC, 55°C wash).

WO 99/21999

PCT/US98/22992

Four clones were identified: 65.1, 65.4, 65.5, and 65.6. The inserts to these clones were subcloned into pBluescriptTM IISK+ and its DNA sequence determined by dideoxy DNA sequencing on both strands. A consensus sequence from these clones was obtained to give both the nucleotide sequence and putative amino acid sequence for human clone 65. The consensus sequence and the derived amino acid sequence are shown in Figures 5A and 5B (SEQ ID NOS:1 and 3, respectively). Clone 65.1 (SEQ ID NO:46) starts at nucleotide position 51 and ends at 227 of SEQ ID NO:1 and is boxed in the figure. The second clone 65.4 (SEQ ID NO:47) starts at nucleotide position 51 and ends at 824 of SEQ ID NO:1. The third clone 65.6 (SEQ ID NO:48) starts at nucleotide position 480 and ends at 1319 of SEQ ID NO:1) in Figs. 5A-5B. This consensus sequence of Figs. 5A-5B (SEQ ID NO:1) is 93% homologous to the mouse clone 65 nucleotide sequence of Fig. 1 (SEQ ID NO:4). See Fig. 6. By homology searching, human clone 65, like mouse clone 65, is found to be a member of the Rho, Rac, and CDC42 family. Because of the homology to the Rho and Rac family, these proteins are believed to be involved in the upregulation of cancer genes.

The clone was placed in a pRK5E plasmid as described above and deposited with the ATCC. Upon transformation into JM109 cells, the cells become ampicillin resistant. Digestion with *Xba*I and *Not*I yields an insert size of 777 basepairs from the ATG to the stop codon.

EXAMPLE 4: *In situ* Hybridization

In situ hybridization is a powerful and versatile technique for the detection and localization of nucleic acid sequences within cell or tissue preparations. It may be useful, for example, to identify sites of gene expression, analyze the tissue distribution of transcription, identify and localize viral infection, follow changes in specific mRNA synthesis, and aid in chromosome mapping.

In situ hybridization was performed following an optimized version of the protocol by Lu and Gillett, Cell Vision 1: 169-176 (1994), using PCR-generated ³³P-labeled riboprobes. Briefly, formalin-fixed, paraffin-embedded human tissues were sectioned, deparaffinized, deproteinized in proteinase K (20 g/ml) for 15 minutes at 37°C, and further processed for *in situ* hybridization as described by Lu and Gillett, *supra*. A (³³-P)UTP-labeled antisense riboprobe was generated from a PCR product and hybridized at 55°C overnight. The slides were dipped in Kodak NTB2 nuclear track emulsion and exposed for 4 weeks.

³³P-Riboprobe synthesis

6.0 µl (125 mCi) of ³³P-UTP (Amersham BF 1002, SA<2000 Ci/mmol) were speed-vacuum dried. To each tube containing dried ³³P-UTP, the following ingredients were added:

- 2.0 µl 5x transcription buffer
- 1.0 µl DTT (100 mM)
- 2.0 µl NTP mix (2.5 mM : 10 µl each of 10 mM GTP, CTP & ATP + 10 µl H₂O)
- 1.0 µl UTP (50 µM)
- 1.0 µl RNAsin
- 1.0 µl DNA template (1 µg)
- 1.0 µl H₂O
- 1.0 µl RNA polymerase (for PCR products T3 = AS, T7 = S, usually)

The tubes were incubated at 37°C for one hour. A total of 1.0 µl RQ1 DNase was added, followed by incubation at 37°C for 15 minutes. A total of 90 µl TE (10 mM Tris pH 7.6/1 mM EDTA pH 8.0) was added, and

WO 99/21999

PCT/US98/22992

the mixture was pipetted onto DE81 paper. The remaining solution was loaded in a MICROCON-50TM ultrafiltration unit, and spun using program 10 (6 minutes). The filtration unit was inverted over a second tube and spun using program 2 (3 minutes). After the final recovery spin, a total of 100 μ l TE was added. Then 1 μ l of the final product was pipetted on DE81 paper and counted in 6 ml of BIOFLUOR IITM.

- 5 The probe was run on a TBE/urea gel. A total of 1-3 μ l of the probe or 5 μ l of RNA Mrk III was added to 3 μ l of loading buffer. After heating on a 95°C heat block for three minutes, the gel was immediately placed on ice. The wells of gel were flushed, and the sample was loaded and run at 180-250 volts for 45 minutes. The gel was wrapped in plastic wrap (SARANTM brand) and exposed to XAR film with an intensifying screen in a -70°C freezer one hour to overnight.

10 ³³P-Hybridization

A. Pretreatment of frozen sections

- The slides were removed from the freezer, placed on aluminum trays, and thawed at room temperature for 5 minutes. The trays were placed in a 55°C incubator for five minutes to reduce condensation. The slides were fixed for 10 minutes in 4% paraformaldehyde on ice in the fume hood, and washed in 0.5 x SSC for 5 minutes, at room temperature (25 ml 20 x SSC + 975 ml s.c. H₂O). After deproteinization in 0.5 μ g/ml proteinase K for 10 minutes at 37°C (12.5 μ l of 10 mg/ml stock in 250 ml prewarmed RNase-free RNase buffer), the sections were washed in 0.5 x SSC for 10 minutes at room temperature. The sections were dehydrated in 70%, 95%, and 100% ethanol, 2 minutes each.

B. Pretreatment of paraffin-embedded sections

- 20 The slides were deparaffinized, placed in s.c. H₂O, and rinsed twice in 2 x SSC at room temperature, for 5 minutes each time. The sections were deproteinized in 20 μ g/ml proteinase K (500 μ l of 10 mg/ml in 250 ml RNase-free RNase buffer; 37°C, 15 minutes) for human embryo tissue, or 8 x proteinase K (100 μ l in 250 ml RNase buffer, 37°C, 30 minutes) for formalin tissues. Subsequent rinsing in 0.5 x SSC and dehydration were performed as described above.

25 C. Prehybridization

- The slides were laid out in a plastic box lined with Box buffer (4 x SSC, 50% formamide) The filter paper was saturated. The tissue was covered with 50 μ l of hybridization buffer (3.75 g dextran sulfate + 6 ml s.c. H₂O), vortexed, and heated in the microwave for 2 minutes with the cap loosened. After cooling on ice, 18.75 ml formamide, 3.75 ml 20 x SSC, and 9 ml s.c. H₂O were added, and the tissue was vortexed well and incubated at 30 42°C for 1-4 hours.

D. Hybridization

1.0 x 10⁶ cpm probe and 1.0 μ l tRNA (50 mg/ml stock) per slide were heated at 95°C for 3 minutes. The slides were cooled on ice, and 48 μ l hybridization buffer was added per slide. After vortexing, 50 μ l ³³P mix was added to 50 μ l prehybridization on the slide. The slides were incubated overnight at 55°C.

35 E. Washes

Washing was done for 2x10 minutes with 2xSSC, EDTA at room temperature (400 ml 20 x SSC + 16 ml 0.25 M EDTA, V_f=4L), followed by RNaseA treatment at 37°C for 30 minutes (500 μ l of 10 mg/ml in 250 ml RNase buffer = 20 μ g/ml), The slides were washed 2x10 minutes with 2 x SSC, EDTA at room temperature. The

WO 99/21999

PCT/US98/22992

stringency wash conditions were as follows: 2 hours at 55°C, 0.1 x SSC, EDTA (20 ml 20 x SSC + 16 ml EDTA, $V_f=4L$).

F. Oligonucleotides

In situ analysis was performed on DNA sequences disclosed herein. The oligonucleotides employed for these analyses are as follows.

(1) Clone 65.11

p1: 5'-GGA TTC TAA TAC GAC TCA CTA TAG GGC AGC GTT GAC TCA GAA AAA CC-3' (SEQ ID NO:49)

p2: 5'-CTA TGA AAT TAA CCC TCA CTA AAG GGA GCA TAT GAA TTT CAG CCC TAA-3' (SEQ ID NO:50)

(2) Clone 320.50

p3: 5'-GGA TTC TAA TAC GAC TCA CTA TAG GGC ACG CAC ATC TGT TTC CGT TTT-3' (SEQ ID NO:51)

p4: 5'-CTA TGA AAT TAA CCC TCA CTA AAG GGA CCA TCC CCG CTC TCT ACC TA-3' (SEQ ID NO:52)

G. Results

In situ analysis was performed on the above DNA sequences disclosed herein. The results from these analyses are as follows.

(1) Clone 65.11

Expression in Mouse tissues: This clone was expressed in developing spinal ganglia of an E15.5 mouse and in the cardiac valve cusps of an adult mouse.

(2) Clone 320.50

Expression in Mouse tissues: This clone was expressed in the pyramidal cell layer of hippocampus and dentate gyrus of an adult mouse brain. It was also expressed in the lung, renal medulla, and whisker follicles of an E15.5 mouse.

EXAMPLE 5: Use of DNA Encoding Clone 65 and 320 Polypeptides as a Hybridization Probe

The following method describes use of a nucleotide sequence encoding a clone 65 or 320 polypeptide as a hybridization probe.

DNA comprising the coding sequence of full-length human clone 65 (as shown in Figures 5A and 5B, SEQ ID NO:3), or of mouse clone 65 (as shown in Figures 1A and 1B, SEQ ID NO:6), or of full-length mouse clone 320 (the partial sequences shown in Figures 2, 3, and 4; SEQ ID NOS:7, 8, and 9, respectively) is employed as a probe to screen for homologous DNAs (such as those encoding naturally- occurring variants of these particular clone 65 and 320 polypeptides in human tissue cDNA libraries or human tissue genomic libraries.

Hybridization and washing of filters containing either library DNAs is performed under the following high-stringency conditions. Hybridization of radiolabeled clone 65-polypeptide- or clone 320-polypeptide-derived probe to the filters is performed in a solution of 50% formamide, 5x SSC, 0.1% SDS, 0.1% sodium pyrophosphate, 50 mM sodium phosphate, pH 6.8, 2x Denhardt's solution, and 10% dextran sulfate at 42°C for 20 hours. Washing of the filters is performed in an aqueous solution of 0.1x SSC and 0.1% SDS at 42°C.

WO 99/21999

PCT/US98/22992

DNAs having a desired sequence identity with the DNA encoding a full-length, native-sequence clone 65 or 320 polypeptide can then be identified using standard techniques known in the art.

EXAMPLE 6: Expression of Clone 65 or 320 Polypeptide in *E. coli*

This example illustrates preparation of an unglycosylated form of clone 65 or 320 polypeptide by recombinant expression in *E. coli*.

The DNA sequence encoding clone 65 or 320 polypeptide is initially amplified using selected PCR primers. The primers should contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector. A variety of expression vectors may be employed. An example of a suitable vector is pBR322 (derived from *E. coli*; see Bolivar *et al.*, *Gene*, 2:95 (1977)) which contains genes for ampicillin and tetracycline resistance. The vector is digested with restriction enzyme and dephosphorylated. The PCR-amplified sequences are then ligated into the vector. The vector will preferably include sequences which encode an antibiotic-resistance gene, a trp promoter, a polyhis leader (including the first six STII codons, polyhis sequence, and enterokinase cleavage site), the clone 65-coding or clone 320-coding region, lambda transcriptional terminator, and an *argU* gene.

The ligation mixture is then used to transform a selected *E. coli* strain using the methods described in Sambrook *et al.*, *supra*. Transformants are identified by their ability to grow on LB plates, and antibiotic-resistant colonies are then selected. Plasmid DNA can be isolated and confirmed by restriction analysis and DNA sequencing.

Selected clones can be grown overnight in liquid culture medium such as LB broth supplemented with antibiotics. The overnight culture may subsequently be used to inoculate a larger-scale culture. The cells are then grown to a desired optical density, during which the expression promoter is turned on.

After the cells are cultured for several more hours, the cells can be harvested by centrifugation. The cell pellet obtained by the centrifugation can be solubilized using various agents known in the art, and the clone 65 or 320 polypeptide can then be purified using a metal-chelating column under conditions that allow tight binding of the protein.

EXAMPLE 7: Expression of Clone 65 or 320 Polypeptide in Mammalian Cells

This example illustrates preparation of a potentially glycosylated form of clone 65 or 320 polypeptide by recombinant expression in mammalian cells.

The vector, pRK5E, may be employed as the expression vector. The appropriate DNA encoding clone 65 or 320 polypeptide is ligated into pRK5E with selected restriction enzymes to allow insertion of the DNA for clone 65 or 320 polypeptide using ligation methods as described in Sambrook *et al.*, *supra*. The resulting vectors are conveniently referred to generically as pRK5E.clone65 or pRK5E.clone320, respectively, in the general description below.

In one embodiment, the selected host cells may be 293 cells. Human 293 cells (ATCC CCL 1573) are grown to confluence in tissue culture plates in medium such as DMEM supplemented with fetal calf serum and optionally, nutrient components and/or antibiotics. About 10 µg pRK5E.clone65 or pRK5E.clone320 DNA is mixed with about 1 µg DNA encoding the VA RNA gene (Thimmappaya *et al.*, *Cell*, 31:543 (1982)) and dissolved in 500 µl of 1 mM Tris-HCl, 0.1 mM EDTA, 0.227 M CaCl₂. To this mixture is added, dropwise, 500 µl of 50 mM HEPES (pH 7.35), 280 mM NaCl, 1.5 mM NaPO₄, and a precipitate is allowed to form for 10 minutes at 25°C. The precipitate is suspended and added to the 293 cells and allowed to settle for about four hours at 37°C. The culture medium is aspirated off and 2 ml of 20% glycerol in phosphate-buffered saline (PBS) is added for 30 seconds. The

WO 99/21999

PCT/US98/22992

293 cells are then washed with serum-free medium, fresh medium is added, and the cells are incubated for about 5 days.

Approximately 24 hours after the transfections, the culture medium is removed and replaced with culture medium (alone) or culture medium containing 200 $\mu\text{Ci/ml}$ ^{35}S -cysteine and 200 $\mu\text{Ci/ml}$ ^{35}S -methionine. After a 12-hour incubation, the conditioned medium is collected, concentrated on a spin filter, and loaded onto a 15% SDS gel. The processed gel may be dried and exposed to film for a selected period of time to reveal the presence of the clone 65 or 320 polypeptide. The cultures containing transfected cells may undergo further incubation (in serum-free medium) and the medium is tested in selected bioassays.

In an alternative technique, the clone 65 or 320 polypeptide may be introduced into 293 cells transiently using the dextran sulfate method described by Somparyrac *et al.*, Proc. Natl. Acad. Sci., 12:7575 (1981). 293 cells are grown to maximal density in a spinner flask and 700 μg pRK5E.clone65 or pRK5E.clone320 DNA is added. The cells are first concentrated from the spinner flask by centrifugation and washed with PBS. The DNA-dextran precipitate is incubated on the cell pellet for four hours. The cells are treated with 20% glycerol for 90 seconds, washed with tissue culture medium, and re-introduced into the spinner flask containing tissue culture medium, 5 $\mu\text{g/ml}$ bovine insulin, and 0.1 $\mu\text{g/ml}$ bovine transferrin. After about four days, the conditioned media are centrifuged and filtered to remove cells and debris. The sample containing expressed clone 65 or 320 polypeptide can then be concentrated and purified by any selected method, such as dialysis and/or column chromatography.

In another embodiment, the clone 65 or 320 polypeptide can be expressed in CHO cells. The pRK5E.clone65 or pRK5E.clone320 can be transfected into CHO cells using known reagents such as CaPO_4 or DEAE-dextran. As described above, the cell cultures can be incubated, and the medium replaced with culture medium (alone) or medium containing a radiolabel such as ^{35}S -methionine. After determining the presence of the clone 65 or 320 polypeptide, the culture medium may be replaced with serum-free medium. Preferably, the cultures are incubated for about 6 days, and then the conditioned medium is harvested. The medium containing the expressed clone 65 or 320 polypeptide can then be concentrated and purified by any selected method.

Epitope-tagged clone 65 or 320 polypeptide may also be expressed in host CHO cells. The clone 65 or 320 polypeptide may be subcloned out of the pRK5 vector. Suva *et al.*, Science, 237: 893-896 (1987); EP 307,247 published 3/15/89. The subclone insert can undergo PCR to fuse in-frame with a selected epitope tag such as a poly-his tag into a baculovirus expression vector. The poly-his-tagged clone 65 or 320 polypeptide insert can then be subcloned into a SV40-driven vector containing a selection marker such as DHFR for selection of stable clones. Finally, the CHO cells can be transfected (as described above) with the SV40-driven vector. Labeling may be performed, as described above, to verify expression. The culture medium containing the expressed poly-His tagged clone 65 or 320 polypeptide can then be concentrated and purified by any selected method, such as by Ni^{2+} -chelate affinity chromatography.

EXAMPLE 8: Expression of Clone 65 or 320 Polypeptide in Yeast

The following method describes recombinant expression of a clone 65 or 320 polypeptide in yeast.

First, yeast expression vectors are constructed for intracellular production or secretion of a clone 65 or 320 polypeptide from the ADH2/GAPDH promoter. DNA encoding a clone 65 or 320 polypeptide and the promoter is inserted into suitable restriction enzyme sites in the selected plasmid to direct intracellular expression. For secretion, DNA encoding a clone 65 or 320 polypeptide can be cloned into the selected plasmid, together with DNA encoding

WO 99/21999

PCT/US98/22992

the ADH2/GAPDH promoter, a native clone 65 or clone 320 signal peptide or other mammalian signal peptide or yeast alpha-factor or invertase secretory signal/leader sequence, and linker sequences (if needed) for expression.

Yeast cells, such as yeast strain AB110, can then be transformed with the expression plasmids described above and cultured in selected fermentation media. The transformed yeast supernatants can be analyzed by precipitation with 10% trichloroacetic acid and separation by SDS-PAGE, followed by staining of the gels with Coomassie Blue stain.

Recombinant clone 65 or 320 polypeptide can subsequently be isolated and purified by removing the yeast cells from the fermentation medium by centrifugation and then concentrating the medium using selected cartridge filters. The concentrate containing the clone 65 or 320 polypeptide may further be purified using selected column chromatography resins.

EXAMPLE 9: Expression of Clone 65 or 320 Polypeptide in Baculovirus-Infected Insect Cells

The following method describes recombinant expression of a clone 65 or 320 polypeptide in baculovirus-infected insect cells.

The sequence coding for clone 65 or 320 polypeptide is fused upstream of an epitope tag contained within a baculovirus expression vector. Such epitope tags include poly-his tags and immunoglobulin tags (like Fc regions of IgG). A variety of plasmids may be employed, including plasmids derived from commercially available plasmids such as pVL1393 (Novagen). Briefly, the sequence encoding clone 65 or 320 polypeptide or the desired portion of the coding sequence (such as the sequence encoding the mature protein if the protein is extracellular) is amplified by PCR with primers complementary to the 5' and 3' regions. The 5' primer may incorporate flanking (selected) restriction enzyme sites. The product is then digested with those selected restriction enzymes and subcloned into the expression vector.

Recombinant baculovirus is generated by co-transfecting the above plasmid and BaculoGoldTM virus DNA (Pharmingen) into *Spodoptera frugiperda* ("Sf9") cells (ATCC CRL 1711) using lipofectin (commercially available from GIBCO-BRL). After 4 - 5 days of incubation at 28°C, the released viruses are harvested and used for further amplifications. Viral infection and protein expression are performed as described by O'Reilley *et al.*, Baculovirus Expression Vectors: A Laboratory Manual (Oxford: Oxford University Press, 1994).

Expressed poly-his-tagged clone 65 or 320 polypeptide can then be purified, for example, by Ni²⁺-chelate affinity chromatography as follows. Extracts are prepared from recombinant virus-infected Sf9 cells as described by Rupert *et al.*, Nature, 362:175-179 (1993). Briefly, Sf9 cells are washed, resuspended in sonication buffer (25 mL HEPES, pH 7.9; 12.5 mM MgCl₂; 0.1 mM EDTA; 10% glycerol; 0.1% NP-40; 0.4 M KCl), and sonicated twice for 20 seconds on ice. The sonicates are cleared by centrifugation, and the supernatant is diluted 50-fold in loading buffer (50 mM phosphate, 300 mM NaCl, 10% glycerol, pH 7.8), and filtered through a 0.45 µm filter. A Ni²⁺-NTA agarose column (commercially available from Qiagen) is prepared with a bed volume of 5 mL, washed with 25 mL of water, and equilibrated with 25 mL of loading buffer. The filtered cell extract is loaded onto the column at 0.5 mL per minute. The column is washed to baseline A₂₈₀ with loading buffer, at which point fraction collection is started. Next, the column is washed with a secondary wash buffer (50 mM phosphate; 300 mM NaCl, 10% glycerol, pH 6.0), which elutes non-specifically bound protein. After reaching A₂₈₀ baseline again, the column is developed with a 0 to 500 mM imidazole gradient in the secondary wash buffer. One-mL fractions are collected and analyzed by SDS-PAGE and silver staining or Western blot with Ni²⁺-NTA-conjugated to alkaline phosphatase (Qiagen).

WO 99/21999

PCT/US98/22992

Fractions containing the eluted His₁₀-tagged clone 65 or 320 polypeptide are pooled and dialyzed against loading buffer.

Alternatively, purification of the IgG-tagged (or Fc-tagged) clone 65 or 320 polypeptide can be performed using known chromatography techniques, including, for instance, Protein A or protein G column chromatography.

5 EXAMPLE 10: Preparation of Antibodies that Bind Clone 65 or 320 Polypeptide

1. Polyclonal Antibodies

10 Polyclonal antisera are generated in female New Zealand White rabbits against murine and human clone 65 polypeptide and against murine clone 320 polypeptide. The antigens used are proteins fused with histidine or with the Fc portion of IgG. Each protein is homogenized with Freund's complete adjuvant for the primary injection and with Freund's incomplete adjuvant for all subsequent boosts. For the primary immunization and the first boost, 3.3
15 μ g per kg body weight is injected directly into the popliteal lymph nodes as described in Bennett *et al.*, *J. Biol. Chem.*, **266**: 23060-23067 (1991) and "Production of Antibodies by Inoculation into Lymph Nodes" by Morton Sigel *et al.* in *Methods in Enzymology*, Vol. 93 (New York: Academic Press, 1983). For all subsequent boosts, 3.3 μ g per kg body weight is injected into subcutaneous and intramuscular sites. Injections are done every 3 weeks with
15 bleeds taken on the following two weeks.

2. Monoclonal Antibodies

Techniques for producing monoclonal antibodies that can specifically bind a clone 65 or 320 polypeptide are known in the art and are described, for instance, in Goding, *supra*. Immunogens that may be employed include purified clone 65 or 320 polypeptide, fusion proteins containing clone 65 or 320 polypeptide, and cells expressing
20 recombinant clone 65 or 320 polypeptide on the cell surface. Selection of the immunogen can be made by the skilled artisan without undue experimentation.

Mice, such as Balb/c, are immunized with the clone 65 or 320 immunogen emulsified in complete Freund's adjuvant and injected subcutaneously or intraperitoneally in an amount from 1 to 100 micrograms. Alternatively, the immunogen is emulsified in MPL-TDM adjuvant (Ribi Immunochemical Research, Hamilton, MT) and injected
25 into the animal's hind foot pads. The immunized mice are then boosted 10 to 12 days later with additional immunogen emulsified in the selected adjuvant. Thereafter, for several weeks, the mice may also be boosted with additional immunization injections. Serum samples may be periodically obtained from the mice by retro-orbital bleeding for testing in ELISA assays to detect antibodies to clone 65 or 320 polypeptide.

After a suitable antibody titer has been detected, the animals "positive" for antibodies can be injected with
30 a final intravenous injection of a clone 65 or 320 polypeptide. Three to four days later, the mice are sacrificed and the spleen cells are harvested. The spleen cells are then fused (using 35% PEG) to a selected murine myeloma cell line such as P3X63AgU.1, available from ATCC, No. CRL 1597. The fusions generate hybridoma cells which can then be plated in 96-well tissue culture plates containing HAT (hypoxanthine, aminopterin, and thymidine) medium to inhibit proliferation of non-fused cells, myeloma hybrids, and spleen cell hybrids.

35 The hybridoma cells will be screened in an ELISA for reactivity against a clone 65 or 320 polypeptide. Determination of "positive" hybridoma cells secreting the desired monoclonal antibodies against a clone 65 or 320 polypeptide is within the skill in the art.

The positive hybridoma cells can be injected intraperitoneally into syngeneic Balb/c mice to produce ascites containing the anti-clone 65 or 320 polypeptide monoclonal antibodies. Alternatively, the hybridoma cells can be

WO 99/21999

PCT/US98/22992

grown in tissue culture flasks or roller bottles. Purification of the monoclonal antibodies produced in the ascites can be accomplished using ammonium sulfate precipitation, followed by gel-exclusion chromatography. Alternatively, affinity chromatography based upon binding of antibody to protein A or protein G can be employed.

EXAMPLE 11: One Use of Antibodies that Bind Clone 65 or 320 Polypeptide

5 1. Cell lines

The established human breast tumor cells BT474 and MDA-MB-231 (which are available from ATCC) are grown in minimum essential medium (Gibco, Grand Island, NY) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Hyclone, Logan, UT), sodium pyruvate, L-glutamine (2mM), non-essential amino acids, and 2x vitamin solution and maintained at 37°C in 5% CO₂. Zhang *et al.*, Invas. & Metas., 11:204-215 (1991); Price
10 *et al.*, Cancer Res., 50:717-721 (1990).

2. Antibodies

Anti-clone 65 or anti-clone 320 monoclonal antibodies that may be prepared as described above are harvested with PBS containing 25mM EDTA and used to immunize BALB/c mice. The mice are given injections i.p. of 10⁷ cells in 0.5 ml PBS on weeks 0, 2, 5 and 7. The mice with antisera that immunoprecipitated ³²P-labeled
15 Wnt-1 are given i.p. injections of a wheat-germ agglutinin-Sepharose (WGA) purified Wnt membrane extract on weeks 9 and 13. This is followed by an i.v. injection of 0.1 ml of the Wnt-1 preparation and the splenocytes are fused with mouse myeloma line X63-Ag8.653. Hybridoma supernatants are screened for Wnt-1 binding by ELISA and radioimmunoprecipitation. MOPC-21 (IgG1) (Cappell, Durham, NC) is used as an isotype-matched control.

Additionally, the anti-ErbB2 IgG₁κ murine monoclonal antibodies 4D5 (ATCC CRL 10463 deposited May
20 24, 1990) and 7C2, specific for the extracellular domain of ErbB2, may be used with the above antibodies. They are produced as described in Fendly *et al.*, Cancer Research, 50:1550-1558 (1990) and WO89/06692.

3. Analysis of cell cycle status and viability

Cells are simultaneously examined for viability and cell cycle status by flow cytometry on a FACSTAR PLUS™ (Becton Dickinson Immunocytometry Systems USA, San Jose, CA). Breast tumor cells are harvested by
25 washing the monolayer with PBS, incubating cells in 0.05% trypsin and 0.53 mM EDTA (Gibco), and resuspending them in culture medium. The cells are washed twice with PBS containing 1% FBS and the pellet is incubated for 30 minutes on ice with 50 µl of 400 µM 7-aminoactinomycin D (7AAD) (Molecular Probes, Eugene, OR), a vital dye which stains all permeable cells. Cells are then fixed with 1.0 ml of 0.5% paraformaldehyde in PBS and simultaneously permeabilized and stained for 16 hours at 4°C with 220 µl of 10 µg/ml HOECHST 33342™ dye (also
30 a DNA binding dye) containing 5% TWEEN 20™.

The data from 1 x 10⁴ cells are collected and stored using LYSYS II™ software and analyzed using PAINT-A-GATE™ software (Becton Dickinson). Darzynkiewica *et al.*, Cytometry, 13:795-808 (1992); Picker *et al.*, J. Immunol., 150:1105-1121 (1993). The viability and percentage of cells in each stage of the cell cycle are determined on gated single cells using 7AAD and Hoechst staining, respectively. (Cell doublets are excluded by pulse analysis
35 of width vs. area of the Hoechst signal.) Cell numbers are determined using a hemocytometer.

4. Affinity of binding to putative receptor

Radioiodinated anti-clone 65 and anti-clone 320 antibodies are prepared by the Iodogen™ method. Fracker *et al.*, Biochem. Biophys. Res. Comm., 80:849-857 (1978). Binding assays are performed using appropriate receptor-expressing cells cultured in 96-well tissue culture plates (Falcon, Becton Dickinson Labware, Lincoln Park,

WO 99/21999

PCT/US98/22992

N.J.). The cells are trypsinized and seeded in wells of 96-well plates at a density of 10^4 cells/well and allowed to adhere overnight. The monolayers are washed with cold culture medium supplemented with 0.1% sodium azide and then incubated in triplicate with 100 μ l of serial dilutions of ^{125} I-anti-clone 65 or clone 320 antibodies in cold culture medium containing 0.1% sodium azide for 4 hours on ice. Non-specific binding is estimated by the
 5 preincubation of each sample with a 100-fold molar excess of nonradioactive antibodies in a total volume of 100 μ l. Unbound radioactivity is removed by two washes with cold medium containing 0.1% sodium azide. The cell-associated radioactivity is detected in a gamma counter after solubilization of the cells with 150 μ l of 0.1 M NaOH/well. The clone 65 polypeptide and clone 320 polypeptide binding constants (K_D) and anti-clone 65 and anti-clone 320 antibody binding affinities are determined by Scatchard analysis.

10 It is expected that the antibodies against clone 65 and clone 320 polypeptides will affect the growth of these cells.

* * * *

Deposit of Material

The following materials have been deposited with the American Type Culture Collection, 10801 University
 15 Blvd., Manassas, VA, USA (ATCC):

<u>Material</u>	<u>ATCC Dep. No.</u>	<u>Deposit Date</u>
pRK5E.h.WIG-3.65.4A	209536	December 10, 1997
pRK5E.m.WIG-3.65.11.3	209535	December 10, 1997
pRK5E.m.WIG-4.320.9	209534	December 10, 1997

20

These deposits were made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of viable cultures of the deposits for 30 years from the date of deposit. The deposits will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement
 25 between Genentech, Inc. and ATCC, which assures permanent and unrestricted availability of the progeny of the cultures of the deposits to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 USC §122 and the Commissioner's rules pursuant thereto (including 37 CFR §1.14 with particular reference to 886 OG 638).

30 The assignee of the present application has agreed that if a culture of the materials on deposit should die or be lost or destroyed when cultivated under suitable conditions, the materials will be promptly replaced on notification with another of the same. Availability of the deposited materials is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.

35 The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the constructs deposited, since the deposited embodiment is intended as a single illustration of certain aspects of the invention and any constructs that are functionally equivalent are within the scope of this invention. The deposits of materials herein do not constitute an admission that the written description herein contained is inadequate to enable the practice of any aspect of the

WO 99/21999**PCT/US98/22992**

invention, including the best mode thereof, nor is it to be construed as limiting the scope of the claims to the specific illustrations that it represents. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims.

WO 99/21999

PCT/US98/22992

Sequence Listing

<110> Genentech, Inc.

<120> POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME

<130> P1176R1PCT

5 <160> 52

<210> 1

<211> 3960

<212> DNA

<213> Human

10 <400> 1

ctccaacagc gcagggcaga gcggctggcg ccgccggagc gcggagccac 50

gaccctccct ggccgccttt gtctactggc cgtgcggccc ggaaccgcca 100

ctctccaggg ccggggacgc gcccgagct gtcggtgaca gctcctccct 150

accgcaaccc tccggggcgg aggggcggtc gggccggggc ctgctagccc 200

15 gcgaccgcaa gcccgcgctc gcggatcgat gccccgcag cagggggacc 250

ccgcgttccc cgaccgctgc gaggcgcctc cggtgccgcc gcgtcgggag 300

cgcggtggac gcgggggacg cgggcctggg gagccggggg gccggggggc 350

tgcggggggt gccgaggggc gcggcgtaa gtgcgtgctg gtcggcgacg 400

gcgcggtggg caagacgagc ctggtggtga gttacaccac caacggctac 450

20 cccaccgagt acatccctac tgccttcgac aacttctccg cggtggtgtc 500

tgtggatggg cggcccgtga gactccaact ctgtgacact gccggacagg 550

atgaatttga caagctgagg cctctctgct acaccaacac agacatcttc 600

ctgctctgct tcagtgtcgt gagccctca tccttcaga acgtcagtga 650

gaaatgggtg ccggagattc gatgccactg tcccaaagcc cccatcatcc 700

25 tagttggaac gcagtcggat ctgagagaag atgtcaaagt cctcattgag 750

ttggacaaat gcaaagaaaa gccagtgcct gaagaggcgg ctaagctgtg 800

cgccgaggaa atcaaagccg cctcctacat cgagtgttca gccttgactc 850

aaaaaacct caaagaggtc tttgatgcag ccatcgtcgc tggcattcaa 900

tactcggaca ctgagcaaca gccaaagaag tctaaaagca ggactccaga 950

30 taaaatgaaa aaactctcca agtcctggtg gaagaagtac tgctgtttcg 1000

tatgatgctg gcaagacacc cagaaaggct attttcagat gaaatcgata 1050

WO 99/21999

PCT/US98/22992

ttagaagcta tattagctga aacaactcct ttactgcgt agaacctata 1100
 tcgagagtgt gtgtatatgt attataggag gagctctcaa ttttatgtat 1150
 tctttctgcc ttttaattttc ttgtttgttt gagcttaggg atgagatact 1200
 tatgcaagat atttttgaag taaattaaac atttttcaca tctctggaaa 1250
 5 tttagagttc tagacctctg gttaatttat atctaataatg aagaagacac 1300
 ctctaactctg gatgttaaga atgaagttct gctacattat aatgtacaga 1350
 agagcaaaag ggaggaacac tatgggttaac cctctcttga ttaagggcta 1400
 cttaatgcac agtgcattat gtacacaggt caaccatggt aacaatagtt 1450
 cttagctttg aaactccatg caaaccatgc ctttttttta aggagcaaaa 1500
 10 atctgagaaa aaaagtgaga gacctctgcc taaaaactt caaaccagtc 1550
 acttttgtca attgctaata cccagttact tatgatttaa aaacaaccaa 1600
 cagaaaacat cccacagact gtatggcact ctgtagtcaa aaaaggaaac 1650
 tttcttattg ggacttttct ttcttagtcc agttgtgttg acacatatga 1700
 acacagacaa agtgctatgc ggaggaaagc aagtgttggt cagtagtttc 1750
 15 atgttttagg gagtggttcc tgtggagatc agaaagtgc atttgctttc 1800
 ggtactgtaa tacatgcacc aaactgcctc aatcctaggt aacgagggca 1850
 acagggagca cctgtctgga ttgtttttaa acctccatac tcaagctgtc 1900
 tcttcggcag ggaggtgaat actcttgaaa ggccaacagc aagtgtttgt 1950
 gggacacaac acagataatt ttttcttaag tcgaccaaga tgtacttctc 2000
 20 tgtgtgcaca cccatgcaca ctcatgcaca cagatacata ggtctgtatg 2050
 gctgtatttg ctgttgattc agactttcac accattaatg gggaaaagcg 2100
 tggccacaaa aacagatgct aggaagcttg gcttcctctt cttgttgacc 2150
 cttttttgaa ccaacatctt ttttattata ttcagagtat gtttttaagt 2200
 gtatcttaat atatacattt tttaggacat cttaaataa aacaaaaaat 2250
 25 aaaatgaaca tctcttgaaa cctgttataa caaccagtta aagccacaga 2300
 tggctttcag ggcagtagca gcagaggcca gtggactctg aggactcctg 2350
 aggggcgggg cgtgtagcca gccagggtgca tgccgggacc atggcccca 2400
 tacttggtg cttcctgtga cagtgaata catccttcaa ggtggcagct 2450
 gttagggtg aatcttctgg agaaaaaggt gccatctcag gagaatagct 2500

WO 99/21999

PCT/US98/22992

tttactctgg taggaatgct tccgagacac cacaaggcag cctgaacact 2550
 cagttgcagg gtcgggcttg cgggtgggtga cccagagcca ccaaagtcac 2600
 atccacaact aatgagggaa atctgtaaag ccagtttagat agaagagttt 2650
 tatttttctg tgggttttgt gttgtctttt ttatgttaaa aagaaatcca 2700
 5 gtttgtgttt ttctatagaa aaagtaaaag atcagggttat acttttaggtt 2750
 aggggttcta ttatttcctg ttagtaaata aaattaacaa atttctttgt 2800
 ttaacaaaag attaactctt aaaccactaa aatacataga ctgattgatt 2850
 attcaacaca ttggaattga tgtcggtcac agtttcctga agcatttagt 2900
 tacaacctga aggaataaaa tgatttgtgg aaatgcttaa aatagacctt 2950
 10 actgaataca gtctcatctt gccgcgctg gcttacctat ctgtggaaag 3000
 ctaggcttcc caggtgggct ctgcctgtct ggtgcctgga ggtgtgggag 3050
 ggaagatgag ttatttaact ggtaagcgat ttgaaacact atttttatat 3100
 taaagtaaag ggcattggag atagtgcata ttcattttta agatagaaca 3150
 caaaacttga aagaagtttt atgcgtgtga cagtgtatgg ggctgcagtt 3200
 15 ggtctccctg gaggggactt ccacacctcc tgcctttagg ccatgggtgg 3250
 aaagtgtca gtgaagtaca cctgtgtggc ccagttctga aagctttata 3300
 cagttgaatt ttaagtgggg ttgataacac cttggactgt tagtgttaaa 3350
 aatctagtgg gttgacctt aaatgcacag tttttaaaat atattgctgc 3400
 attttataga atagtaaagg tacgattata cttgagattt tcctccattt 3450
 20 ttatttcttc gtgaacatag agtttggggc cgaaaatggt tttaaagtat 3500
 gtgtttgagt taaatataaa gttgggtcac ttcaaagcta aaaaattggt 3550
 aaacttgcag cttggtattg cagagaagat tttataagaa ttttgcttta 3600
 gagaatgcca ctttggctga actacaagtg taggccacca ttataattta 3650
 taaatccagc atacttcaaa actgtttggt atctcttggt accatgtatg 3700
 25 tataaatgga ctttttataa cttgttctc tgcttgacag actcaagaga 3750
 aactaccag gtattacaca agccaaaatg ggagcaaggc cttctctcca 3800
 gactatcgta acctggtgcc ttaccaagtt gtgcttttct gttttcaagt 3850
 gtaaagtatg ttgagcagaa tgttgtactt gaaaatgcta taagttagat 3900
 ggtatgaaat aaattctgac ttatgaatat aaaaaaaaaa aaaaaaaaaa 3950

WO 99/21999

PCT/US98/22992

aaaaaaaaaa 3960

<210> 2

<211> 3960

<212> DNA

5 <213> Human

<400> 2

```

          tttttttttt tttttttttt tttttttttt atattcataa gtcagaattt  50
          atttcatacc atctcactta tagcattttc aagtacaaca ttctgctcaa 100
          catcatttac acttgaaaac agaaaagcac aacttggttaa ggcaccagggt 150
10      tacgatagtc tggagagaag gccttgctcc cattttggct tgtgtaatac 200
          ctgggtagtt tctcttgagt ctgtcaagca gagaacaagg ttataaaagg 250
          tccatttata catacatggt aacaagagat aacaaacagt tttgaagtat 300
          gctggattta taaattataa tgggtggccta cacttgtagt tcagccaaag 350
          tggcattctc taaagcaaaa ttcttataaa atcttctctg caataccaag 400
15      ctgcaagttt aacaattttt tagctttgaa gtgaaccaac tttatatatta 450
          actcaaacac atacttttaa aacatttttcg gcccacaaact ctatgttcac 500
          gaagaaataa aaatggagga aaatctcaag tataatcgta cctttactat 550
          tctataaaat gcagcaatat attttaaaaa ctgtgcattt aaagggtcaac 600
          ccactagatt tttaacacta acagtccaag gtgttatcaa cccacttaa 650
20      aattcaactg tataaagctt tcagaactgg gccacacagg tgtacttcac 700
          tgagcacttt ccacccatgg cctaaaggca ggagggtgtg aagtcccctc 750
          cagggagacc aactgcagcc ccatacactg tcacacgcat aaaacttctt 800
          tcaagttttg tgttctatct taaaaatgaa tttgcastat actccatgcc 850
          atttacttta atataaaaaat agtgtttcaa atcgcttacc agttaataa 900
25      ctcatcttcc ctcccacacc tccaggcacc agacaggcag agcccacctg 950
          ggaagcctag ctttccacag ataggtaagc caggcgcggc aagatgagac 1000
          tgtattcagt taggtctatt ttaagcattt ccacaaatca ttttattcct 1050
          tcaggttgta actaaatgct tcaggaaact atgaccgaca tcaattccaa 1100
          tgtgttgaat aatcaatcag tctatgtatt ttagtggttt aaagattaat 1150
30      cttttgttaa acaaagaaat ttgttaattt tatttactaa caggaataaa 1200
          tagaaccctt aacctaaagt ataacctgat cttttacttt ttctatagaa 1250

```

WO 99/21999

PCT/US98/22992

aaacacaaac tggatttctt tttaacataa aaaagacaac acaaaaccca 1300
 cagaaaaata aaactcttct atctaactgg ctttacagat ttccctcatt 1350
 agttgtggat gtgacttttg tggctctggg tcacccaccg caagcccgac 1400
 cctgcaactg agtgttcagg ctgccttggt gtgtctcgga agcattccta 1450
 5 ccagagtaaa agctattctc ctgagatggc acctttttct ccagaagatt 1500
 cagccctaac agctgccacc ttgaaggatg tatttcactg tcacaggaag 1550
 cagccaagta tggggggccat ggtcccggca tgcacctggc tggctacacg 1600
 ccccgccctt caggagtect cagagtccac tggcctctgc tgctactgcc 1650
 ctgaaagcca tctgtggctt taactgggtg ttttaacagg tttcaagaga 1700
 10 tgttcatttt attttttggt tagatttaag atgtcctaaa aaatgtatat 1750
 attaagatac acttaaaaac atactctgaa tataataaaa aagatgttgg 1800
 ttcaaaaaag ggtcaacaag aagaggaagc caagcttcct agcatctggt 1850
 tttgtggcca cgcttttccc cattaatggt gtgaaagtct gaatcaacag 1900
 caatacagc catacagacc tatgtatctg tgtgcatgag tgtgcatggg 1950
 15 tgtgcacaca gagaagtaca tcttggtcga cttagaanaa aattatctgt 2000
 gttgtgtccc acaaacactt gctgttggcc tttcaagagt attcacctcc 2050
 ctgccgaaga gacagcttga gtatggaggt ttaaaaacaa tccagacagg 2100
 tgctccctgt tgccctcggt acctaggatt gaggcagttt ggtgcatgta 2150
 ttacagtacc gaaagcaaat gtcactttct gatctccaca ggaaccactc 2200
 20 cctaaaacat gaaactactg accaacactt gctttcctcc gcatagcact 2250
 ttgtctgtgt tcatatgtgt caacacaact ggactaagaa agaaaagtcc 2300
 caataagaaa gtttcctttt ttgactacag agtgccatac agtctgtggg 2350
 atgttttctg ttggttggtt ttaaatcata agtaactggg tattagcaat 2400
 tgacaaaagt gactggtttg aagttttgta ggcagaggtc tctcactttt 2450
 25 tttctcagat ttttgctcct taaaaaaaag gcatggtttg catggagttt 2500
 caaagctaag aactattggt accatgggtg acctgtgtac ataatgcact 2550
 gtgcattaag tagcccttaa tcaagagagg gttaaccata gtgttctctc 2600
 cttttgctct tctgtacatt ataatgtagc agaacttcat tcttaacatc 2650
 cagattagag gtgtcttctt catattagat ataaattaac cagaggtcta 2700

WO 99/21999

PCT/US98/22992

gaactctaaa tttccagaga tgtgaaaaat gtttaattta cttcaaaaat 2750
 atcttgcata agtatctcat ccctaagctc aaacaaacaa gaaaattaaa 2800
 ggcagaaaga atacataaaa ttgagagctc ctctataat acatatacac 2850
 acactctcga tataggttct acgcagtaaa aggagttggt tcagctaata 2900
 5 tagcttctaa tatcgatttc atctgaaaat agcctttctg ggtgtcttgc 2950
 cagcatcata cgaaacagca gtacttcttc caccaggact tggagaggtt 3000
 tttcatttta tctggagtcc tgcttttaga cttctttggc tgttgctgag 3050
 tgtccgagta ttgaatgcca gcgacgatgg ctgcatcaaa gacctctttg 3100
 aggttttttt gagtcaaggc tgaacactcg atgtaggagg cggctttgat 3150
 10 ttctcggcg cacagcttag ccgcctcttc aggcactggc ttttctttgc 3200
 atttgtccaa ctcaatgagg actttgacat cttctctgag atccgactgc 3250
 gttccaacta ggatgatggg ggctttggga cagtggcatc gaatctccgg 3300
 caccatttc tctactgacgt tctggaagga tgaggggctc acgacactga 3350
 agcagagcag gaagatgtct gtgttggtgt agcagagagg cctcagcttg 3400
 15 tcaaattcat cctgtccggc agtgtcacag agttggagtc tcacggggccg 3450
 cccatccaca gacaccaccg cggagaagtt gtcgaaggca gtagggatgt 3500
 actcgggtggg gtagccgttg gtggtgtaac tcaccaccag gctcgtcttg 3550
 cccaccgcgc cgtcgcgcgc cagcacgcac ttgacgccgc gccctcggc 3600
 accccccgca cgtccccggc cccccggctc cccaggcccc cgtccccgc 3650
 20 gtccaccgcg ctcccgacgc ggcggcaccg gaggcgcctc gcagcggtcg 3700
 gggaaacgcg ggtccccctg ctgcgggggc atcgatccgc gacgcggggc 3750
 ttgcggtcgc gggctagcag ggccccggcc gaccgcccct ccgccccgga 3800
 gggttgcggt agggaggagc tgtcaccgac agctgcgggc gcgtccccgg 3850
 ccctggagag tggcggttcc gggccgcacg gccagtagac aaaggcggcc 3900
 25 agggagggtc gtggctccgc gctccggcgg cgcagccgc tctgccttgc 3950
 gctggttgag 3960

<210> 3

<211> 258

<212> PRT

30 <213> Human

<400> 3

WO 99/21999

PCT/US98/22992

	Met	Pro	Pro	Gln	Gln	Gly	Asp	Pro	Ala	Phe	Pro	Asp	Arg	Cys	Glu	
	1				5					10					15	
	Ala	Pro	Pro	Val	Pro	Pro	Arg	Arg	Glu	Arg	Gly	Gly	Arg	Gly	Gly	
					20					25					30	
5	Arg	Gly	Pro	Gly	Glu	Pro	Gly	Gly	Arg	Gly	Arg	Ala	Gly	Gly	Ala	
					35					40					45	
	Glu	Gly	Arg	Gly	Val	Lys	Cys	Val	Leu	Val	Gly	Asp	Gly	Ala	Val	
					50					55					60	
10	Gly	Lys	Thr	Ser	Leu	Val	Val	Ser	Tyr	Thr	Thr	Asn	Gly	Tyr	Pro	
					65					70					75	
	Thr	Glu	Tyr	Ile	Pro	Thr	Ala	Phe	Asp	Asn	Phe	Ser	Ala	Val	Val	
					80					85					90	
	Ser	Val	Asp	Gly	Arg	Pro	Val	Arg	Leu	Gln	Leu	Cys	Asp	Thr	Ala	
					95					100					105	
15	Gly	Gln	Asp	Glu	Phe	Asp	Lys	Leu	Arg	Pro	Leu	Cys	Tyr	Thr	Asn	
					110					115					120	
	Thr	Asp	Ile	Phe	Leu	Leu	Cys	Phe	Ser	Val	Val	Ser	Pro	Ser	Ser	
					125					130					135	
20	Phe	Gln	Asn	Val	Ser	Glu	Lys	Trp	Val	Pro	Glu	Ile	Arg	Cys	His	
					140					145					150	
	Cys	Pro	Lys	Ala	Pro	Ile	Ile	Leu	Val	Gly	Thr	Gln	Ser	Asp	Leu	
					155					160					165	
	Arg	Glu	Asp	Val	Lys	Val	Leu	Ile	Glu	Leu	Asp	Lys	Cys	Lys	Glu	
					170					175					180	
25	Lys	Pro	Val	Pro	Glu	Glu	Ala	Ala	Lys	Leu	Cys	Ala	Glu	Glu	Ile	
					185					190					195	
	Lys	Ala	Ala	Ser	Tyr	Ile	Glu	Cys	Ser	Ala	Leu	Thr	Gln	Lys	Asn	
					200					205					210	
30	Leu	Lys	Glu	Val	Phe	Asp	Ala	Ala	Ile	Val	Ala	Gly	Ile	Gln	Tyr	
					215					220					225	
	Ser	Asp	Thr	Gln	Gln	Gln	Pro	Lys	Lys	Ser	Lys	Ser	Arg	Thr	Pro	
					230					235					240	
	Asp	Lys	Met	Lys	Asn	Leu	Ser	Lys	Ser	Trp	Trp	Lys	Lys	Tyr	Cys	
					245					250					255	
35	Cys	Phe	Val													
					258											
	<210>	4														
	<211>	2251														
	<212>	DNA														
40	<213>	Mouse														

WO 99/21999

PCT/US98/22992

<400> 4

atggccccgc agcaaggccg gccggcgctg cccgccccgct gcgagccgcc 50
 ggcggcgccg ccggtaccgc ctccgagaga gcgcgggggg cgcgggggcg 100
 gcggggcccg ggtgtccggg ggtcgggggc gcgcggggcg cgccgagggg 150
 5 cgcgggcgtca agtgcggtgt ggtcggcgac ggcgcggtgg gcaagaccag 200
 cctggtggtc agctacacca ctaacggcta cccaccgag tacatcccta 250
 cggccttcga caacttctcg gccgtggtgt ctgtagatgg gcggcctgtg 300
 agactccagc tctgtgacac tgcaggacag gatgagtttg acaagctgag 350
 gccctctgc tacaccaaca cagacatctt cctgctgtgc ttcagcgtgg 400
 10 tgagccccac atccttccag aacgtgggcg agaagtgggt tccagagatt 450
 cgacgtcact gcccaaaggc ccccatcatc ctggtcggga cacagtcgga 500
 cctcagggag gacgtcaaag tgctcataga actggacaag tgcaaagaga 550
 agccggtgcc tgaagaggcg gcgaagctgt gcgcggagga agtcaaagct 600
 gtctcctaca tcgagtgtc agcgttgact cagaaaaacc tcaaagaggt 650
 15 ttccgacgcc gccattgttg ctggtatcca gcactcagac tcccagctac 700
 agccaaagaa gtctaaaagc aggaccccg ataaggtgcg ggacctgtcc 750
 aagtcttggg ggaggaagta ttgctgctg gcctgactct cgcaaatagc 800
 aggtgtttta gctgcaacag ctctttatgg acgaggctgt cataggatga 850
 gccccaaagc accctcttct gcccttaact tcctgtgtgc gggagcttag 900
 20 ggctgagatt catatgcaaa atacgttttt ttaaaaattg aaagttacat 950
 ttttttctg ttaagtctgg aagctttgag ctgtagacct ccggattaat 1000
 ttatattcca tatgaaaagg gctcttcaaa gcgggggtgt agcatgaagt 1050
 tctgctgtgt tgtacaggac aaaggagaat gaatgggacc ttctcctgat 1100
 taagggttac tgagggtca gtgcaggga cgtgtgcacc aggcttgggtg 1150
 25 agagtgagca agcgtgagct ttgaaaccac acgagccacc cccggttttg 1200
 taagggcaaa gatctgaaac cagcaagggc cttctgctta cgaaacctcg 1250
 agcccatccc ttctgtttac tcagattctc ttaggatttt aaaacaacca 1300
 aacatcccac agcctactgg catagtgttg gcgaacagtg cacttgcttg 1350
 ttacggtttt gttttgtttt tttaaatacac gtgaccagtt atattgctat 1400
 30 gaaaatgggtg gagatgcctc gtagaaggcg agtgctgggt gcacatgtga 1450

WO 99/21999

PCT/US98/22992

ctttttcttc agggagcgac tcatggtgag accagagagg gctcttagct 1500
 tgcaggactg gcttctgcag ggcattctgtg tcctgctgtt aaaagcagga 1550
 ggagggtgctt gtctgggagc tttaagtgtg ctgggctcat atcgtcccgt 1600
 ttgcaaggaa ttggggccacc ttgagaggcc atagttagtg gctatgggac 1650
 5 acacacacac tttttcetta agtccaccaa aatgcctgcc tgtacacaca 1700
 cacacacaca cacacacaca cacacacaca cacactggct ggtttgctga 1750
 tggaaccctt agaccaccct cccaccccca cccctcccca agcatggctg 1800
 caagtgtcag ggcaccacac cttcctcttc ttgacatttc tttgaacaga 1850
 catcattttg taggatctta atttatacat ttttttcagg tcataaaatg 1900
 10 tgggatgaac atactttgaa cccagtgcc ttcagggtcc attgactagg 1950
 gaggcactgt cttaggggac aggtatgtgc aaggccttac ccaccagtgg 2000
 cttctcgctg caggatcatgt ttgtggcact tgttctttaa ggtgagggtc 2050
 ttatgaccga ctgttctgag acagccctgt gtcaggcaag ctctttcaca 2100
 gggttgtagg tatttccaag acgcatagg aaccagacag tgaatcatag 2150
 15 ctatcagttt gctgtgggca aggaacctct ttttggccac ctggtaacaa 2200
 aattttatgt ctgtaaattt tttcttgcta tttaaaaaaa aaaaaaaaaa 2250
 a 2251
 <210> 5
 <211> 2251
 20 <212> DNA
 <213> Mouse
 <400> 5
 tttttttttt ttttttttaa atagcaagaa aaaatttaca gacataaaat 50
 tttgttacca ggtggccaaa aagagggtcc ttgcccacag caaactgata 100
 25 gctatgattc actgtctggt tcctatggcg tcttggaat acctacaacc 150
 ctgtgaaaga gcttgccctga cacagggctg tctcagaaca gtcggtcata 200
 agaccctcac cttaaagaac aagtgccaca aacatgacct gcagcgagaa 250
 gccactggtg ggtaaggcct tgcacatacc tgtcccctaa gacagtgcct 300
 ccctagtcaa tggaccctga aggcactggg gttcaaagta tgttcatccc 350
 30 acattttatg acctgaaaaa aatgtataaa ttaagatcct acaaaatgat 400
 gtctgttcaa agaaatgtca agaagaggaa ggtgtggtgc cctgacactt 450

WO 99/21999

PCT/US98/22992

gcagccatgc ttggggaggg gtgggggtgg gagggtggtc taagggttcc 500
 atcagcaaac cagccagtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt 550
 gtgtgtgtac aggcaggcat tttggtggac ttaaggaaaa agtgtgtgtg 600
 tgtcccatag ccatcaacta tggcctctca aggtggccca attccttgca 650
 5 aacgggacga tatgagccca gcacacttaa agtcccaga caagcacctc 700
 ctcttgcttt taacagcagg acacagatgc cctgcagaag ccagtcctgc 750
 aagctaagag ccctctctgg tctcaccatg agtcgtccc tgaagaaaat 800
 gtcacatgtg caccagcac tcgccttcta cgaggcatct ccaccatttt 850
 catagcaata taactgggtca cgtgatttaa aaaaacaaaa caaaaccgta 900
 10 acaagcaagt gcactgttcg ccaacactat gccagtaggc tgtgggatgt 950
 ttggttggtt taaaatccta agagaatctg agtaaacaga agggatgggc 1000
 tcgaggtttc gtaagcagaa ggcccttgct ggtttcagat ctttgccctt 1050
 aaaaaaccgg ggggtggctcg tgtggtttca aagctcacgc ttgctcactc 1100
 tcaccaagcc tgggtgcacac gtgccctgca ctgagccctc agtagccctt 1150
 15 aatcaggaga aggtcccatt cattctcctt tgtcctgtac aacacagcag 1200
 aacttcatgc tgacaccccg ctttgaagag cccttttcat atggaatata 1250
 aattaatccg gaggtctaca gctcaaagct tccagactta acagaaaaaa 1300
 aatgtaactt tcaattttta aaaaaacgta ttttgcatat gaatctcagc 1350
 cctaagctcc cgcacacagg aagttaaggg cagaagaggg tgctttgggg 1400
 20 ctcatcctat gacagcctcg tccataaaga gctgttgagc cttaaacc 1450
 tgctatttgc gagagtcagg ccaggcagca atacttcctc caccaagact 1500
 tggacaggtc ccgcacctta tccgggggtcc tgctttttaga cttctttggc 1550
 tgtagctggg agtctgagtg ctggatacca gcaacaatgg cggcgtcgaa 1600
 aacctctttg aggtttttct gagtcaacgc tgagcactcg atgtaggaga 1650
 25 cagctttgac ttcctccgcg cacagcttcg ccgcctcttc aggcaccggc 1700
 ttctctttgc acttgtccag ttctatgagc actttgacgt cctccctgag 1750
 gtccgactgt gtcccgacca ggatgatggg ggcctttggg cagtgcgctc 1800
 gaatctctgg aaccacttc tcgcccacgt tctggaagga tgtggggctc 1850
 accacgctga agcacagcag gaagatgtct gtgttggtgt agcagagggg 1900

WO 99/21999

PCT/US98/22992

cctcagcttg tcaaactcat cctgtcctgc agtgtcacag agctggagtc 1950
 tcacaggccg cccatctaca gacaccacgg ccgagaagtt gtcgaaggcc 2000
 gtagggatgt actcgggtggg gtagccgtta gtggtgtagc tgaccaccag 2050
 gctgggtcttg cccaccgcgc cgtcgccgac cagcacgcac ttgacgccgc 2100
 5 gtccctcggc gccgcccgcg cgcccccgac ccccggaacac cccggggccc 2150
 cgcgccccgc gccccccgcg ctctcggcga ggcgggtaccg gcggcgccgc 2200
 cggcggctcg cagcggggcgg gcagcgccgg ccggccttgc tgcggggcca 2250
 t 2251

<210> 6
 10 <211> 261
 <212> PRT
 <213> Mouse

<400> 6
 Met Ala Pro Gln Gln Gly Arg Pro Ala Leu Pro Ala Arg Cys Glu
 15 1 5 10 15
 Pro Pro Ala Ala Pro Pro Val Pro Pro Arg Arg Glu Arg Gly Gly
 20 20 25 30
 Arg Gly Ala Arg Gly Pro Gly Val Ser Gly Gly Arg Gly Arg Ala
 35 40 45
 Gly Gly Ala Glu Gly Arg Gly Val Lys Cys Val Leu Val Gly Asp
 20 50 55 60
 Gly Ala Val Gly Lys Thr Ser Leu Val Val Ser Tyr Thr Thr Asn
 65 70 75
 Gly Tyr Pro Thr Glu Tyr Ile Pro Thr Ala Phe Asp Asn Phe Ser
 25 80 85 90
 Ala Val Val Ser Val Asp Gly Arg Pro Val Arg Leu Gln Leu Cys
 95 100 105
 Asp Thr Ala Gly Gln Asp Glu Phe Asp Lys Leu Arg Pro Leu Cys
 110 115 120
 Tyr Thr Asn Thr Asp Ile Phe Leu Leu Cys Phe Ser Val Val Ser
 30 125 130 135
 Pro Thr Ser Phe Gln Asn Val Gly Glu Lys Trp Val Pro Glu Ile
 140 145 150
 Arg Arg His Cys Pro Lys Ala Pro Ile Ile Leu Val Gly Thr Gln
 35 155 160 165
 Ser Asp Leu Arg Glu Asp Val Lys Val Leu Ile Glu Leu Asp Lys
 170 175 180

WO 99/21999

PCT/US98/22992

	Cys	Lys	Glu	Lys	Pro	Val	Pro	Glu	Glu	Ala	Ala	Lys	Leu	Cys	Ala	
					185					190					195	
	Glu	Glu	Val	Lys	Ala	Val	Ser	Tyr	Ile	Glu	Cys	Ser	Ala	Leu	Thr	
					200					205					210	
5	Gln	Lys	Asn	Leu	Lys	Glu	Val	Phe	Asp	Ala	Ala	Ile	Val	Ala	Gly	
					215					220					225	
	Ile	Gln	His	Ser	Asp	Ser	Gln	Leu	Gln	Pro	Lys	Lys	Ser	Lys	Ser	
					230					235					240	
10	Arg	Thr	Pro	Asp	Lys	Val	Arg	Asp	Leu	Ser	Lys	Ser	Trp	Trp	Arg	
					245					250					255	
	Lys	Tyr	Cys	Cys	Leu	Ala										
					260	261										

<210> 7
 <211> 2822
 15 <212> DNA
 <213> Mouse

<400> 7
 cccacgcgtc cgctgaatgt atgttggtta gaaagtagcc tttctgcttc 50
 ctgcccattgg ccagttctcc accctctctt tgggtgttctt tgtggggagg 100
 20 gcactgtggt ttgtcgcagc cctggacttc gagaggctcc cagaacccag 150
 gatcaccagc ctctgtctg tttgcttcac tcctttccca gggaggactt 200
 gggactgtcc tgtctgacag gacggatctg agttcccgaa gcaaaccagc 250
 tcaccacata gatagctagt ttaaacaatg ttttaaaata agggcacctc 300
 tgtttcaaaa gtgacatctg ctgtgttggt ttcgaggcct gatactctta 350
 25 caaggtttga aaaaaaatgt gtgtatccat tcatgggctt ggtagccttc 400
 tggtcacctc agtcctgtgg ctcttaactt attgcccac aatattcatt 450
 tcccctcagc tacaatgaat tgcaagcaaa agatgttgaa aaaaagcact 500
 aatttagttt aaaatgtcac tttttggttt ttattctaca aaaaccatga 550
 agttctctct ctctctctct ctctctctta gttgttaaata cagattatgt 600
 30 tctttttttg tttttgtttt tagtgattca tgtttatgag cagagtggag 650
 ttttaacaatc ctagctttta aaaaaaccta tttaatgtaa gatattctac 700
 gcacccctca gatattttgt atatccccta tggccttttag tctgtacttt 750
 taatgtacat atttctgtct tgtgtgattt gtagatttca ctgggttaaaa 800
 gagagaacat tgaaaggctt atgccaagtg gaagatagaa tataaaataa 850

WO 99/21999

PCT/US98/22992

aaatgttact tgtatattgg taagaggttt cagttgtcct tcagctaatt 900
 catgtagaga aatatttttag ttgaagccac aagagacagc ttagggcagt 950
 tatgtgttca aataacagaa gaacagactt tttttttttt ttaaaccaaa 1000
 cccaaactgt tgggaaacct caatagagct ctatatgtat tggaacaaaa 1050
 5 gtggaattct cttctcctat atatgttcct tcaaaaagag agagagaatc 1100
 aagcagatgg cttaaagctg gtcacaggat tgctcacatt cttttggcat 1150
 tatgcatgcg acttaattgt ttgagagtgt gttgctattg taacatccca 1200
 gagatgaatc aaaaaggctc accctctcac ccaggagcag cttttcagct 1250
 tatatacaca tgcattgtaca tgtgtgtgat atgcatgtgt gcatgcatgt 1300
 10 ttgtattttt gtgcttgcca ctataactat tgcacctctc tattcggttt 1350
 gactgaagag gggctcttggt ggacatctct gtgtcccagt ctttatggga 1400
 agaaagcaag ggtctgcaga gaacaggaac taaagaatcc ctgtgtgatg 1450
 tgcaattaat agaaggctc ctgctttctg gaaatgtaga ccagaatctg 1500
 gccaggactg tagactgata cattatctgg tcctttgcct ttttcttttc 1550
 15 cctccctgcc cctccccctc ttgctttatg gataaccttg taacatattg 1600
 aaacctttaa aggaaaccaa gaatgcatta ttacacacac acacacacac 1650
 acacacacac acacacacac acacacacta cagtagacca acatatagag 1700
 tgtttaaaat agcttttctg ggcaaattca aacaacttgt ggctctagga 1750
 cgcacatctg tttccgtttt tcttcagttg tatattgacc agtattcttt 1800
 20 attgctaaaa catatactcg gggtagcaat gtcagcatct tttcccttcc 1850
 catcctggag agcattcaag accttcccag tacaggaaca tcaatgaagc 1900
 atttatatac aggcggtggc aagcagaacc acatccaaaa tggtcagtgt 1950
 cgggctctag ggcaaggcta tcttgttcca gtctgtttc tttgtgctcc 2000
 tgacctttgg ggctgccact tcccaggacg accactgcct gccacactg 2050
 25 tccccccctc ccccggggg gattttccca atagccagtt cccatgtgtc 2100
 tttttctgca acggtattca agccaatgga accttcagat agggcccaag 2150
 agcaggatga cacaacctgt ggacaagagc tatattaact tgatcactag 2200
 tatgagctaa tattaacatg atcacccatg aaaggcgcct gcaagagctg 2250
 tttagtctga aatataggta gagagcgggg atggcaaggt tgcttgtaac 2300

WO 99/21999

PCT/US98/22992

ttctggtaca tgttgaatgc acacacgcat ggaggcaagc tctaaatcac 2350
 tgcactgtta ctgtaaagca tactttaaaa atatttattg ttttgaaaag 2400
 cattttctag tcttccctct cttggtggag ctgtaaacia gatggcatgt 2450
 tgtgaagggt caagatgatt tttttttaaa tgcagaaac atttagacac 2500
 5 ctaagaacta aaacttataa aagggatctt tgaatttgcc tgttaacatg 2550
 gattaatgtt tacacttaca gctgatgatt ggacgggtgtt ttatgttagg 2600
 gaaatgcctt gttaacgaac ttcataagc agatgtaatt aaagggtgat 2650
 gtgagccaat ctagaagggt gaacagtgtt ttcaaagaac ggagagactt 2700
 acattttaga ccaatcttta tacattttgc tgagctagaa aggagataaa 2750
 10 gattatttat ttttgttcat atcttgact tttctattaa aatcatttta 2800
 tgaaawmmaa aaaaaaaaaa aa 2822

<210> 8

<211> 727

<212> DNA

15 <213> Mouse

<400> 8

cccacgcgtc cgcataatgtc tcctttgtga ggatcaacag ctgcctggca 50
 gtggcggctt acgaggatgg gatccttaac atttgggacc tgagaaccgg 100
 aaggttccct atctttcgtt ttgagcatga cgcaagaata caagcccttg 150
 20 cgctgagcca agaaaagccc attgttgcca cggcttctgc ttttgacgtt 200
 gtgatgttgt accccaacga ggaggggcat tggcatgtgg cctcggagtt 250
 tgaagttcag aagctggttg actacctga aatagttccg aatactggga 300
 ggtaccctgt ggcaatagcc acagccgggg atctgggtgta cctgctgaag 350
 gccgacgact cagccagaac ccttcattat gtcaatggcc agcctgccac 400
 25 atgtctggat gtctcagcca gccagggtgc ctttggagtg aagagtctag 450
 gatgggtgta tgaaggaaac aagatcctgg tgtacagcct ggaagcagag 500
 cgctgcctct cgaagctggg caatgcactt ggagacttta cctgtgtcaa 550
 catccgggat agccctccca acctcatggt cagcggcaac atggacagga 600
 gagtgaggat tcatgacctc cgcagcgata agatcgccct gtcgctgtct 650
 30 gccatcagc tgggggtgtc cgcaattcca aatggataac tggaaagggt 700
 gtcagtggag gccaggagg gtggtgt 727

WO 99/21999

PCT/US98/22992

<210> 9
 <211> 2526
 <212> DNA
 <213> Mouse

5 <400> 9
 cccacgcgtc cgcatatgtc tcctttgtga ggatcaacag ctcgctggca 50
 gtggcggctt acgaggatgg gatccttaac atttgggacc tgagaaccgg 100
 aaggttccct atctttcgtt ttgagcatga cgcaagaata caagcccttg 150
 cgctgagcca agaaaagccc attgttgcca cggtttctgc ttttgacgtt 200
 10 gtgatgttgt accccaacga ggaggggcat tggcatgtgg cctcggagtt 250
 tgaagttcag aagctggttg actaccttga aatagttccg aatactggga 300
 ggtaccctgt ggcaatagcc acagccgggg atctgggtgta cctgctgaag 350
 gccgacgact cagccagaac ccttcattat gtcaatggcc agcctgccac 400
 atgtctggat gtctcagcca gccaggttgc ctttggagtg aagagtctag 450
 15 gatgggtgta tgaaggaaac aagatcctgg tgtacagcct ggaagcagag 500
 cgctgcctct cgaagctggg caatgcactt ggagacttta cctgtgtcaa 550
 catccgggat agccctccca acctcatggt cagcggcaac atggacagga 600
 gagtgaggat ccatgacctc cgcagcgata agatcgccct gtcgctgtct 650
 gcccatcagc tgggggtgtc cgcagtccag atggatgact ggaaggttgt 700
 20 cagtggaggc gaggaggggc tgggtgtctgt gtgggattac cgcatgaacc 750
 agaagctgtg ggaagtgcac tccaggcacc ctgtgcgcta tctctccttc 800
 aatagccaca gcctcatcac tgccaacgtg ccctacgaga aggtgctgcg 850
 aaactccgac ctcgacaact ttgcctgtca caggagacat cgtggcctga 900
 tccatgccta tgaatttgct gtggaccagc tggcctttca gagccccctt 950
 25 cctgtctgcc gcttaccctg tgacatcatg gctggataca gctatgacct 1000
 cgcactgtct ttcccccatg acagtattta ggggtgtcacc tcatgtagac 1050
 gtggaaaggg cagttttaca aatgttagag ttggagagag gctctgcagc 1100
 acatgggtggg agtttgggga cagtgtcctg tatgactgtg gccacacagc 1150
 cctgttgccc tgtacagaac cagactccat tgctgccttt ctctcctcc 1200
 30 tcctcctcct caggctttgg taggactggc tgatgactca gagttaacct 1250
 ttccaggggt ggctcctccc cctcagccta tggcagcagt gacaccccc 1300

WO 99/21999

PCT/US98/22992

ctcgttccat aggccaggga cacagggcct tcacttgac tgtctcctgg 1350
 gtgtggtgct gaggggtggaa ccagaatctc acacgcatag gcaagcgtca 1400
 gcctccaagc tgcctcccca gctgtcagcc tccccagctg tctcctccag 1450
 gcaccctcca gtgcagcccc tcctctggga ttcacaccgt tgataattat 1500
 5 agggccacct tacctgtagg agctgttctg tcctgtacat gtgctatgaa 1550
 ggagacagcc atccttcctg cagagggaaa gggtcattgc acagggatag 1600
 ggtcagtctc caagcctagc cgggtggtgtc tcttcctgac aaacgcagcc 1650
 atagctcacc cactctgcct tcagagtgtc atggacaaat ccacacatag 1700
 tggccaggag acccagtcag agctcttcag aatccccaca gaccaggcac 1750
 10 ctaacacacc tgcacagagg ccaccaggtc tcaggagaca aagttcctct 1800
 cccagggaaat accagctcaa aaaacaagtg ggctggcaaa ctccacattg 1850
 ggtctgccga gagcaagaaa aaagaggggg gtgggggagc tccatgggggt 1900
 ggatcccagg ctggcagcag gaagggtgctg gaaggcctga gaggggtgtgc 1950
 agtgccctcc ccgagccctg gtgggtctcct cctgtgtgct gggatggagt 2000
 15 ctagtggggtt tgtggcatga tctcagatct tggcattgag gcctctcccc 2050
 atgcacaagt gcccagggga gctcacctcc ctcttgctgg gctggcgccc 2100
 cctgctggcc tgggtcttgc gtgtcctcac tcgagcattc ccagtcctaa 2150
 gctgtccact ggagacattt ctgtcagaga aattggctgt gcggtcagct 2200
 cctttctggg cttcgcagcc atgaaaggcc actgaagagc agaggtgact 2250
 20 agagtagttt caagcataca tgcccttcta gcccacaatc cctgccccct 2300
 acccccacag agcatctgtc ctcgctgggt cctgccactg cacctgctcc 2350
 caggggtgggg gacaggctgg ctccctgtgc tgctctgaa gccagaagac 2400
 accaggacac agccctggga gccaggggtg gtcacacatc tgcagcttgc 2450
 cttttgcctt aagcggccac ttctgctctg ttattaaagg ttctacactg 2500
 25 aaaaaaaaaa aaaaaaaaaa aaaaaa 2526

<210> 10

<211> 2526

<212> DNA

<213> Mouse

30 <400> 10

tttttttttt tttttttttt ttttttcagt gtagaacctt taataacaga 50

WO 99/21999

PCT/US98/22992

gcagaagtgg ccgcttaagg caaaaggcaa gctgcagatg tgtgaccacc 100
 cctggctccc agggctgtgt cctgggtgtct tctggcttca gaggcagcac 150
 agggagccag cctgtccccc accctgggag caggtgcagt ggcaggagcc 200
 agcgaggaca gatgctctgt gggggtaggg ggcagggatt gggggctaga 250
 5 agggcatgta tgcttgaaac tactctagtc acctctgctc ttcagtggcc 300
 tttcatggct gcgaagccca gaaaggagct gaccgcacag ccaatttctc 350
 tgacagaaat gtctccagtg gacagcttag gactgggaat gctcgagtga 400
 ggacacagca agaccaggcc agcagggggc gccagcccag caagaggagag 450
 gtgagctccc ctgggcactt gtgcatgggg agaggcctca atgccaagat 500
 10 ctgagatcat gccacaaacc cactagactc catcccagca cacaggagga 550
 gaccaccagg gctcggggag ggcactgcac acctctcag gccttccagc 600
 accttctgc tgccagcctg ggatccacc catggagctc cccaccccc 650
 ctcttttttc ttgctctcg cagacccaat gtggagtttg ccagcccact 700
 tgttttttga gctgggtattc cctgggagag gaactttgtc tctgagacc 750
 15 tgggtggctc tgtgcagggtg tgtaggtgc ctggtctgtg gggattctga 800
 agagctctga ctgggtctcc tggccactat gtgtggattt gtccatgaca 850
 ctctgaaggc agagtgggtg agctatggct gcgtttgtca ggaagagaca 900
 ccaccggcta ggcttggaga ctgaccctat cctgtgcaa tgacccttct 950
 cctctgcagg aaggatggct gtctccttca tagcacatgt acaggacaga 1000
 20 acagctccta caggtaaggt ggcctataa ttatcaacgg tgtgaatccc 1050
 agaggagggg ctgcactgga gggccttgagg aggagacagc tggggaggct 1100
 gacagctggg gaggcagctt ggaggctgac gcttgccctat gcgtgtgaga 1150
 ttctggttcc acctcagca ccacaccag gagacagtgc aagtgaaggc 1200
 cctgtgtccc tggcctatgg aacgaggggg ggtgtcactg ctgccatagg 1250
 25 ctgaggggga ggagccacc ctggaaaggt taactctgag tcatcagcca 1300
 gtcctaccaa agcctgagga ggaggaggag gaggagaaag gcagcaatgg 1350
 agtctggttc tgtacagggc aacagggtctg tgtggccaca gtcatacagg 1400
 aactgtccc caaactccca ccatgtgctg cagagcctct ctccaactct 1450
 aacatttgta aaactgcctt ttccacgtct acatgagggt acaccctaaa 1500

WO 99/21999

PCT/US98/22992

tactgtcatg ggggaaagac agtgcgaggt catagctgta tccagccatg 1550
 atgtcacggg gtaagcggca gacaggaagg gggctctgaa aggccagctg 1600
 gtccacagca aattcatagg catggatcag gccacgatgt ctctgtgac 1650
 aggcaaagtt gtcgaggtcg gagtttcgca gcaccttctc gtagggcacg 1700
 5 ttggcagtga tgaggctgtg gctattgaag gagagatagc gcacaggggtg 1750
 cctggagtgc acttcccaca gcttctgggt catgcggtaa tcccacacag 1800
 acaccagccc ctctcgctt cactgacaa ccttccagtc atccatctgg 1850
 actgcggaca ccccagctg atgggcagac agcgacaggg cgatcttctc 1900
 gctgcggagg tcatggatcc tactctcct gtccatgttg ccgctgacca 1950
 10 tgagggtggg agggctatcc cggatgttga cacaggtaaa gtctccaagt 2000
 gcattgcca gcttcgagag gcagcgctct gcttccaggc tgtacaccag 2050
 gatcttgttt ccttcataca cccatcctag actcttctc ccaaaggcaa 2100
 cctggctggc tgagacatcc agacatgttg caggctggcc attgacataa 2150
 tgaagggttc tggctgagtc gtcggccttc agcagggtaca ccagatcccc 2200
 15 ggctgtggct attgccacag ggtacctccc agtattcgga actatttcaa 2250
 ggtagtcaac cagcttctga acttcaaact ccgaggccac atgccaatgc 2300
 ccctcctcgt tggggtacaa catcacaacg tcaaaagcag aagccgtggc 2350
 aacaatgggc ttttcttggc tcagcgcaag ggcttgtatt cttgcgtcat 2400
 gctcaaaacg aaagataggg aaccttccgg ttctcaggtc ccaaagtta 2450
 20 aggatcccat cctcgtaagc cgccactgcc agcgagctgt tgatcctcac 2500
 aaaggagaca tatgcggacg cgtggg 2526

<210> 11
 <211> 204
 <212> DNA
 25 <213> Mouse

<400> 11
 cagaggggtg gtgggaaaga gtgaattatt taatttttaa tggtataata 50
 aagccaatgt agttgagacc aaggaaatga gcattgagaa cacaaacttg 100
 aagtctgggt ccagggttgt tggacctcac acctgtctc tgagccaccc 150
 30 ggaagtgaca taaaggacgc tgtgtgatca agttctggac acttttcttg 200
 gatg 204

WO 99/21999

PCT/US98/22992

<210> 12
 <211> 2224
 <212> DNA
 <213> Mouse

5 <400> 12
 cccacgcgtc cgcgcggtgg gcaagaccag cctggtggtc agctacacca 50
 ctaacggcta cccacccgag tacatcccta cggccttcga caacttctcg 100
 gccgtggtgt ctgtagatgg gcggcctgtg agactccagc tctgtgacac 150
 tgcaggacag gatgagtttg acaagctgag gcccctctgc tacaccaaca 200
 10 cagacatctt cctgctgtgc ttcagcgtgg tgagccccac atccttccag 250
 aacgtgggcg agaagtgggt tccagagatt cgacgtcact gcccaaaggc 300
 ccccatcatc ctggtcggga cacagtcgga cctcagggag gacgtcaaag 350
 tgctcataga actggcttct gcagggcatc tgtgtcctgc tgttaaaagc 400
 aggaggaggt gcttgtctgg gagctttaag tgtgtcgggc tcatatcgtc 450
 15 ccgtttgcaa ggaattgggc caccttgaga ggccatagtt gatggctatg 500
 ggacacacac acactttttc cttaagtcca ccaaaatgcc tgccctgtaca 550
 cacacacaca cacacacaca cacacacaca cacacacact ggctggtttg 600
 ctgatggaac ccttagacca ccctcccacc cccacccctc cccaagcatg 650
 gctgcaagtg tcagggcacc acaccttcct cttcttgaca tttctttgaa 700
 20 cagacatcat tttgtaggat cttaatttat acattttttt caggtcataa 750
 aatgtgggat gaacatactt tgaaccccag tgccttcagg gtccattgac 800
 tagggaggca ctgtcttagg ggacaggtat gtgcaaggcc ttaccaccca 850
 gtggcttctc gctgcaggtc atgtttgtgg cacttgttct ttaaggtgag 900
 ggtcttatga ccgactgttc tgagacagcc ctgtgtcagg caagctcttt 950
 25 cacagggttg taggtatttc caagacgcca taggaaccag acagtgaatc 1000
 atagctatca gtttgctgtg ggcaaggaac ctcttttttg ccacctggta 1050
 acaaaatttt atgtctgtaa attttttctt gctattttaa aaaaaaaaaat 1100
 caatcttacg tttttctgta ggaaaaaaaa aaacaagtaa aagaacaggc 1150
 catatttcag gtcaaaggct tcttcctgct ggtaaattggg actgaagact 1200
 30 ttcttacatc attattaaaa ggctaattgc tgaaccacta gagtatatga 1250
 actgtttgtg aatgatatta gccatagtct cctgaggtgt ttccttgtgg 1300

WO 99/21999

PCT/US98/22992

cctgagtggg aacattgttt tgcttatgga gatgctgtaa ctgacctagt 1350
 gactcagctt atcctattgt gcatggctgt ctggaaagcc agcgtacaag 1400
 tggggccttg cctgccctgt gtacagaggg tgggtgggaa agagtgaatt 1450
 atttaatttt aaatgttata ataaagccaa tgtagttgag accaaggaaa 1500
 5 tgagcattga gaacacaaac ttgaagtctg gtgccagggt tgttggaacct 1550
 cacaccctgt ctctgagcca cccggaagtg acataaagga cgctgtgtga 1600
 tcaagttctg gacacttttc tgggatgcgt accactggac tatttatgtc 1650
 acaaacttag tgggttgacg ctgccctgca agttttcaat gtccctgcat 1700
 cctatgaagt cataatgtct gactgtactg gaggttttcc tgcatttttt 1750
 10 acttttcgaa aatagagggt tgggctgaga attctaaacg catgtgcctg 1800
 ggtgggacgt caagtcaggg ttctcatcaa agctgagaag tggctggaat 1850
 gttcagcttg gtgtctgggg aggatcctgt gagctatgta gagaggtggc 1900
 tcttcagcct gactcagtgt gggctgaacg aagtacctgc agaacacacg 1950
 gtagcaggct ccaaaatcgt cacctcaagc atgcgtgcaa gcaaacttcc 2000
 15 gagaactccg ttttctgctc ggcagacgtg tgagcagcta cccagaagtc 2050
 tcaagccaaa aggggagcct cgctcgctgg ctctctgca ggtgccttat 2100
 cgacctgtgc tcttctcttt tcccgtgtca aagatgttgg acaggatctt 2150
 gtacttgaaa catactacaa atgagttact atgaaataaa ttctgacctg 2200
 tggaccgaaa aaaaaaaaaa aaaa 2224
 20 <210> 13
 <211> 2004
 <212> DNA
 <213> Mouse
 <400> 13
 25 cccacgcgtc cgcacgtgac cagttatatt gctatgaaaa tgggtggagat 50
 gcctcgtaga aggcgagtgc tgggtgcaca tgtgacattt tcttcaggga 100
 gcgactcatg gtgagaccag agagggctct tagcttgacg gactggcttc 150
 tgcagggcat ctgtgtcctg ctgttaaaag caggaggagg tgcttgtctg 200
 ggagctttta gtgtgctggg ctcatatcgt cccgtttgca aggaattggg 250
 30 ccaccttgag aggccatagt tgatggctat gggacacaca cacacttttt 300
 ccttaagtcc accaaaatgc ctgcctgtac acacacacac acacacacac 350

WO 99/21999

PCT/US98/22992

acacacacac acacacacac tggctgggtt getgatggaa cccttagacc 400
 accctccac cccacccct cccaagcat ggctgcaagt gtcagggcac 450
 cacaccttc tcttcttgac atttctttga acagacatca tttttagga 500
 tcttaattta tacatTTTTT tcaggtcata aaatgtggga tgaacatact 550
 5 ttgaaccca gtgccttcag ggtccattga ctagggaggc actgtcttag 600
 gggacaggta tgtgcaaggc cttaccacc agtggcttct cgtgcaggc 650
 catgtttgtg gcacttggtc ttttaaggta gggctttatg accgactgtt 700
 ctgagacagc cctgtgtcag gcaagctctt tcacagggtt gtaggtatTT 750
 ccaagacgcc ataggaacca gacagtgaat catagctatc agtttgctgt 800
 10 gggcaaggaa cctctTTTTg gccacctggc aacaaaattt tatgtctgta 850
 aatttttct tgctatttaa aaaaaaaaaa tcaatcttac gtttttctgt 900
 aggaaaaaaaa aaaacaagta aaagaacagg ccatatttca ggtcaaaggc 950
 ttcttcctgc tggtaaattg gactgaagac tttcttacat cattattaaa 1000
 aggctaattg ctgaaccact agagtatatg aactgtttgt gaatgatatt 1050
 15 agccatagtc tcctgagggtg tttccttggt gcctgagtg taacattgtt 1100
 ttgcttatgg agatgctgta actgacctag tgactcagct ttcctattg 1150
 tgcattggctg tctggaaagc cagcgtacaa gtggggcttt gcctgccctg 1200
 tgtacagagg gtgggtggga aagagtgaat tatttaattt taaatgttat 1250
 aataaagcca atgtagttga gaccaaggaa atgagcattg agaacacaaa 1300
 20 cttgaagtct ggtgccaggg ttgttggaac tcacaccctg tctctgagcc 1350
 acccggaagt gacataaagg acgctgtgtg atcaagttct ggacactttt 1400
 ctgggatgctg taccactgga ctatttatgt cacaaatcta gtgggttgac 1450
 gctgccctgc aagttttcaa tgtccctgca tcctatgaag tcataatgtc 1500
 tgactgtact ggaggttttc ctgcattttt tacttttcga aaatagaggc 1550
 25 ttgggctgag aattctaaac gcatgtgcct ggggtgggacg tcaagtcagg 1600
 gttctcatca aagctgagaa gtggctggaa tgttcagctt ggtgtctggg 1650
 gaggatcctg tgagctatgt agagagggtg ctcttcagcc tgactcagt 1700
 tgggctgaac gaagtacctg cagaacacac ggtagcaggc tccaaaatcg 1750
 tcacctcaag catgcgtgca agcaaacttc cgagaactcc gttttctgct 1800

WO 99/21999

PCT/US98/22992

cggcagacgt gtgagcagct acccagaagt ctcaagccaa aaggggagcc 1850
 tcgctcgctg gtcctctgc aggtgcctta tcgacctgtg ctcttctctt 1900
 ttcccgtgtc aaagatgttg gacaggatct tgtacttgaa acatactaca 1950
 aatgagttac tatgaaataa attctgacct gtggaccgaa aaaaaaaaaa 2000
 5 aaaa 2004
 <210> 14
 <211> 1016
 <212> DNA
 <213> Mouse
 10 <400> 14
 cccacgcgtc cgcgccgagg gacgcggcgt caagtgcgtg ctggtcggcg 50
 acggcgcggt gggcaagacc agcctgggtg tcagctacac cactaacggc 100
 taccaccacg agtacatccc tacggccttc gacaacttct cggccgtggt 150
 gtctgtagat gggcggcctg tgagactcca gctctgtgac actgcaggac 200
 15 aggatgagtt tgacaagctg agggccctct gctacaccaa cacagacatc 250
 ttcctgctgt gcttcagcgt ggtgagcccc acatccttcc agaacgtggg 300
 cgagaagtgg gttccagaga ttcgacgtca ctgccc aaag gccccatca 350
 tcctggtcgg gacacagtcg gacctcaggg aggacgtcaa agtgctcata 400
 gaactggaca agtgcaaaga gaagccggtg cctgaagagg cggcgaagct 450
 20 gtgcgcggag gaagtcaaag ctgtctccta catcgagtgc tcagcgttga 500
 ctcagaaaaa cctcaaagag gttttcgacg ccgccattgt tgctggtatc 550
 cagcactcag actcccagct acagccaaag aagtctaaaa gcaggacccc 600
 ggataagggtg cgggacctgt ccaagtcttg gtggaggaag tattgctgcc 650
 tggcctgact ctcgcaaata gcagggtgttt aagctgcaac agctctttat 700
 25 ggacgaggct gtcataggat gagccccaaa gcaccctctt ctgcccttaa 750
 cttcctgtgt gcgggagctt agggctgaga ttcatatgca aaatacgttt 800
 ttttaaaaat tgaaagttac attttttttc tgttaagtct ggaagctttg 850
 agctgttaga cctccggatt aatttatatt ccatatgaaa agggctcttc 900
 aaaagcgggg gtgtcagcat gaagttctgc tgggtgtttgt acaggacaaa 950
 30 ggagaatgaa tggggaacct tcctcctgaa ttaaggggct aactgaaggg 1000
 ctcaattgca agggca 1016

WO 99/21999

PCT/US98/22992

<210> 15
 <211> 4075
 <212> DNA
 <213> Mouse

5 <400> 15
 cccacgcgtc cggcgcgagc ttagcagatc tccacttacc gaacatctag 50
 agagtcgcgc cgcgcgccga cggagcggac atgggcagag cgatgggtggc 100
 caggctaggg ctgggggttgc tgcttctggc actgctccta cccacgcaga 150
 tttactgcaa ccaaacatct gttgcaccgt ttcccggtaa ccagaatatt 200
 10 tctgcttccc caaatccaag taacgctacc accagagggg gtggcagctc 250
 cctgcagtcc acagctggtc tcctgggctc tctctctctc tcttccacat 300
 ctctactgtt agagactcag gccaggaaac gtctctactt ccccatcctc 350
 tagacctacc ccaaattggca accacaagtc caatgtgatc aggaagaaac 400
 aggtccacct cgaattggct gttaccatat ctcaacagaa aacacggaga 450
 15 attcgaaatt cgacgggatt aaaggacgcg tgaaagggtt gagagaagag 500
 agatgccgct attgaatctg ctggagtttt acatcccaag atgaagacag 550
 cattcagaat tgatgtgatt tccttgaatg tggcttagga aaagtggaca 600
 cttaaaactc tcacttgaaa ttgggcacag gtttgatgta gagataagga 650
 cgggggtgcgg aatggagacc cattttgtca ttgattcatc tgaccgataa 700
 20 ggccatagtg cagttaggtg atattcgaaa gcttctttga tgctctttat 750
 gtatatgttg gaaggaacta ccaggcgttg ctttaaattc ccaatgtgtt 800
 gtttcgttac tactaattta ataccgtaag ctctaggtaa agttccatgt 850
 tgttgaactc tgactgttct ctttggaatt gaacgttttg catcctcctc 900
 ctgtggcttt aggtctgaca ttgtatttga cctttactag taattaacat 950
 25 gtgccaggca atggtggatt ggaacccatc cccaagtcca gccaccactg 1000
 aataaatctg atttcaaaag tcaaacagta gacatttccc attgtcgttt 1050
 ctcaactacc acaagcacca aattcactag agtacactgg ttccagagag 1100
 cagaatcatg ttggccttgg ctaatttcaa aatgctgtct tttactttgg 1150
 tatatgttga gggctttttc ataatttaaa gtgtgttctg ttagcaaggc 1200
 30 aaaaattatg agtcttaatt ctacaggcaa atatgcaaag gagccaaaac 1250
 tgtaaaccce gcatttggga tgtgaagact ggaagctaac tctcattgaa 1300

WO 99/21999

PCT/US98/22992

ttcacaaagt cttttatata atttctgtac atactttttt tttttttaag 1350
 agaaaaacaa acggtggatc agaatagcca cgtttggaat actttggtta 1400
 tccattcata ttttttagata gttattggtc ctgtgcctga aagggggcctt 1450
 ggttctaccg taagtttttc caatttcctt gatatacaca taccttctaa 1500
 5 aacctagaca tttcctgaaa aaaatctttt gttcgcattg tcacacactg 1550
 atgcttaccg gtacagtagt cttgataacc agagtcattt tctccatctt 1600
 tagaaacctt cctgggaaga aggagagctc acagaccga agctactgtg 1650
 tgtgtgaatg aacactcccc ttgcctcaca cctgaatgct gtacatctat 1700
 ttgattgtaa attgtgtttg tgtatttatg ctttgattca tagtaacttc 1750
 10 tcatgttatg gaattgattt gcattgaaca caaactgtaa aaaaaaaaaa 1800
 aaaaaggcg gcccgcgcc cgcgatggc ccgcagcaag gccggccggc 1850
 gctgccgcc cgctgcgagc cgccggcggc gccgccggtta ccgcctcgcc 1900
 gagagcgcg ggggcgcggg gcgcgcgggc ccgggggtgtc cgggggtcgg 1950
 ggggcgcg ggcgcgccga gggacgcggc gtcaagtgcg tgctggtcgg 2000
 15 cgacggcgcg gtgggcaaga ccagcctggt ggtcagctac accactaacg 2050
 gctacccac cgagtacatc cctacggcct tcgacaactt ctggccgtg 2100
 gtgtctgtag atgggcggcc tgtgagactc cagctctgtg aactgcagg 2150
 acaggatgag ttgacaagc tgaggccct ctgctacacc aacacagaca 2200
 tcttctgct gtgcttcagc gtggtgagcc ccacatcctt ccagaacgtg 2250
 20 ggcgagaagt gggttccaga gattcgact cactgccccaa agggcccat 2300
 catcctggtc gggacacagt cggacctcag ggaggacgtc aaagtgtca 2350
 tagaactgga caagtgcaaa gagaagccgg tgcctgaaga ggcggcgaag 2400
 ctgtgcgcg aggaagtcaa agctgtctcc tacatcgagt gctcagcgtt 2450
 gactcagaaa aacctcaaag aggttttcga cgccgccatt gttgctggta 2500
 25 tccagcactc agactccag ctacagccaa agaagtctaa aagcaggacc 2550
 ccggataagg tgcgggacct gtccaagtct tgggtggagga agtattgctg 2600
 cctggcctga ctctcgcaaa tagcagggtg ttaagctgca acagctcttt 2650
 atggacgagg ctgtcatagg atgagcccca aagcaccctc ttctgccctt 2700
 aacttctgt gtgcgggagc ttagggctga gattcatatg caaatacgt 2750

WO 99/21999

PCT/US98/22992

ttttttaaaa attgaaagtt acattttttt tctgttaagt ctggaagctt 2800
 tgagctgtag acctccggat taatttatat tccatatgaa aagggctctt 2850
 caaagcgggg tgtcagcatg aagttctgct gtgttgtaga ggacaaagga 2900
 gaatgaatgg gaccttctcc tgattaaggg ctactgaggg ctcagtgcag 2950
 5 ggcacgtgtg caccaggctt ggtgagagtg agcaagcgtg agctttgaaa 3000
 ccacacgagc ccccccggt tttgtaaggg caaagatctg aaaccagcaa 3050
 gggccttctg cttacgaaac ctgagccca tcccttctgt ttactcagat 3100
 tctcttagga ttttaaaaca accaaacatc ccacagccta ctggcatagt 3150
 gttggcgaac agtgcacttg cttgttacgg ttttgttttg tttttttaa 3200
 10 tcacgtgacc agttatattg ctatgaaaat ggtggagatg cctcgtagaa 3250
 ggcgagtgtt ggggtgcacat gtgacatttt cttcagggag cgactcatgg 3300
 tgagaccaga gagggctctt agcttgcagg actggcttct gcagggcatc 3350
 tgtgtcctgc tgttaaaagc aggaggaggt gcttgtctgg gagctttaag 3400
 tgtgctgggc tcatatcgtc ccgtttgcaa ggaattgggc caccttgaga 3450
 15 ggccatagtt gatggctatg ggacacacac acactttttc ctttaagtcca 3500
 ccaaatgcc tgctgttaga cacacacaca cacacacaca cacacacaca 3550
 cacacacact ggctggtttg ctgatggaac ccttagacca ccctcccacc 3600
 cccacccctc cccaagcatg gctgcaagtg tcagggcacc acaccttcct 3650
 cttcttgaca tttctttgaa cagacatcat tttgtaggat ctttaatttat 3700
 20 acattttttt caggtcataa aatgtgggat gaacatactt tgaaccccag 3750
 tgccttcagg gtccattgac tagggaggca ctgtcttagg ggacaggtat 3800
 gtgcaaggcc ttaccacca gtggcttctc gctgcaggtc atgtttgtgg 3850
 cacttgttct ttaaggtagg ggtcttatga ccgactgttc tgagacagcc 3900
 ctgtgtcagg caagctcttt cacaggggtg taggtatttc caagacgcca 3950
 25 taggaaccag acagtgaatc atagctatca gtttgctgtg ggcaagggaac 4000
 ctctttttgg ccacctggta acaaaatttt atgtctgtaa attttttctt 4050
 gctattttaa aaaaaaaaaa aaaaa 4075

<210> 16

<211> 847

30 <212> DNA

<213> Mouse

WO 99/21999

PCT/US98/22992

<400> 16

cgcggtgggc aagaccagcc tgggtggtcag ctacaccact aacggctacc 50
 ccaccgagta catccctacg gccttcgaca acttctcggc cgtgggtgtct 100
 gtagatgggc ggcctgtgag actccagctc tgtgacactg caggacagga 150
 5 tgagtttgac aagctgaggc ccctctgcta caccaacaca gacatcttcc 200
 tgctgtgctt cagcgtgggtg agccccacat ccttccagaa cgtggggcgag 250
 aagtgggttc cagagattcg acgtcactgc ccaaaggccc ccatcatcct 300
 ggtcgggaca cagtcggacc tcagggagga cgtcaaagtg ctcatagaac 350
 tggcttctgc agggcatctg tgcctgctg ttaaaagcag gaggaggtgc 400
 10 ttgtctggga gctttaagtg tgctgggctc atatcgtecc gtttgcaagg 450
 aattgggcca ccttgagagg ccatagttga tggctatggg acacacacac 500
 actttttcct taagtccacc aaaatgcctg cctgtacaca cacacacaca 550
 cacacacaca cacacacaca cacacactgg ctggtttgct gatggaaccc 600
 ttagaccacc ctcccacccc caccctccc caagcatggc tgcaagtgtc 650
 15 agggcaccac accttctct tcttgacatt tctttgaaca gacatcattt 700
 tgtaggatct taatttatac atttttttca ggtcataaaa tgtgggatga 750
 acatactttg aaccccagtg ccttcagggc ccattgacta gggaggcact 800
 gtcttagggg acaggtatgt gcaaggcctt acccaccagt ggcttct 847

<210> 17

20 <211> 1363

<212> DNA

<213> Mouse

<220>

<221> Unknown

25 <222> 504

<223> Any nucleotide

<400> 17

cccacgcgtc cgtatgaaaa tgggtggagat gcctcgtaga aggcgagtgc 50
 tgggtgcaca tgtgacattt tcttcagggg gcgactcatg gtgagaccag 100
 30 agagggctct tagcttgacg gactggcttc tgcagggcat ctgtgtcctg 150
 ctgttaaaag caggaggagg tgcttgtctg ggagctttaa gtgtgctggg 200
 ctcatatcgt cccgtttgca aggaattggg ccaccttgag aggccatagt 250
 tgatggctat gggacacaca cacacttttt ccttaagtcc accaaaatgc 300

WO 99/21999

PCT/US98/22992

ctgcctgtac acacacacac acacacacac acacacacac acacacacac 350
 tggctggttt gctgatggaa cccttagacc accctccac cccacccct 400
 cccaagcat ggctgcaagt gtcagggcac cacaccttc tcttcttgac 450
 atttctttga acagacatca ttttgtagga tcttaattta tacatttttt 500
 5 tcangtcata aaatgtggga tgaacatact ttgaacocca gtgccttcag 550
 ggtccattga ctagggaggc actgtcttag gggacaggta tgtgcaaggc 600
 cttaccacc agtggcttct cgctgcaggc catgtttgtg gcacttggtc 650
 ttttaagggtga gggctctatg accgactgtt ctgagacagc cctgtgtcag 700
 gcaagctctt tcacagggtt gtaggtattt ccaagacgcc ataggaacca 750
 10 gacagtgaat catagctatc agtttgctgt gggcaaggaa cctctttttg 800
 gccacctggt aacaaaattt tatgtctgta aattttttct tgctatttaa 850
 aaaaaaaaaat caatcttaag tttttctgta ggaaaaaaaa aaacaagtaa 900
 aagaacaggc catatttcag gtcaaaggct tcttccttct ggtaaattggg 950
 actgaagact ttcttacatc attattaaaa ggctaattgc tgaaccacta 1000
 15 gagtatatga actgtttgtg aatgatatta gccatagtct cctgaggtgt 1050
 ttccttgtgg cctgagtggc aacattgttt tgcttatgga gatgctgtaa 1100
 ctgacctagt gactcagctt atcctattgt gcatggctgt ctggaaagcc 1150
 agcgtacaag tggggctttg cctgccctgt gtacagaggg tgggtgggaa 1200
 agagtgaatt atttaatttt aaatgttata ataaagccaa tgtagttgag 1250
 20 accaaggaaa tgagcattga gaacacaaac ttgaagtctg gtgccagggt 1300
 tgttggacct cacacctgt ctctgagcca cccggaagtg acataaagga 1350
 cgctgtgtga tca 1363

<210> 18
 <211> 1953
 25 <212> DNA
 <213> Mouse

<400> 18
 cccacgcgtc cggtgaccag ttatattgct atgaaaatgg tggagatgcc 50
 tcgtagaagg cgagtgtggt gtgcacatgt gacattttct tcaggagagc 100
 30 actcatgggtg agaccagaga gggctcttag cttgcaggac tggcttctgc 150
 agggcatctg tgtcctgctg ttaaaagcag gaggaggtgc ttgtctggga 200

WO 99/21999

PCT/US98/22992

gctttaagtg tgctgggctc atatcgctccc gtttgcaagg aattggggcca 250
 ccttgagagg ccatagttga tggctatggg acacacacac actttttcct 300
 taagtccacc aaaatgcctg cctgtacaca cacacacaca cacacacaca 350
 cacacacaca cacacactgg ctggtttgct gatggaaccc ttagaccacc 400
 5 ctcccacccc caccctccc caagcatggc tgcaagtgtc agggcaccac 450
 accttcctct tcttgacatt tctttgaaca gacatcattt tgtaggatct 500
 aatttataca tttttttcag gtcataaaat gtgggatgaa catactttga 550
 accccagtgc cttcaggggc cattgactag ggaggcactg tcttagggga 600
 caggtatgtg caaggcctta cccaccagtg gcttctcgct gcaggtcattg 650
 10 tttgtggcac ttgttcttta aggtgagggt cttatgaccg actgttctga 700
 gacagccctg tgtcaggcaa gctctttcac agggttgtag gtatttccaa 750
 gacgccatag gaaccagaca gtgaatcata gctatcagtt tgctgtgggc 800
 aaggaacctc tttttggcca cctggtaaca aaattttatg tctgtaaatt 850
 ttttcttgct atttaaaaaa aaaaatcaat cttacgtttt tctgtaggaa 900
 15 aaaaaaaaaac aagtaaaaga acaggccata tttcagggtca aaggcttctt 950
 cctgctggta aatgggactg aagactttct tacatcatta ttaaaaggct 1000
 aattgctgaa ccactagagt atatgaactg tttgtgaatg atattagcca 1050
 tagtctcctg aggtgtttcc ttgtggcctg agtggtaaca ttgttttgct 1100
 tatggagatg ctgtaactga cctagtgact cagcttatcc tattgtgcat 1150
 20 ggctgtctgg aaagccagcg tacaagtggg gctttgectg ccctgtgtac 1200
 agaggggtggg tgggaaagag tgaattattt aattttaaat gttataataa 1250
 agccaatgta gttgagacca aggaaatgag cattgagaac acaaacttga 1300
 agtctgggtg cagggttggt ggacctcaca ccctgtctct gagccacccg 1350
 gaagtgacat aaaggacgct gtgtgatcaa gttctggaca cttttctggg 1400
 25 atgcgtacca ctggactatt tatgtcacia atctagtggg ttgacgctgc 1450
 cctgcaagtt ttcaatgtcc ctgcatccta tgaagtcata atgtctgact 1500
 gtactggagg ttttctgca ttttttactt ttcgaaaata gaggtttggg 1550
 ctgagaattc taaacgcatg tgccctgggtg ggacgtcaag tcagggttct 1600
 catcaaagct gagaagtggc tggaatgttc agcttggtgt ctggggcagg 1650

WO 99/21999

PCT/US98/22992

ctccaaaatc gtcacctcaa gcatgcgtgc aagcaaactt ccgagaactc 1700
 cgtttttctgc tcggcagacg tgtgagcagc taccagaag tctcaagcca 1750
 aaaggggagc ctgcctcgct ggctcctctg caggtgcctt atcgacctgt 1800
 gctcttctct tttcccgtgt caaagatggt ggacaggatc ttgtacttga 1850
 5 aacatactac aaatgagtta ctatgaaata aattctgacc tgtggaccga 1900
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1950
 aaa 1953
 <210> 19
 <211> 841
 10 <212> DNA
 <213> Mouse
 <400> 19
 cccacgcgtc cgcggacgcg tggttcaggg tccattgact agggaggcac 50
 tgtcttaggg gacaggatg tgcaaggcct taccaccag tggcttctcg 100
 15 ctgcaggcca tgtttgtggc acttgttctt taaggtagg gtcttatgac 150
 cgactgttct gagacagccc tgtgtcaggc aagctcttct acagggttgt 200
 aggtatttcc aagacgccat aggaaccaga cagtgaatca tagctatcag 250
 ttgctgtgg gcaaggaacc tctttttggc cacctggtaa caaaatttta 300
 tgtctgtaaa ttttttcttg ctatttaaaa aaaaaaatca atcttacgtt 350
 20 tttctgtagg aaaaaaaaaa acaagtaaaa gaacaggcca tatttcaggt 400
 caaaggcttc ttcctgctgg taaatgggac tgaagacttt cttacatcat 450
 tattaagg ctaattgctg aaccactaga gtatatgaac tgtttgtgaa 500
 tgatattagc catagtctcc tgagggtgtt ccttggtggc tgagtggtaa 550
 cattgttttg cttatggaga tgctgtaact gacctagtga ctcagcttat 600
 25 cctattgtgc atggctgtct ggaaagccag cgtacaagtg gggctttgcc 650
 tgccctgtgt acagaggggtg ggtgggaaag agtgaattat ttaatttta 700
 atgttataat aaagccaatg tagttgagac caaggaaatg agcattgaga 750
 acacaaactt gaagtctggg gccagggttg ttggacctca caccctgtct 800
 ctgagccacc cggaagtgc ataaaggacg ctgtgtgatc a 841
 30 <210> 20
 <211> 14
 <212> DNA
 <213> Artificial sequence

WO 99/21999

PCT/US98/22992

<220>
 <221> Artificial sequence
 <222> 1-14
 <223> Sequence is synthesized

5 <400> 20
 ttttgtacaa gctt 14

<210> 21
 <211> 44
 <212> DNA

10 <213> Artificial sequence

<220>
 <221> Artificial sequence
 <222> 1-44
 <223> Sequence is synthesized

15 <400> 21
 ctaatacgac tcactatagg gctcgagcgg ccgcccgggc aggt 44

<210> 22
 <211> 43
 <212> DNA

20 <213> Artificial sequence

<220>
 <221> Artificial sequence
 <222> 1-43
 <223> Sequence is synthesized

25 <400> 22
 tgtagcgtga agacgacaga aagggcgtgg tgcggagggc ggt 43

<210> 23
 <211> 10
 <212> DNA

30 <213> Artificial Sequence

<220>
 <221> Artificial sequence
 <222> 1-10
 <223> Sequence is synthesized

35 <400> 23
 acctgcccgg 10

<210> 24
 <211> 11
 <212> DNA

40 <213> Artificial sequence

<220>
 <221> Artificial sequence
 <222> 1-11
 <223> Sequence is synthesized

45 <400> 24

WO 99/21999

PCT/US98/22992

accgccctcc g 11

<210> 25

<211> 22

<212> DNA

5 <213> Artificial sequence

<220>

<221> Artificial sequence

<222> 1-22

<223> Sequence is synthesized

10 <400> 25

ctaatacgac tcactatagg gc 22

<210> 26

<211> 21

<212> DNA

15 <213> Artificial sequence

<220>

<221> Artificial sequence

<222> 1-21

<223> Sequence is synthesized

20 <400> 26

tgtagcgtga agacgacaga a 21

<210> 27

<211> 22

<212> DNA

25 <213> Artificial sequence

<220>

<221> Artificial sequence

<222> 1-22

<223> Sequence is synthesized

30 <400> 27

tcgagcggcc gcccgggcag gt 22

<210> 28

<211> 22

<212> DNA

35 <213> Artificial sequence

<220>

<221> Artificial sequence

<222> 1-22

<223> Sequence is synthesized

40 <400> 28

agggcgtggt gcggagggcg gt 22

<210> 29

<211> 20

<212> DNA

45 <213> Artificial sequence

WO 99/21999

PCT/US98/22992

<220>
 <221> Artificial sequence
 <222> 1-20
 <223> Sequence is synthesized

5 <400> 29
 accacagtcc atgccatcac 20

<210> 30
 <211> 20
 <212> DNA

10 <213> Artificial sequence

<220>
 <221> Artificial sequence
 <222> 1-20
 <223> Sequence is synthesized

15 <400> 30
 tccaccaccc tggtgctgta 20

<210> 31
 <211> 163
 <212> DNA

20 <213> Artificial sequence

<220>
 <221> Artificial sequence
 <222> 1-163
 <223> Sequence is synthesized

25 <400> 31
 tgtaatacga ctactatag ggcgaattgg gcccgacgtc gcatgctccc 50
 ggccgcatg gccgcgggat tatcactagt gcggccgcct gcaggtcgac 100
 catatgggag agctcccaac gcgttggatg catagcttga gtattctata 150
 gtgtcaccta aat 163

30 <210> 32
 <211> 163
 <212> DNA

<213> Artificial sequence

<220>
 35 <221> Artificial sequence
 <222> 1-163
 <223> Sequence is synthesized

<400> 32
 atttaggtga cactatagaa tactcaagct atgcatccaa cgcgttggga 50

40 gctctcccat atggtcgacc tgcaggcggc cgcactagt attatcccgc 100
 ggccatggcg gccgggagca tgcgacgtcg ggcccaattc gccctatagt 150
 gagtcgtatt aca 163

WO 99/21999

PCT/US98/22992

<210> 33
 <211> 24
 <212> DNA
 <213> Artificial sequence

5 <220>
 <221> Artificial sequence
 <222> 1-24
 <223> Sequence is synthesized

<400> 33
 10 cagaggggtgg gtgggaaaga gtga 24

<210> 34
 <211> 24
 <212> DNA
 <213> Artificial Sequence

15 <220>
 <221> Artificial
 <222> 1-24
 <223> Sequence is synthesized

<400> 34
 20 cacagcgtcc tttatgtcac ttcc 24

<210> 35
 <211> 23
 <212> DNA
 <213> Artificial Sequence

25 <220>
 <221> Artificial sequence
 <222> 1-23
 <223> Sequence is synthesized

<400> 35
 30 gtggcccatg ctctggcaga ggg 23

<210> 36
 <211> 24
 <212> DNA
 <213> Artificial sequence

35 <220>
 <221> Artificial sequence
 <222> 1-24
 <223> Sequence is synthesized

<400> 36
 40 gactggagca aggtcgctcct cgcc 24

<210> 37
 <211> 24
 <212> DNA
 <213> Artificial sequence

45 <220>

WO 99/21999

PCT/US98/22992

<221> Artificial sequence
 <222> 1-24
 <223> Sequence is synthesized

 <400> 37
 5 gcaccaccca caaggaagcc atcc 24

 <210> 38
 <211> 24
 <212> DNA
 <213> Artificial sequence

 10 <220>
 <221> Artificial sequence
 <222> 1-24
 <223> Sequence is synthesized

 <400> 38
 15 gacgaaaggg aagccggcat cacc 24

 <210> 39
 <211> 24
 <212> DNA
 <213> Artificial sequence

 20 <220>
 <221> Artificial sequence
 <222> 1-24
 <223> Sequence is synthesized

 <400> 39
 25 gagaaggctcg tggttcgagca aacc 24

 <210> 40
 <211> 24
 <212> DNA
 <213> Artificial sequence

 30 <220>
 <221> Artificial sequence
 <222> 1-24
 <223> Sequence is synthesized

 <400> 40
 35 cttctcgtgt acttcctgtg cctg 24

 <210> 41
 <211> 24
 <212> DNA
 <213> Artificial sequence

 40 <220>
 <221> Artificial sequence
 <222> 1-24
 <223> Sequence is synthesized

 <400> 41
 45 cacgtcagct ggcgttgcca gctc 24

WO 99/21999

PCT/US98/22992

<210> 42
 <211> 50
 <212> DNA
 <213> Artificial Sequence

5 <220>
 <221> Artificial sequence
 <222> 1-50
 <223> Sequence is synthesized

<400> 42
 10 caacttctcg gccgtggtgt ctgtagatgg gcggcctgtg agactccagc 50

<210> 43
 <211> 24
 <212> DNA
 <213> Artificial sequence

15 <220>
 <221> Artificial sequence
 <222> 1-24
 <223> Sequence is synthesized

<400> 43
 20 gcacacacgc atggaggcaa gctc 24

<210> 44
 <211> 24
 <212> DNA
 <213> Artificial sequence

25 <220>
 <221> Artificial sequence
 <222> 1-24
 <223> Sequence is synthesized

<400> 44
 30 gccatcttgt ttacagctcc acca 24

<210> 45
 <211> 50
 <212> DNA
 <213> Artificial sequence

35 <220>
 <221> Artificial sequence
 <222> 1-50
 <223> Sequence is synthesized

<400> 45
 40 ctcttgacct ttggggctgc cacttcccag gacgaccact gcctgcccac 50

<210> 46
 <211> 177
 <212> DNA
 <213> Human

45 <400> 46

WO 99/21999

PCT/US98/22992

gaccctccct ggccgccttt gtctactggc cgtgcggccc ggaaccgcca 50
 ctctccaggg ccggggacgc gcccgagct gtcggtgaca gctcctccct 100
 accgcaaccc tccggggcgg aggggcggtc gggccgggcc ctgctagccc 150
 gcgaccgcaa gcccgcgctc gcggatc 177

5 <210> 47
 <211> 774
 <212> DNA
 <213> Human

<400> 47

10 gaccctccct ggccgccttt gtctactggc cgtgcggccc ggaaccgcca 50
 ctctccaggg ccggggacgc gcccgagct gtcggtgaca gctcctccct 100
 accgcaaccc tccggggcgg aggggcggtc gggccgggcc ctgctagccc 150
 gcgaccgcaa gcccgcgctc gcggatcgat gccccgcag cagggggacc 200
 ccgcgttccc cgaccgctgc gaggcgcctc cggtgccgcc gcgtcgggag 250
 15 cgcggtggac gcgggggacg cgggcctggg gagccggggg gccgggggag 300
 tgcggggggg gccgaggggc gcggcgtcaa gtgcgtgctg gtcggcgacg 350
 gcgcggtggg caagacgagc ctggtggtga gttacaccac caacggctac 400
 cccaccgagt acatccctac tgccttcgac aacttctccg cggtggtgtc 450
 tgtggatggg cggcccgtga gactccaact ctgtgacact gccggacagg 500
 20 atgaatttga caagctgagg cctctctgct acaccaacac agacatcttc 550
 ctgctctgct tcagtgtcgt gagccctca tccttcaga acgtcagtga 600
 gaaatgggtg ccggagattc gatgccactg tcccaaagcc cccatcatcc 650
 tagttggaac gcagtcggat ctgagagaag atgtcaaagt cctcattgag 700
 ttggacaaat gcaaagaaaa gccagtgcct gaagaggcgg ctaagctgtg 750
 25 cgccgaggaa atcaaagccg cctc 774

<210> 48
 <211> 840
 <212> DNA
 <213> Human

30 <400> 48

caacttctcc gcggtggtgt ctgtggatgg gcggcccggtg agactccaac 50
 tctgtgacac tgccggacag gatgaatttg acaagctgag gcctctctgc 100
 tacaccaaca cagacatctt cctgctctgc ttcagtgtcg tgagcccctc 150

WO 99/21999

PCT/US98/22992

atccttccag aacgtcagtg agaaatgggt gccggagatt cgatgccact 200
 gtcccaaagc ccccatcatc ctagttggaa cgcagtcgga tctcagagaa 250
 gatgtcaaag tcctcattga gttggacaaa tgcaaagaaa agccagtgcc 300
 tgaagaggcg gctaagctgt gcgccgagga aatcaaagcc gcctcctaca 350
 5 tcgagtgttc agccttgact caaaaaaacc tcaaagaggt ctttgatgca 400
 gccatcgteg ctggcattca atactcggac actcagcaac agccaaagaa 450
 gtctaaaagc aggactccag ataaaatgaa aaacctctcc aagtcctggg 500
 ggaagaagta ctgctgtttc gtatgatgct ggcaagacac ccagaaaggc 550
 tattttcaga tgaaatcgat attagaagct atattagctg aaacaactcc 600
 10 ttttactgcy tagaacctat atcgagagtg tgtgtatatg tattatagga 650
 ggagctctca attttatgta ttctttctgc ctttaatttt cttgtttggt 700
 tgagcttagg gatgagatac ttatgcaaga tatttttgaa gtaaattaaa 750
 catttttcac atctctggaa atttagagtt ctagacctct ggtaatttta 800
 tatctaatat gaagaagaca cctctaattct ggatgttaag 840

15 <210> 49
 <211> 47
 <212> DNA
 <213> Artificial sequence

<220>
 20 <221> Artificial sequence
 <222> 1-47
 <223> Sequence is synthesized

<400> 49
 ggattctaatac gactcact atagggcagc gttgactcag aaaaacc 47

25 <210> 50
 <211> 48
 <212> DNA
 <213> Artificial sequence

<220>
 30 <221> Artificial sequence
 <222> 1-48
 <223> Sequence is synthesized

<400> 50
 ctatgaaatt aaccctcact aaagggagca tatgaatttc agccctaa 48

35 <210> 51
 <211> 48
 <212> DNA
 <213> Artificial sequence

WO 99/21999

PCT/US98/22992

<220>

<221> Artificial sequence

<222> 1-48

<223> Sequence is synthesized

5 <400> 51

ggattctaatacgcactcactatagggcacgcacatctgtttccgtttt 48

<210> 52

<211> 47

<212> DNA

10 <213> Artificial sequence

<220>

<221> Artificial sequence

<222> 1-47

<223> Sequence is synthesized

15 <400> 52

ctatgaaattaacctcactaaagggacca tccccgctctctaccta 47

WHAT IS CLAIMED IS:

1. Isolated nucleic acid comprising DNA having at least about 800 nucleotides and at least about a 70% sequence identity to (a) a DNA molecule encoding a human clone 65 polypeptide comprising the sequence of amino acids 1 to 258 of Figures 5A and 5B (SEQ ID NO:3), or (b) a complement of the DNA molecule of (a).
- 5 2. The nucleic acid of claim 1 having at least one clone 65 biological activity.
3. Isolated nucleic acid comprising DNA having at least about 700 nucleotides and at least about a 95% sequence identity to (a) a DNA molecule encoding a human clone 65 polypeptide comprising the sequence of amino acids 1 to 258 of Figures 5A and 5B (SEQ ID NO:3), or (b) a complement of the DNA molecule of (a).
4. The nucleic acid of claim 3 comprising DNA encoding a human clone 65 polypeptide having
10 amino acid residues 1 to 258 of Figures 5A and 5B (SEQ ID NO:3), or a complement thereof.
5. Isolated nucleic acid comprising DNA having at least about 800 nucleotides and at least about a 70% sequence identity to (a) a DNA molecule encoding a mouse clone 65 polypeptide comprising the sequence of amino acids 1 to 261 of Figures 1A and 1B (SEQ ID NO:6), or (b) a complement of the DNA molecule of (a).
6. The nucleic acid of claim 5 comprising DNA having at least about a 85% sequence identity to (a) a DNA
15 molecule encoding a mouse clone 65 polypeptide comprising the sequence of amino acids 1 to 261 of Figures 1A and 1B (SEQ ID NO:6), or (b) a complement of the DNA molecule of (a).
7. The nucleic acid of claim 5 comprising DNA encoding a mouse clone 65 polypeptide having amino acid residues 1 to 261 of Figures 1A and 1B (SEQ ID NO:6), or a complement thereof.
8. Isolated nucleic acid comprising DNA having at least about 800 nucleotides and at least about a
20 70% sequence identity to (a) a DNA molecule encoding the same full-length polypeptide encoded by the human clone 65 polypeptide cDNA in ATCC Deposit No. 209536 (pRK5E.h.WIG-3.65.4A), or (b) a complement of the DNA molecule of (a).
9. Isolated nucleic acid comprising SEQ ID NO:11, 12, 13, 14, 15, 16, 17, 18, or 19.
10. A vector comprising the nucleic acid of claim 1.
- 25 11. A host cell comprising the vector of claim 10.
12. A process for producing a clone 65 polypeptide comprising culturing the host cell of claim 11 under conditions suitable for expression of the clone 65 polypeptide and recovering the clone 65 polypeptide from the cell culture.
13. Isolated clone 65 polypeptide encoded by the nucleic acid of claim 1.
- 30 14. The polypeptide of claim 13 that is human clone 65 or mouse clone 65.
15. Isolated clone 65 polypeptide encoded by a nucleic acid of claim 9.
16. A chimeric molecule comprising a clone 65 polypeptide fused to a heterologous amino acid sequence.
17. The chimeric molecule of claim 16 wherein said heterologous amino acid sequence is an epitope
35 tag sequence or an Fc region of an immunoglobulin.
18. An antibody which specifically binds to a clone 65 polypeptide.
19. The antibody of claim 18 wherein said antibody is a monoclonal antibody.
20. Isolated nucleic acid having at least about 800 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human clone 65 polypeptide comprising

WO 99/21999

PCT/US98/22992

the sequence of amino acids 1 to 258 of Figures 5A and 5B (SEQ ID NO:3), or (b) a complement of the DNA molecule of (a), and, if the test DNA molecule has at least about a 70% sequence identity to (a) or (b), isolating the test DNA molecule.

21. A polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with
 5 (a) a DNA molecule encoding a human clone 65 polypeptide comprising the sequence of amino acids 1 to 258 of Figures 5A and 5B (SEQ ID NO:3), or (b) a complement of the DNA molecule of (a), and if the test DNA molecule has at least about a 70% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
22. Isolated nucleic acid encoding mouse clone 320 comprising DNA having at least about 500
 10 nucleotides and having at least about a 97% sequence identity to (a) a DNA molecule comprising the sequence of nucleotides 1 to 2822 of Figure 2 (SEQ ID NO:7), or (b) a complement of the DNA molecule of (a).
23. Isolated nucleic acid encoding mouse clone 320 comprising DNA having at least about 700 nucleotides and having at least about a 70% sequence identity to (a) a DNA molecule comprising the sequence of nucleotides 1 to 727 of Figure 3 (SEQ ID NO:8), or (b) a complement of the DNA molecule of (a).
- 15 24. The nucleic acid of claim 23 having at least about a 95% sequence identity to (a) or (b).
25. The nucleic acid of claim 23 having about 100% sequence identity to (a) or (b).
26. Isolated nucleic acid encoding mouse clone 320 comprising DNA having at least about 700 nucleotides and having at least 75% sequence identity to (a) a DNA molecule comprising the sequence of nucleotides 1 to 2526 of Figures 4A and 4B (SEQ ID NO:9), or (b) a complement of the DNA molecule of (a).
- 20 27. The nucleic acid of claim 26 having at least about 90% sequence identity to (a) or (b).
28. Isolated nucleic acid encoding mouse clone 320 comprising DNA having at least about 500 nucleotides and having at least about a 97% sequence identity to (a) a DNA molecule comprising the sequence of nucleotides 1 to 2822 of Figure 2 (SEQ ID NO:7), or (b) a complement of the DNA molecule of (a) and comprising DNA having at least about 700 nucleotides and having at least about a 70% sequence identity to (c) a DNA molecule
 25 comprising the sequence of nucleotides 1 to 727 of Figure 3 (SEQ ID NO:8), or (d) a complement of the DNA molecule of (c).
29. Isolated nucleic acid encoding mouse clone 320 comprising DNA having at least about 500 nucleotides and having at least about a 97% sequence identity to (a) a DNA molecule comprising the sequence of nucleotides 1 to 2822 of Figure 2 (SEQ ID NO:7), or (b) a complement of the DNA molecule of (a) and comprising
 30 DNA having at least about 700 nucleotides and having at least a 75% sequence identity to (c) a DNA molecule comprising the sequence of nucleotides 1 to 2526 of Figures 4A and 4B (SEQ ID NO:9), or (d) a complement of the DNA molecule of (c).
30. Isolated nucleic acid encoding mouse clone 320 comprising DNA having at least about 700 nucleotides and having at least about a 70% sequence identity to (a) a DNA molecule comprising the sequence of
 35 nucleotides 1 to 727 of Figure 3 (SEQ ID NO:8), or (b) a complement of the DNA molecule of (a) and comprising DNA having at least about 700 nucleotides and having at least a 75% sequence identity to (c) a DNA molecule comprising the sequence of nucleotides 1 to 2526 of Figures 4A and 4B (SEQ ID NO:9), or (d) a complement of the DNA molecule of (c).

WO 99/21999

PCT/US98/22992

31. Isolated nucleic acid encoding mouse clone 320 comprising DNA having at least about 500 nucleotides and having at least about a 97% sequence identity to (a) a DNA molecule comprising the sequence of nucleotides 1 to 2822 of Figure 2 (SEQ ID NO:7), or (b) a complement of the DNA molecule of (a) and comprising DNA having at least about 700 nucleotides and having at least a 75% sequence identity to (c) a DNA molecule
 5 comprising the sequence of nucleotides 1 to 2526 of Figures 4A and 4B (SEQ ID NO:9), or (d) a complement of the DNA molecule of (c) and comprising DNA having at least about 700 nucleotides and having at least about a 70% sequence identity to (e) a DNA molecule comprising the sequence of nucleotides 1-727 of Figure 3 (SEQ ID NO:8), or (f) a complement of the DNA molecule of (e).

32. Isolated nucleic acid encoding mouse clone 320 comprising DNA having at least about 500
 10 nucleotides and having at least about a 95% sequence identity to (a) a DNA molecule encoding the same polypeptide encoded by the mouse clone 320 polypeptide cDNA in ATCC Deposit No. 209534 (pRK5E.m.WIG-4.320.9), or (b) a complement of the DNA molecule of (a).

33. The nucleic acid of claim 32 that is about 3 kilobases in length.

34. The nucleic acid of claim 32 comprising DNA that encodes the same polypeptide encoded by the
 15 mouse clone 320 polypeptide cDNA in ATCC Deposit No. 209534 (pRK5E.m.WIG-4.320.9).

35. Isolated polypeptide encoded by the nucleic acid of claim 22.

36. Isolated nucleic acid having at least about 500 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding the same polypeptide encoded by the mouse clone 320 polypeptide cDNA in ATCC Deposit No. 209534 (pRK5E.m.WIG-4.320.9), or (b) a complement of the
 20 DNA molecule of (a), and, if the test DNA molecule has at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.

37. A polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding the same polypeptide encoded by the mouse clone 320 polypeptide cDNA in ATCC Deposit No. 209534 (pRK5E.m.WIG-4.320.9), or (b) a complement of the DNA molecule of (a), and if the test DNA
 25 molecule has at least about a 95% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.

38. A composition comprising the polypeptide of claim 13 and a carrier therefor.

39. A composition comprising an antagonist to the polypeptide of claim 13 and a carrier therefor.

30 40. A composition comprising the polypeptide of claim 15 and a carrier therefor.

41. A composition comprising an antagonist to the polypeptide of claim 15 and a carrier therefor.

42. A composition comprising the polypeptide of claim 35 and a carrier therefor.

43. A composition comprising an antagonist to the polypeptide of claim 35 and a carrier therefor.

1 / 23

1 ATGGCCCCG AGCAAGCCG GCCGGCGCTG CCCGCCCGT GCGAGCCGCC GCGGGCGCG CCGGTACCG CTCGCCGAGA GCGGGGGGG GCGGGGGCG
TACCGGGCG TCGTTCCGG CGGCCGGAC CGCGGGCG GCGCGGGCG GCGCGGGCG GCGCGGGCG GCGCGGGCG GCGCGGGCG
1 M A P Q Q G R P A L P A R C E P P A A P P P P R R E R G G R G A R
101 GCGGGCCCC GGTGTCCGG GGTGCGGGG GGTGCGGGG GGTGCGGGG GGTGCGGGG GGTGCGGGG GGTGCGGGG GGTGCGGGG
CGCGGGGGG CCACAGGCC CCAGCCCCG CGCGGGGGG CGCGGGGGG CGCGGGGGG CGCGGGGGG CGCGGGGGG CGCGGGGGG
35 G P G V S G G R G R A G G A E G R G V K C V L V G D G A V G K T S
201 CCTGGTGGT AGCTACACCA CTAACGGCTA CCCACCGAG TACATCCCTA CGCCTTCTG CAATTCTCG GCCGTGGTGT CTGTAGATGG GCGGCCGTGT
GGACCAACAG TCGATGTGGT GATTGCCGAT GGTGCGGGG GGTGCGGGG GGTGCGGGG GGTGCGGGG GGTGCGGGG GGTGCGGGG
68 L V V S Y T T N G Y P T E Y I P T A F D N F S A V V S V D G R P V
301 AGACTCCAG TCTGTGACAC TGCAGGACAG GATGAGTTG ACAAGCTGAG GCCCTCTCTG TACACCAACA CAGACATCTT CCTGCTGTGC TTCAGCGTGG
TCTGAGGTG AGACACTGTG ACCTCCTGTC CTACTCAAAC TGTTCCGACTC CGGGGAGAG ATGTGGTGT GTCTGTAGAA GGACGACACG AAGTCGCACC
101 R L Q L C D T A G Q D E F D K L R P L C Y T N T D I F L L C F S V V
401 TGAGCCCCAC ATCTTCCAG AACGTGGGG AGAGTGGT TCCAGAGATT CGACGTACT GCCCAAAGG CCCCATCATC CTGTCGGGA CACAGTCGGA
ACTCGGGGTG TAGGAAGGTG TTGCACCCG TCTTCAACCA AGGTCTCTAA GCTGCAGTGA CCGGTTTCCG GGGGTAGTAG GACCAAGCCT GTGTGAGCCT
135 S P T S F Q N V G E K W V P E I R R H C P K A P I I L V G T Q S D
501 CCTCAGGAG GACGTCAAAG TGCTCATAGA ACTGGACAAG TGCAAGAGA AGCGGTGCC TGAAGAGCG GCGAAGCTGT GCGCGGAGGA AGTCAAAGCT
GGAGTCCCTC CTGCAGTTTC ACAGTATCT TGACCTGTTT ACCTTCTCT TCGGCCACG ACTTCTCCG CGCTTCGACA CGCGCCTCCT TCAGTTTCGA
168 L R E D V K V L I E L D K C K E K P V P E E A A K L C A E E V K A
601 GTCTCCTACA TCGAGTGCTC AGCGTGTACT CAGAAAACC CAGAAAGAGT TTTTCGACGC GCCATTGTG CTGGTATCCA GCACTCAGAC TCCCAGCTAC
CAGAGGATG AGCTCAGAG TCGCAACTGA GTCTTTTGG AGTTTCTCCA AAAGCTGCG CGGTAAACAAC GACCATAGGT CGTGAGTCTG AGGGTCGATG
201 V S Y I E C S A L T Q K N L K E V F D A A I V A G I Q H S D S Q L Q
701 AGCCAAAGAA GTCTAAAGC AGGACCCCGG ATAAGGTGGG GGACCTGTCC AAGTCTTGGT GGAGGAAGTA TTGCTGCCCTG GCCTGACTCT CGCAAATAGC
TCGGTTTCTT CAGATTTTCG TCCTGGGGG TATTTCCACG CCTGGACAGG TTCAGAACCA CTCCTTCTAT AACGACGGAC CGGACTGAGA GCGTTTATCG
235 P K K S K S R T P D K V R D L S K S W R K Y C C L A O
801 AGGTGTTTAA GCTGCAACAG CTCCTTATGG ACGAGGCTGT CATAGGATGA GCCCAAAGC ACCCTCTTCT GCCCTTAACT TCCTGTGTGC GGGAGCTTAG
TCCACAAATT CGACGTTGTC GAGAAATACC TGCTCCGACA GTATCCTACT CCGGTTTTCG TGGGAGAAGA CGGGAATTGA AGGACACACG CCCTCGAATC
901 GGCTGAGATT CATATGCAA ATACGTTTTT TTAATAATTG AAAGTTACAT TTTTCTCTG TTAAGTCTGG AAGCTTTGAG CTGTAGACCT CCGGATTAAT
CCGACTCTAA GTATACGTTT TATGCAAAA AATTTTAACT TTTCAATGTA AAAAAAGAC AATTCAGACC TTCGAAACTC GACATCTGGA GGCCTAATTA

WO 99/21999

PCT/US98/22992

2 / 23

1001 TTATATTCCA TATGAAAAGG GCTCTTTCAA GCGGGGTGTC AGCATGAAGT TCTGCTGTGT TGTACAGGAC AAAGAGAAT GAATGGGACC TTCTCCTGAT
AATATAAGGT ATACTTTTCC CGAGAAAGTTT CGCCCCACAG TCGTACTTCA AGACGACACA ACATGTCTTG TTTCTCTTTA CTTACCCCTGG AAGAGGACTA

1101 TAAGGGCTAC TGAGGGCTCA GTGCAGGGCA CGTGTGCACC AGGCTTGGTG AGAGTGAGCA AGCGTGAGCT TTGAAACCAC ACAGCCACC CCCGGTTTTG
ATTCCCCGATG ACTCCCGAGT CACGTCCCGT CACGACGTTG GCACACGTTG TCCGAACCAC TCTCACTCGT TCGCACTCGA AACTTTGGTG TGCTCGGTGG GGGCCAAAAC

1201 TAAGGGCAAA GATCTGAAAC CAGCAAGGC CTTCTGCTTA CGAAACCTCG AGCCCATCCC TTCGTGTTAC TCAGATCTC TTAGGATTTT AAAACAACCA
ATTCCCCGTTT CTAGACTTTG GTCTTTCCCG GAAGACGAAT GCTTTGGAGC TCGGGTAGGG AAGACAAATG AGCTAAGAG AATCCTAATAA TTTTGTGGT

1301 AACATCCCAC AGCCTACTGG CATAGTGTG GCGAACAGTG CACTTGCTTG TTACGGTTT GTTTGTGTTT TTAAATCAC GTGACCAGTT ATATTGCTAT
TTGTAGGGTG TCGGATGACC GTATCACAAAC CGTTGTGCAC GTGAACGAAC AATGCCAAA CAAAACAAA AAATTAGTG CACTGTCAA TATAACGATA

1401 GAAAATGGTG GAGATGCCTC GTAGAAGCG AGTGCTGGT GCACATGTA CATTTCTTC AGGAGCGAC TCATGGTGAG ACCAGAGAGG GCTCTTAGCT
CTTTTACCAC CTCTACGGAG CATCTCCGC TCACGACCCA CGGTACACT GTAAAGAAG TCCCTCGCTG AGTACCCTC TGGTCTCTCC CGAGAAATCGA

1501 TGCAGGACTG GCTTCTGCAG GGCATCTGTG TCCTGCTGTT AAAAGCAGGA GGAGGTGCTT GTCTGGGAGC TTAAAGTGTG CTGGGCTCAT ATCGTCCCCT
ACGTCCTGAC CGAAGACGTC CCGTAGACAC CCGTACGAC AGGACGACAA TTTTCGTCCT CCTCCACGAA CAGACCCTCG AAATTCACAC GACCCGAGTA TAGCAGGGCA

1601 TTGCAAGGAA TTGGGCCACC TTGAGAGGCC ATAGTTGATG GCTATGGGAC ACACACACAC TTTTCTCTTA AGTCCACCAA AATGCCCTGCC TGTACACACA
AACGTTCCTT AACCCGGTGG AACTCTCCGG TATCAACTAC CGATACCCTG TGTGTGTG AAAAAGGAAT TCAGGTGGTT TTACGGACGG ACATGTGTGT

1701 CACACACACA CACACACACA CACACACACA CACACTGGCT TGGAAACCTT AGACACCCCT CCCACCCCA CCCCTCCCA AGCATGGCTG
GTGTGTGTGT GTGTGTGTGT GTGTGTGTGT GTGTGTGTGT GTGTGTGTGT ACCITGGGA TCTGGTGGG GGTGGGGGT GGGAGGGGT TCGTACCGAC

1801 CAAGTGTCAG GGCACCACAC CTTCTCTCTT TTGACATTTC TTTGAACAGA CATCATTTTG TAGGATCTTA ATTTATACAT TTTTTCAGG TCATAAAATG
GTTACAGTC CCGTGGTGTG GAAGGAGAAG AACTGTGTCT GTAGTAAAC ATCCTAGAAT TAAATATGTA AAAAAGTCC AGTATTTTAC

1901 TGGGATGAAC ATACTTTGAA CCCCAGTGCC TTCAGGGTCC ATTGACTAGG GAGGCACTGT CTTAGGGGAC AGGTATGTG AAGCCCTTAC CCACCAGTGG
ACCTTACTTG TATGAAACTT GGGGTACCG AAGTCCAGG TAACTGATCC CTCCGTGACA GAATCCCCCTG TCCATACACG TTCCGGAATG GGTGGTCACC

2001 CTTCTCGCTG CAGGTCAATGT TTGTGGCACT TGTTCTTTAA GGTGAGGGTC TTATGACCGA CTGTTCTGAG ACAGCCCTGT GTCAGGCAAG CTCTTTCACA
GAAGAGCGAC GTCCAGTACA AACACCGTGA ACAAGAAAT CCACCTCCAG AATACTGGCT GACAAGACTC TGTCGGGACA CAGTCCGTTT GAGAAAGTGT

2101 GGGTTGTAGG TATTCCCAAG ACGCCATAGG AACACAGACAG TGAATCATAG CTATCAGTTT GCTGTGGGCA AGGAACCTCT TTTTGGCCAC CTGGTAACAA
CCCAACATCC ATAAAGGTTT TGCGGTATCC TTGGTCTGTC ACTTAGTATC GATAGTCAA CGACACCCCT TCCTTGGAGA AAAACCGGTG GACCATTTGT

2201 AATTTTATGT CTGTAAATTT TTCTTGCTA TTTAAAAAA AAAAAAAA A
TTAAAAATACA GACATTTTAA AAAGAACGAT AAATTTT TTTT T

SUBSTITUTE SHEET (RULE 26)

FIG. 1B

1 CCCACGCGTC CGCTGAATGT ATGTTGGTTA GAAAGTAGCC TTTCTGCTTC CTGCCCATGG CCAGTTCTCT ACCCTCTCTT TGGTGTCTT TGTGGGGAGG
GGGTGCGCAG GCGACTTACA TACAACCAAT CTTTCATCGG AAAGACGAAG GACGGGTACC GGTCAAGAGG TGGGAGAGAA ACCACAAGAA ACACCCCTCC

101 GCACTGTGGT TTGTGCGAGC CCTGGACTTC GAGAGGCTCC CAGAACCAG GATCACCAGC CTCCTGTCTG TTTGCTTCAC TCCTTTCCCA GGGAGGACTT
CGTGACACCA AACAGCGTCG GGACCTGAAG CTCTCCGAGG GTCTTGGGTC CTAGTGGTCG GAGGACAGAC AAACGAAAGTG AGGAAAGGT CCCTCCTGAA

201 GGGACTGTCC TGCTGACAG GACGATCTG AGTCCCGAA GCAACCAGC TCACCACATA GATAGTAGT TTAAACAATG TTTTAAATA AGGCACCTC
CCCTGACAGG ACAGACTGTC CTGCCCTAGAC TCAAGGGCTT CGTTTGGTCG AGTGTGTAT CTATCGATCA AATTGTTCAC AAAATTTTAT TCCCGTGGAG

301 TGTTCAAAA GTGACATCTG CTGTGTGTT TTCGAGGCCT GATACTCTA CAAGGTTGA AAAAAATGT GTGTATCCAT TCATGGGCTT GGTAGCCTTC
ACAAAGTTTT CACTGTAGAC GACACAACA AAGCTCCGGA CTATGAGAA GTTCCAAACT TTTTTTTACA CACATAGGTA AGTACCCGAA CCATCGGAAG

401 TGGTCACCTC AGTCCCTGGG CTCTTAACCT ATTGCCAAC AATATTCATT TCCCCTCAGC TACAATGAAT TGCAAGCAAA AGATGTTGAA AAAAAGCACT
ACCAAGTGAG TCAGGACACC GAGAAATTGAA TAACGGGTTG TTATAAGTAA AGGGAGTCG ATGTTACTTA ACGTTCGTTT TCTACAACTT TTTTTCGTGA

501 AATTAGTTT AAAATGTCAC TTTTGTGTT TTATTCTACA AAAACCATGA AGTCTCTCT CTCTCTCTTA GTTGTTAAAT CAGATTATGT
TTAAATCAA TTTTACAGTG AAAAACCAA AATAAGATGT TTTTGGTACT TCAAGAGAGA GAGAGAGAA GAGAGATTA CAACAATTA GTCTAATACA

601 TCTTTTGTG TTTTGTGTT TAGTGATTCA TGTTTATGAG CAGAGTGGAG TTAAACAATC CTAGCTTAA AAAAAACCTA TTAAATGTAA GATATTCTAC
AGAAAAAAC AAAAACAAA ATCACTAAGT ACAAATCTC GTCTCACCTC AAATTGTAG GATCGAAAT TTTTGTGAT AAATTACATT CTATAAGATG

701 GCATCCTTCA GATATTTTGT ATATCCCCTA TGGCCTTTAG TCTGTACTTT TAATGTACAT ATTTCTGTCT TGTGTGATTT GTAGATTTC A CTGGTAAAA
CGTAGGAAGT CTATAAACA TATAGGGGAT ACCGGAATC AGACATGAA ATTACATGTA TAAAGACAGA ACACACTAAA CATCTAAAGT GACCAATTT

801 GAGAGAACAT TGAAAGGCTT ATGCCAAGTG GAAGATAGAA TATAAATAA AAATGTTACT TGTATATTGG TAAGAGGTTT CAGTTGTCTT TCAGCTAATT
CTCTCTTGTA ACTTTCCGAA TACGGTTCAC CTTCTATCTT ATATTTTATT TTTACAATGA ACATATAACC ATTCTCCAAA GTCAACAGGA AGTCGATTAA

901 CATGTAGAGA AATATTTTAG TTGAAGCCAC AAGAGACAGC TTAGGGCAGT TATGTGTTCA AATAACAGAA GAACAGACTT TTTTTTTTTT TTAAACCAA
GTACATCTCT TTATAAAATC AACTTCGGTG TTCTCTGTCT AATCCCGTCA ATACACAAGT TTATTGTCTT CTTGTCTGAA AAAAAAAA AATTGTGTTT

1001 CCCAAACTGT TGGGAAACCT CAATAGAGCT CTATATGTAT TGGAACAAA GTGGAATTCT CTTCTCCTAT ATATGTTCTT TCAAAAAGAG AGAGAGAATC
GGGTTTGACA ACCCTTTGGA GTTATCTCGA GATATACATA ACCTTGTTTT CACCTTAAGA GAAAGAGGATA TATACAAGGA AGTTTTTCTC TCTCTCTTAG

1101 AAGCAGATGG CTAAAGCTG GTCACAGGAT TGCTCACATT CTTTGGCAT TATGCATCG ACTTAATTGT TTGAGAGTGT GTTGTATTG TAACATCCCA
TTCTCTACC GAATTTCGAC CAGTGTCTTA ACGAGTGTA ACGAACCGTA ATACGTACGC TGAATTAAACA AACTCTACA CAACGATAAC ATTGTAGGGT

1201 GAGATGAATC AAAAAGGCTC ACCCTCTCAC CCAGGAGCAG CTTTTCAGCT TATATACACA TGCATGTACA TGTGTGTGAT ATGCATGTGT GCATGCATGT
CTCTACTTAG TTTTTCGGAG TGGGAGAGTG GGTCCCTCGTC GAAAGTCGA ATATATGTGT ACGTACATGT ACACACACTA TACGTACACA CGTACGTACA

1301 TTGTATTTTT GTGCTTGCCA CTATAACTAT TGCACCTCTC TATTCGGTTT GACTGAAGAG GGGTCTTGTT GGACATCTCT GTGTCCCAGT CTTTATGGGA
AACATAAAAA CACGAACGGT GATATTGATA ACGTGGAGAG ATAAGCCAAA CTGACTTCTC CCCAGAACAC CCTGTAGAGA CACAGGGTCA GAAATACCCCT

1401 AGAAAGCAAG GGTCCTGCAGA GAACAGGAAC TAAAGAATCC CTGTGTGATG TGCAATTAAAT AGAAGGCCTC CTGCTTTCTG GAAATGTAGA CCAGAACTCTG
TCTTTCGTTT CCAGACGTCT CTGTCTCTTG ATTTCCTTAG GACACACTAC ACGTTAATTA TCTTCCGGAG GACGAAAGAC CTTTACATCT GGTCTTAGAC

1501 GCCAGGACTG TAGACTGATA CATATCTGG TCCTTTGCCT TTTTCTTTT CCTCCCTGCC CCTCCCTCTG TTGCTTTATG GATAACCTTG TAACATATTTG
CGGTCCCTGAC ATCTGACTAT GTAATAGACC AGGAAACGGA AAAAGAAAAG GGAGGGGAG AACGAAATAC CTATTGGAAC ATTGATATAAC

1601 AAACCTTTAA AGGAAACCAA GAATGCATTA TTACACACAC ACACACACAC ACACACACTA CAGTAGACCA ACATATAGAG
TTTGGAAATT TCCTTTGGTT CTTACGTAAT AATGTGTGTG TGTGTGTGTG TGTGTGTGTG TGTGTGTGTG GTCATCTGGT TGTATATCTC

1701 TGTTTAAAT AGCTTTTCTG GGCAAAATCA AACAACTTGT GGCTCTAGGA CGCACATCTG TTTCCGTTTT TCTTCAGTTG TATATTGACC AGTATTCTTT
ACAAATTTTA TCGAAAAGAC CCGTTTAAAT TTGTGAACA CCGAGATCCT GCGTGTAGAC AAAGGCAAAA AGAAGTCAAC ATATAACTGG TCATAAGAAA

1801 ATTGCTAAAA CATATACTCG GGTAGCAAT GTCAGCATCT TTTCCCTTCC CATCCTGGAG AGCATTCAAG ACCTTCCCAG TACAGGAACA TCAATGAAGC
TAACGATTTT GTATATGAGC CCCATCGTTA CAGTCGTAGA AAAGGAAGG GTAGGACCTC TCGTAAAGTT TCGAAGGTC TGGAAAGGTC ATGTCCTTGT AGTTACTTTCG

1901 ATTTATATAC AGGCGGTGGC AAGCAGAAAC ACATCCAAA TGGTCAGTGT CGGGCTCTAG GGCAAGGCTA TCTTGTTCCTA GTCCCTGTTC TTTGTGCTCC
TAAATATATG TCCGCCACCG TTCGTCTTGG TGTAGTTT ACCAGTCACA GCCCGAGATC CCGTTCCGAT AGAACAAGGT CAGGACAAAG AAACACGAGG

2001 TGACCTTTGG GGCTGCCACT TCCAGGACG ACCACTGCCT GCCCACACTG TCCCCCCTC CCCCCGGGG GATTTTCCCA ATAGCCAGTT CCCATGTGTC
ACTGGAAACC CCGACGGTGA AGGTCCCTGC TGGTGACGGA CCGGTGTGAC AGGGGGGAG GGGGGCCCC CTAATAAGGT TATCGGTCAA GGTACACAG

2101 TTTTCTTGCA ACGGTATTCA AGCCAATGGA ACCTTCAGAT AGGGCCCAAG AGCAGGATGA CACAACCTGT GGACAAGAGC TATATTAACT TGATCACTAG
AAAAGACGT TGCCATAAGT TCGGTTACCT TGGAAGTCTA TCCCGGGTTC TCGTCCFACT GTGTTGGACA CCTGTTCTCG ATATAATTGA ACTAGTGATC

2201 TATGAGCTAA TATTAAATG ATCACCCTAT AAAGGCGCT GCAAGAGCTG TTTAGTCTGA AATATAGGTA GAGAGCGGGG ATGGCAAGGT TGCTTGTAAAC
ATACTCGATT ATAAATTGTAC TAGTGGGTAC TTTCCGGTAC CTTCTCGAC AAATCAGACT TTATATCCAT CTCTCGCCCC TACCGTTCCA ACGAACATTG

2301 TTCTGGFACA TGTTGAATGC ACACACGCAT GGAGGCAAGC TCTAAATCAC TGCACGTGTA CTGTAAAGCA TACTTTAAAA ATATTATTG TTTTGAAAAAG
AAGACCATGT ACAACTTACG TGTGTGCGTA CCTCCGTTCTG AGATTTAGTG ACGTGACAAT GACATTTCTG ATGAAAATTTT TATAAATAAC AAAACTTTTC

2401 CATTTCCTAG TCTTCCCTCT CTGGTGGAG CTGTAAACAA GATGCATGT TGGAAGGTT CAAGATGATT TTTTTTTAAA TCGCAGAAAC ATTTAGACAC
GTAAAAGATC AGAAGGGAGA GAACCACTC GACATTGTGT CTACCGTACA ACACTTCCAA GTTCTACTAA AAAAAATTT AGCGTCTTTG TAAATCTGTG

2501 CTAAGAACTA AAACCTATAA AAGGATCTT TGAATTGCC TGTTAACATG GATTAATGTT TACACTTACA GCTGATGATT GGACGGTGTG TTATGTTAGG
GATTCTTGAT TTTGAATATT TTCCCTAGAA ACTTAAACGG ACAATTGTAC CTAATTACAA ATGTGAATGT CGACTACTAA CCTGCCACAA AATACAAATCC

2601 GAAATGCCCT GTTAACGAAC TTCATGAAGC AGATGTAATT AAAGGTTGAT GTGAGCCAAT CTAGAAGGTT GAACAGTGTG TTCAAAGAAC GGAGAGACTT
CTTACGGAA CAATTGCTTG AAGTACTTCG TCTACATTA TTTCCAACTA CACTCGGTTA GATCTTCCAA AGTTTCTTG CCTCTCTGAA

2701 ACATTTTGA CCAATCTTTA TACATTTTGC TGAGCTAGAA AGGAGATAAA GATTATTAT TTTTGTTCAT ATCTGTACT TTCTATTA AATCATTTA
TGTAATAATCT GGTAGAAAT ATGTAAACG ACTCGATCTT TCCTCTATTT CTAATAAATA AAAACAAGTA TAGAACATGA AAAGATAATT TTAGTAAAT

2801 TGAAAWMMAA AAAAAAAAAA AA
ACTTWKKTT TTTTTTTTTT TT

FIG.-2C

6 / 23

CCCACGCGTCCGCATATGTCTCCTTTGTGAGGATCAACAGCTCGCTGGCAGTGGCGGCTT
ACGAGGATGGGATCCTTAACATTTGGGACCTGAGAACCGGAAGGTTCCCTATCTTTCGTT
TTGAGCATGAGGCAAGAATACAAGCCCTTGCGCTGAGCCAAGAAAAGCCCATTTGTTGCCA
CGGCTTCTGCTTTTGACGTTGTGATGTTGTACCCCAACGAGGAGGGGCATTGGCATGTGG
CCTCGGAGTTTGAAGTTCAGAAGCTGGTTGACTACCTTGAAATAGTTCCGAATACTGGGA
GGTACCCTGTGGCAATAGCCACAGCCGGGGATCTGGTGTACCTGCTGAAGGCCGACGACT
CAGCCAGAACCCTTCATTATGTCAATGGCCAGCCTGCCACATGTCTGGATGTCTCAGCCA
GCCAGGTTGCCTTTGGAGTGAAGAGTCTAGGATGGGTGTATGAAGGAAACAAGATCCTGG
TGTACAGCCTGGAAGCAGAGCGCTGCCTCTCGAAGCTGGGCAATGCACTTGGAGACTTTA
CCTGTGTCAACATCCGGGATAGCCCTCCCAACCTCATGGTCAGCGGCAACATGGACAGGA
GAGTGAGGATTCATGACCTCCGCAGCGATAAGATCGCCCTGTCGCTGTCTGCCCCATCAGC
TGGGGGTGTCCGCAATTCCAAATGGATAACTGGAAAGGTTGTCAGTGGAGGCCAGGAGGG
GTGGTGT

FIG. 3

7 / 23

1 CCCACGGCTC CGCATATGTC TCCTTTGTGA GGATCAACAG CTCGCTGGCA GTGGCGGCTT ACGAGGATGG GATCCTTAAC ATTTGGGACC TGAGAACCGG
GGGTGCGCAG GCGTATACAG AGGAAACACT CCTAGTTGTC GAGCGACCGT CACCGCCGAA TGCTCCTACC CTAGGAATTG TAAACCCCTGG ACTCTTGGCC

101 AAGGTTCCCT ATCTTTCGTT TTGAGCATGA CGCAAGAATA CAAGCCCTTG CGCTGAGCCA AGAAAAGCCC ATTGTGCCA CGGCTTCTGC TTTTGACGTT
TTCCAAAGGA TAGAAAGCAA AACTCGTACT GCGTTCCTTAT GTTCGGGAAC GCGACTCGGT TCTTTTCGGG TAACAACGGT GCCGAAGAGG AAAACTGCAA

201 GTGATGTTGT ACCCCAAACGA GGAGGGGCAT TGGCATGTGG CCTCGGAGTT TGAAGTTCAG AAGCTGGTGG ACTACCTTGA AATAGTTCCG AATACTGGGA
CACTACAACA TGGGGTTGCT CTCTCCCGTA ACCGTACACC GGAGCCTCAA ACTTCAAGTC TTCGACCAAC TGATGGAAC TTTATCAAGC TTTATGACCTT

301 GGTACCCCTGT GGCAATAGCC ACAGCCGGG ATCTGGTGA CCTGCTGAAG GCCGACGACT CAGCCAGAAC CCTTCATTAT GTCAATGGCC AGCCTGCCAC
CCATGGGACA CCGTTPATCGG TGTCGGGCCC TAGACCACAT GGACGACTTC CGGCTGCTGA GTCGGTCTTG GGAAGTAATA CAGTTACCGG TCGGACGGTG

401 ATGTCTGGAT GTCTCAGCCA GCCAGGTTGC CTTTGGAGTG AAGAGTCTAG GATGGGTGTA TGAAGGAAAC AAGATCCTGG TGTACAGCCT GGAAGCAGAG
TACAGACCTA CAGAGTCGGT CGGTCCAACG GAAACCTCAC TTCTCAGATC CTACCACAT ACTTCCCTTG TTCTAGGACC ACATGTGCGA CCTTCGTCTC

501 CGCTGCCTCT CGAAGCTGG CAATGCACTT GGAGACTTTA CCTGTGTCAA CATCCGGGAT AGCCCTCCCA ACCTCATGGT CAGCGGCAAC ATGGACAGGA
GCGACGGAGA GCTTCGACCC GTTACGTGAA CCTCTGAAAT GGACACAGT GTAGGCCCTA TCGGGAGGT TGGAGTACCA GTCGCCGTG TACCTGTCTC

601 GAGTGAGGAT CCATGACCTC CGCAGCGATA AGATCGCCCT GTCGCTGTCT GCCCATCAGC TGGGGGTGTC CGCAGTCCAG ATGGATGACT GGAAGGTTGT
CTCACTCCTA GGTACTGGAG GCGTCGCTAT TCTAGCGGA CAGCGACAGA CCGGTAGTCG ACCCCACAG CCGTCAAGTC TACCTACTGA CCTTCCAACA

701 CAGTGGAGGC GAGGAGGGG TGGTGTCTGT GTGGGATTAC CGCATGAACC AGAAGCTGTG GGAAGTGAC TCCAGGCACC CTGTGCGCTA TCTCTCTTC
GTCACCTCCG CTCCCTCCCG ACCACAGACA CACCCTAATG GCGTACTTGG TCTTCGACAC CCTTCACGTG AGGTCCGTGG GACACGCGAT AGAGAGGAAG

801 AATAGCCACA GCCTCATCAC TGCCAACGTG CCCTACGAGA AGGTGCTGCG AAACCTCCGAC CTCGACAACT TTGCCCTGTCA CAGGAGACAT CGTGGCCTGA
TTATCCGTGT CGGAGTAGTG ACGGTGTCAC GGGATGCTCT TCCACGACGC TTTGAGGCTG GAGCTGTTGA AACGGACAGT GTCCTCTGTA GCACCGGACT

901 TCCATGCCCTA TGAATTTGCT GTGGACCAGC TGGCCTTTCA GAGCCCCCTT CCTGTCTGCC GCTTACCCCG TGACATCATG GCTGGATACA GCTATGACCT
AGGTACGGAT ACTTAAACGA CACCTGGTGC CACCTGCTG ACCGGAAGT CTCGGGGGAA GGACAGACGG CGAATGGGGC ACTGTAGTAC CGACCTATGT CGATACTGGA

1001 CGCACTGTCT TTCCCCCATG ACAGTATTTA GGGTGTACCC TCATGTAGAC GTGGAAAGGG CAGTTTACA AATGTTAGAG TTGGAGAGAG GCTCTGCAGC
GCGTGACAGA AAGGGGTAC TGTCATAAAT CCCACAGTGG AGTACATCTG CACCTTTCCC GTCAAAATGT TTACAATCTC AACCTCTCTC CGAGACGTCG

1101 ACATGGTGG AGTTTGGGA CAGTGTCTG TATGACTGTG GCCACACAGC CCTGTGCCC TGTACAGAAC CAGACTCCAT TGCTGCCCTT CTCCCTCCTCC
TGTACCACCC TCAAACCCCT GTCACAGGAC ATACTGACAC CGGTGTCTG ACATGTCTTG GTCTGAGGTA ACGACGAAA GAGGAGGAGG

1201 TCCTCCTCCT CAGGCTTTGG TAGGACTGGC TGATGACTCA GAGTTAACCT TTCCAGGGGT GGCTCCTCCC CCTCAGCCTA TGGCAGCAGT GACACCCCCC
AGGAGGAGGA GTCCGAAACC ATCCTGACCG ACTACTGAGT CTCAATTGGA AAGGTCCCA CCGAGGAGG GGAGTCGGAT ACCGTCGTCA CTGTGGGGGG
1301 CTCGTTCCAT AGGCCAGGA CACAGGCCCT TCACTTGAC TGTCTCCTGG GTGTGGTGCT GAGGTGGAA CCAGAATCTC ACACGCATAG GCAAGCGTCA
GAGCAAGGTA TCCGGTCCCT GTGTCCCGGA AGTGAACGTG ACAGAGGACC CACACCACGA CTCCCACCTT GGTCTTAGAG TGTGCGTATC CGTTCCGAGT
1401 GCCTCCAAGC TGCCTCCCCA GCTGTACGCC TCCCCAGCTG TCTCCTCCAG GCACCCCTCA GTGCAGCCCC TCCTCTGGGA TTCACACCGT TGATAATTAT
CGGAGGTTCG ACGGAGGGGT CGACAGTCCG AGGGTTCGAC AGAGGAGGTC CGTGGAGGT CACGTCCGGG AGGAGACCCT AAGTGTGGCA ACTATTATA
1501 AGGGCCACCT TACCTGTAGG AGCTGTTCTG TCCCTGTACAT GTGCTATGAA GGAGACAGCC ATCCTTCCCTG CAGAGGGAA GGTTCATTGC ACAGGGATAG
TCCCGGTGGA ATGGACATCC TCGACAAGAC AGGACATGTA CACGATACTT CCTCTGTCCG TAGGAAGGAC GTCTCCCTTT CCCAGTAAAG TGTCCCTATC
1601 GGTCAGTCTC CAAGCCTAGC CCGTGGTGTG TCTTCTGTAC AAACGCAGCC ATAGCTCACC CACTCTGCCCT TCAGAGTGTG ATGGACAAAT CCACACATAG
CCAGTCAGAG GTTCGGATCG GCCACCACAG AGAAGGACTG TTTGCGTCGG TATCGAGTGG GTGAGACGGA AGTCTCACAG TACCTGTTTA GGTGTGTATC
1701 TGGCCAGGAG ACCAGTTCAG AGCTCTTCAG AATCCCCACA GACCAGGCAC CTAACACACC TGCACAGAGG CCACCAGGTC TCAGGAGACA AAGTTCCTCT
ACCGTCTCTC TGGTCAAGTC TCGAGAAAGTC TTAGGGGTGT TTAGGGGTGT CTGGTCCGTG GATTGTGTGG ACGTGTCTCC GGTGTCCAG AGTCCCTCTGT TTCAAGGAGA
1801 CCCAGGGAAT ACCAGCTCAA AAAACAAGTG GGCTGGCAA CTCCACATTG GGCTGCCGA GAGCAAGAAA AAAGAGGGGG GTGGGGGAGC TCCATGGGGT
GGGTCCCTTA TGGTCGAGTT TTTTGTTCAC CCGACCGTTT GAGGTGTAAC CCAGACGGCT CTCGTTCTTT TTTCTCCCCC CACCCCTCG AGGTACCCCA
1901 GGATCCCAGG CTGGCAGCAG GAAGGTGCTG GAAGGCCTGA GAGGTGTGC AGTGCCCTCC CCGAGCCCTG GTGGTCTCCT CCTGTGTGCT GGGATGGAGT
CCTAGGGTCC GACCGTCGTC CTTCCACGAC CTTCCGGACT CTCCACACAG TCACGGGAGG GGCTCGGGAC CACCAGAGGA GACACACGA CCTACCTCA
2001 CTAGTGGGTT TGTGGCATGA TCTCAGATCT TGGCATTGAG GCCTCTCCCC ATGCACAAAT GCCCAGGGA GCTCACCTCC CTCTTGCTGG GCTGGCGCCC
GATCACCCAA ACACCGTACT AGAGTCTAGA ACCGTAACTC CGGAGAGGGG TACGTGTTCA CCGGTCCCCCT CGAGTGGAGG GAGAACGACC CGACCGCGGG
2101 CCTGCTGGCC TGGTCTTGCT GTGTCTCTAC TCGAGCATTC CCAGTCTTAA GCTGTCCACT GGAGACATTT CTGTCAAGGA AATTGGCTGT GCGGTCAGCT
GGACGACCGG ACCAGAACGA CACAGGAGTG AGCTCGTAAG GGTCAAGATT CGACAGGTGA CCTCTGTAAA GACAGTCTCT TTAACCGACA CGCCAGTCTGA
2201 CCTTCTGGG CTTTCGAGCC ATGAAAGGCC ACTGAAGAGC AGAGTGACT AGAGTAGTTT CAAGCATACA TGCCCTTCTA GCCCCAATC CCTGCCCTCT
GGAAAGACCC GAAGCGTCGG TACTTTCCGG TGACTTCTCG TCTCCACTGA TCTCATCAA GTTCGTATGT ACGGGAAGAT CCGGGGTAG GGACGGGGGA
2301 ACCCCCACAG AGCATCTGTC CTCGCTGGCT CCTGCCACTG CACCTGCTCC CAGGGTGGG GACAGGCTGG CTCCCCTGTG TGCCTCTGAA GCCAGAAGAC
TGGGGGTGTC TCGTAGACAG GAGCGACCGA GGACGGTGAC GTGGACGAGG GTCCCACCCC CTGTCCGACC GAGGACACG ACGGAGACTT CGGTCTTCTG
2401 ACCAGGACAC AGCCCTGGGA GCCAGGGGTG GTCACACATC TGCAGCTTGC CTTTGTGCTT AAGCGGCCAC TTCTGCTCTG TTATTAAGG TTCTACACTG
TGGTCCCTGT TCGGACCCCT CGGTCCCCAC CAGTGTGTAG ACGTGGAACG GAAAACGGAA TTCGCCGGTG AAGACGAGAC AATAATTTC AACATGTGAC
2501 AAAAAAAAAA AAAAAAAAAA AAAAAA
TTTTTTTTTT TTTTTTTTTT TTTTTT

9/23

1 CTCCAACAGC GCAGGGCAGA GCGGCTGGCG CCGCCGGAGC GCGGAGCCAC GACCCCTCCCT GGCCGCCTTT GTCTACTGGC CGTGGGGCCC GGAACCGCCA
GAGGTTGTGCG CGTCCCGTCT CGCCGACCGC GGCGGCTCG CGCCTCGGTG CTGGGAGGGA CCGCGGAAA CAGATGACCG GCACGCCGGG CCTTGGCGGT

101 CTCTCCAGGG CCGGGGACGC GCCCGCAGCT GTCGGTGACA GCTCCTCCCT ACCGCAACCC TCCGGGGCGG AGGGCGGTC GGGCCGGGCC CTGCTAGCCC
GAGAGGTCCC GGCCCTGCG CGGGCGTCGA CAGCCACTGT CGAGGAGGGA TGGCGTTGG AGGCCCGCC TCCCGCCAG CCGGGCCCGG GACGATCGGG

201 GCGACCGCAA GCGCGCGCTC GCGGATCGAT GCCCCCGCAG CAGGGGACC CCGCGTTCCC CGACCGCTGC GAGCGCCTC CGGTGCCGCC GCGTCGGGAG
CGCTGGCGTT CCGGCGCGAG CGCCTAGCTA CCGGGCGTC GTCCTCCCTGG GCGCAAGG GCTGGCGACG CTCCCGGGAG GCCACGGCGG CGCAGCCCTC

1 M P P Q Q G D P A F P D R C E A P P V P P R R E

301 CGCGGTGGAC GCGGGGACG CGGCCCTGG GAGCCGGGG GCGGGGGCG TCGGGGGGT GCCGAGGGG GCGGCGTCAA GTGCGTGCTG GTCGGCGACG
GCGCCACCTG CGCCCTCTGC GCCCGGACCC CTCGGCCCGC CGGCCCGCC CGGCTCCCG CGCGCAGTT CACGCACGAC CAGCCGCTGC

25 R G G R G G R G P G E P G R A G G A E G R G V K C V L V G D G

401 GCGCGTGG CAAGACGAGC CTGGTGGTGA GTTACACCAC CAACGGTAC CCCACCGAGT ACATCCCTAC TGCCTTCGAC AACTTCTCCG CGGTGCTGC
CGGCCACCC GTTCTGCTCG GACCACCACT CAATGTGGTG GTTGGCGATG GGTGGCTCA TGTAGGATG ACGAAGCTG TTGAAGAGGC GCCACCACAG

59 A V G K T S L V V S Y T T N G Y P T E Y I P T A F D N F S A V V S

501 TGTGGATGG CGGCCCGTGA GACTCCAACT CTGTGACACT GCGGACAGG ATGAATTGA CAAGCTGAG CCTCTCTGCT ACACCAACAC AGACATCTC
ACACCTACCC GCGGGGCACT CTGAGGTTGA GACACTGTGA CCGCTGTCC TACTTAACT GTTCGACTCC GGAGAGACGA TGTGTTGTG TCTGTAGAAG

92 V D G R P V R L Q L C D T A G Q D E F D K L R P L C Y T N T D I F

601 CTGCTCTGCT TCAGTGTGCT GAGCCCTCA TCCTTCCAGA ACCTCAGTGA GAAATGGGTG CCGGAGATTC GATGCCACTG TCCCAAAGCC CCCATCATCC
GACGAGACGA AGTCACAGCA CTCGGGGAGT AGGAAGTCT TGCAGTCACT CTTTACCCAC GGCCTCTAAG CTACGGTGAC AGGGTTTCGG GGTAGTAGG

125 L L C F S V V S P S S F Q N V S E K W V P E I R C H C P K A P I I L

701 TAGTTGGAAC GCAGTCGGAT CTCAGAGAAG ATGTCAAAGT CCTCATTTAG TTGGACAAAT GCAAAGAAA GCCAGTGCCT GAAGAGGCGG CTAAGCTGTG
ATCAACCTTG CGTCAGCCTA GAGTCTCTC TACAGTTTCA GGAGTAACTC AACCTGTTA CGTTTCTTTT CCGTCACGGA CTCTCTCCGC GATTCGACAC

159 V G T Q S D L R E D V K V L I E L D K C K E K P V P E E A A K L C

801 CGCCGAGGAA ATCAAAGCCG CCTCCTACAT CGAGTGTTC GCTTGACTC AAAAAACCT CAAAGAGGTC TTTGATGCAG CCATCGTCGC TGGCATTCAA
GCGGCTCCTT TAGTTTCGGC GGAGGATGTA GCTCACAACT CGGAACAGT TTTTTCGGA GTTCTCCAG AAACCTAGTC GTAGCAGCG ACCGTAAGTT

192 A E E I K A A S Y I E C S A L T Q K N L K E V F D A A I V A G I Q

10 / 23

11/23

2101 TGGCCACAAA AACAGATGCT AGGAAGCTTG GCTTCCCTCTT CTGTGTTGACC CTTTMTTGAA CCAACATCTT TTTTATTATA TTCAGAGTAT GTTMTTAAAGT
ACCGGTGTTT TTGTCTACGA TCCTTCGAAC CGAAGGAGAA GAACAACCTG GAAAAAACTT GGTGTAGAA AAAATAATAT AGTCTCATA CAAAAATTCA

2201 GTATCTTAAT ATATACATTT TTTAGGACAT CTAAATCTA AACAAAAAT AAAATGAACA TCTCTTGAAA CCTGTAAAA CAACCAGTTA AAGCCACAGA
CATAGAAATTA TATATGTAAA AATCCTGTA GAATTTAGAT TTGTTTTTTA TTTTACTTGT AGAGAACTTT GGACAAATTT GTTGGTCAAT TTCGGTGTCT

2301 TGGCTTTCAG GGCAGTAGCA GCAGAGGCCA GTGGACTCTG AGGAGCGGG CGTGTAGCCA GCCAGGTGCA TGCCGGGACC ATGGCCCCCA
ACCGAAAGTC CCGTCATCGT CGTCTCCGGT CACCTGAGAC TCCTGAGGAC TCCCGCCCC GCACATCGGT CGGTCCACGT ACGGCCCTGG TACCGGGGGT

2401 TACTTGGCTG CTTCTCTGTGA CAGTGAAATA CATCCTTCAA GGTGGCAGCT GTTAGGGCTG AATCTTCTGG AGAAAAAGGT GCCATCTCAG GAGAATAGCT
ATGAACCGAC GAAGGACACT GTCACCTTTAT GTAGGAAGTT CCACCGTCCA CAATCCCGAC TTAGAAGACC TCTTTTCCCA CGGTAGAGTC CTCCTTATCGA

2501 TTTACTCTGG TAGGAATGCT TCCGAGACAC CACAAGCAG CCTGAACACT CAGTGCAGG GTCGGGCTG CCGTGGGTGA CCCAGAGCCA CCAAAGTCAC
AAATGAGACC ATCCTTACGA AGGCTCTGTG GTGTCTCGTC GGACTTGTGA GTCAACGTCC CAGCCCCAAC GCCACCCACT GGTCTCGGT GGTTCAGTG

2601 ATCCACAAC TATGAGGAA ATCTGTAAAG CCAGTTAGAT AGAAGAGTTT TATTTTCTG TGGTMTTGT GTTGTCTTTT TTATGTTAAA AAGAAATCCA
TAGGTGTGA TTACTCCCTT TAGACATTTT GGTCAATCTA TCTTCTCAA ATAAAAAGAC ACCCAAAACA CAACAGAAA AATACAATTT TTTCTTTAGGT

2701 GTTGTGTTT TTCTATAGAA AAGTAAAG ATCAGGTTAT ACTTAGGTT AGGGTTCTA TTTATTCCTG TTAGTAAATA AAATTAACAA ATTTCTTTGT
CAACACACAA AAGATATCTT TTTTATTTT TAGTCCAATA TGAAATCCAA TCCCAAGAT AAATAAGGAC AATCATTTAT TTTAATMTGT TAAAGAAACA

2801 TTAACAAAAG ATTAATCTTT AAACCACTAA AATACATAGA CTGATTGATT ATTCAACACA TTGGAATTGA TGTCCGTCAT AGTTTCCTGA AGCATTTAGT
AATGTMTT TAATTAGAAA TTTGGTGATT TTATGTATCT GACTAACTAA TAAGTGTGT AACCTTAACT ACAGCCAGTA TCAAAGGACT TCGTAAATCA

2901 TACAACCTGA AGGAATAAAA TGATTTGTG AAATGCTTAA AATAGACCTA ACTGAATACA GTCTCATCTT GCCGCGCCTG GCTTACCTAT CTGTGGAAAG
ATGTTGGACT TCCTTATTTT ACTAAACACC TTTACGAATT TTATCTGGAT TGACTTATGT CAGAGTAGAA CGGCGCGGAC CGAATGGATA GACACCTTTC

3001 CTAGGCTTCC CAGGTGGGCT CTGCCCTGTCT GGTGCCCTGGA GGAAGATGAG TTATTTAACT GGTAAAGCGAT TTGAAACACT ATTTTATATAT
GATCCGAAG GTCCACCCGA GACGGACAGA CCACGGACCT CCACACCCTC CTTCTACTC AATAAATTGA CCATTGCTA AACTTTGTGA TAAAAATATA

3101 TAAAGTAAAT GGCATGGAGT ATAGTGCAA TTCTATTTTA AGATAGACA CAAAACTGA AAGAGTTTT ATGCGTGTGA CAGTGTATGG GGTGCAAGT
ATTTTCATTTA CCGTACCCTCA TATCACGTTT AAGTAAAAAT TCTATCTTGT GTTTTGAACT TTCTTCAAAA TACGCACACT GTCACATACC CCGACGTCAA

3201 GGTCTCCCTG GAGGGGACTT CCACACCCTC TGCCTTTAGG CCATGGGTG AAAGTGCTA GTGAAGTACA CCTGTGTGSC CCAGTCTGA AAGCTTTATA
CCAGAGGAC CTCCCCGTGA GGTGTGGAG ACGGAAATCC GTTACCGAGT CACTTCATGT GGACACACCG GGTCAAGACT TTCGAAATAT

3301 CAGTTGAATT TTAAGTGGG TTGATAACAC CTGGACTGT TAGTGTAAA AATCTAGTG GTTGACCTTT AAATGCACAG TTTTAAAAT ATATTGCTGC
GTCAACTTAA AATTCACCCC AACTATTGTG GAACCTGACA ATCACAATTT TTAGATCACC CAACTGGAAA TTTACGTGTC AAAATTTTA TATAACGACG

3401 ATTTTATAGA ATAGTAAAGG TACGATTATA CTTGAGATTT TCCTCCATTT TTATTCTTC GTGAACATAG AGTTGGGGC CGAAAATGTT TTAAAAGTAT
TAAAAATATCT TATCATTTCC ATGCTAATAT GAACTCTAAA AGGAGGTAAA AATAAAGAAG CACTTGATC TCAAACCCCG GCTTTTACAA AAATTTTATA

3501 GTGTTTGAGT TAAATATAAA GTTGGTTCAC TTCAAAGCTA AAAAATTGTT AAACITGCAG CTTGGTATTG CAGAGAAGAT TTTATAAGAA TTTTGCTTTA
CACAAACTCA ATTTATATTT CAACCAAGTG AAGTTTCGAT TTTTAAACAA TTTGAACGTC GAACCATAC GTCTCTTCTA AAATATTCTT AAAACGAAAT

3601 GAGAAAGCCA CTTTGGCTGA ACTACAAGTG TAGGCCACCA TTATAATTTA TAAATCCAGC ATACTTCAA ACTGTTTGT ATCTCTTGT ACCATGTATG
CTCTTACGGT GAAACCGACT TGATGTTTAC ATCCGGTGGT AATATTAAAT ATTTAGGTG TATGAAGTTT TGACAAACAA TAGAGAACAA TGGTACATAC

3701 TATAAATGGA CCTTTTATAA CCTTGTCTC TGCTTGACAG ACTCAAGAGA AACTACCCAG GTATTACACA AGCCAAAATG GGAGCAAGGC CTCTCTCCA
ATATTTACCT GGAAAATATT GGAACAAGAG ACGAACTGTC TGAGTTCTCT TTGATGGGTC CATAATGTGT TCGGTTTAC CCTCGTTCCG GAAGAGAGGT

3801 GACTATCGTA ACCTGGTGCC TTACCAAGTT GTGCTTTCT GTTTTCAAGT GTAAATGATG TTGAGCAGAA TGTGTACTT GAAAATGCTA TAAAGTATGAT
CTGATAGCAT TGGACCAACGG AATGGTTCAA CACGAAAAGA CAAAAGTTCA CATTTACTAC AACTCGTCTT ACAACATGAA CTTTTFACGAT ATTCACTCTA

3901 GGTATGAAAT AAATCTGAC TTATGAATAT AAAAAAAA AAAAAAAA
CCATACTTTA TTTAAGACTG AATACTTATA TTTTTTTT TTTTTTTT TTTTTTTT

FIG. 5D

mouse.cl.65 1 M A P Q Q G R P A L P A R C E P P A A P P V P P R R E R G G R G A R G P G V S G G R G R A G G A E G
human.cl.65 1 M P P Q Q G D P A F P D R C E . . . A P P V P P R R E R G G R G R G P G E P G G R G R A G G A E G

mouse.cl.65 51 R G V K C V L V G D G A V G K T S L V V S Y T T N G Y P T E Y I P T A F D N F S A V V S V D G R P V
human.cl.65 48 R G V K C V L V G D G A V G K T S L V V S Y T T N G Y P T E Y I P T A F D N F S A V V S V D G R P V

mouse.cl.65 101 R L Q L C D T A G Q D E F D K L R P L C Y T N T D I F L L C F S V V S P T S F Q N V G E K W V P E I
human.cl.65 98 R L Q L C D T A G Q D E F D K L R P L C Y T N T D I F L L C F S V V S P S S F Q N V S E K W V P E I

mouse.cl.65 151 R R H C P K A P I I L V G T Q S D L R E D V K V L I E L D K C K E K P V P E E A A K L C A E E V K A
human.cl.65 148 R C H C P K A P I I L V G T Q S D L R E D V K V L I E L D K C K E K P V P E E A A K L C A E E I K A

mouse.cl.65 201 V S Y I E C S A L T Q K N L K E V F D A A I V A G I Q H S D S Q L Q P K K S K S R T P D K V R D L S
human.cl.65 198 A S Y I E C S A L T Q K N L K E V F D A A I V A G I Q Y S D T Q Q P K K S K S R T P D K M K N L S

mouse.cl.65 251 K S W W R R K Y C C L A
human.cl.65 248 K S W W K K Y C C F V

FIG._6




FIG. 7




FIG. 8




FIG. 9

17 / 23

5' - CCCACGCGTCCGCGCGGTGGGCAAGACCAGCCTGGTGGTCAGCTACACCACTAACG
GCTACCCCAACGAGTACATCCCTACGGCCTTCGACAACCTCTCGGC
CGTGGTGTCTGTAGATGGGCGGCCTGTGAGACTCCAGCTCTGTGACACTGCAGGACAGG
ATGAGTTTGACAAGCTGAGGCCCCTCTGCTACACCAACACAGACATCTTCCTGCTGTGCTTCA
GCGTGGTGGAGCCCCACATCCTTCCAGAACGTGGGCGAGAAGTGGGTTCAGAGATTTCGAC
GTCAGTGGCCAAAGGCCCCCATCATCCTGGTCGGGACACAGTCGGACCTCAGGGAGGACGTCA
AAGTGCTCATAGAACTGGCTTCTGCAGGGCATCTGTGTCTGCTGTTAAAAGCAGGAGGAG
GTGCTTGTCTGGGAGCTTTAAGTGTGCTGGGCTCATATCGTCCCGTTTGCAAGGAATTG
GGCCACCTTGAGAGGCCATAGTTGATGGCTATGGGACACACACACACTTTTTCCTTAAGTCC
ACCAAATGCCTGCCTGTACACACACACACACACACACACACACACACACACACACT
GGCTGGTTTGCTGATGGAACCCTTAGACCACCCTCCCACCCCCACCCCTCCCCAAGCATGGC
TGCAAGTGTCAGGGCACCAACCTTCTCTTGACATTTCTTTGAACAGACATCATTT
TGTAGGATCTTAATTTATACATTTTTTTTCAGGTCATAAAATGTGGGATGAACATACT
TTGAACCCCAAGTGCCTTCAGGGTCCATTGACTAGGGAGGCACTGTCTTAGGGGACAGGTAT
GTGCAAGGCCTTACCCACCAGTGGCTTCTCGCTGCAGGTCATGTTTGTGGCACTTGTTCTT
TAAGGTGAGGGTCTTATGACCGACTGTTCTGAGACAGCCCTGTGTCAGGCAAGCTCTTT
CACAGGGTTGTAGGTATTTCCAAGACGCCATAGGAACCAGACAGTGAATCATAGCTATCAGT
TTGCTGTGGGCAAGGAACCTCTTTTTTGGCCACCTGGTAACAAAATTTTATGTCT
GTAAATTTTTTTCTTGCTATTTAAAAAATAATCAATCTTACGTTTTTCTGTAGGAAA
AAAAAAACAAGTAAAAGAACAGGCCATATTTTCAGGTCAAAGGCTTCTTCCTGCTG
GTAAATGGGACTGAAGACTTTCTTACATCATTATTAAAAGGCTAATTGCTGAACCA
CTAGAGTATATGAACTGTTTGTGAATGATATTAGCCATAGTCTCCTGAGGTGTTT
CCTTGTGGCCTGAGTGGTAACATTGTTTTGCTTATGGAGATGCTGTAAGTACCTAGTGACTCAGC
TTATCCTATTGTGCATGGCTGTCTGGAAAGCCAGCGTACAAGTGGGGCTTTCCTGCCCTGTGTA
CAGAGGGTGGGTGGGAAAGAGTGAATTATTTAATTTTAAATGTTATAATAAGCCAATGTAGTTGA
GACCAAGGAAATGAGCATTGAGAACACAACTTGAAGTCTGGTGCCAGGGTTGTTGGACCTC
ACACCCTGTCTCTGAGCCACCCGGAAGTGACATAAAGGACGCTGTGTGATCAAGT
TCTGGACACTTTTCTGGGATGCGTACCCTGGACTATTTATGTCACAAATCTAGTGGGT
GACGCTGCCCTGCAAGTTTTCAATGTCCCTGCATCCTATGAAGTCATAATGTCTGAC
TGTAAGTGGAGGTTTTCTGCATTTTTTTACTTTTTCGAAAATAGAGGTTTGGGCTGAGAAT
TCTAAACGCATGTGCCTGGGTGGGACGTCAAGTCAGGGTTCTCATCAAAGCTGAGAA
GTGGCTGGAATGTTTCAAGCTTGGTGTCTGGGGAGGATCCTGTGAGCTATGTAGA
GAGGTGGCTCTTCAGCCTGACTCAGTGTGGGCTGAACGAAGTACCTGCAGAACACACGGT
AGCAGGCTCCAAAATCGTCACCTCAAGCATGCGTGCAAGCAAACCTTCCGAGAACTCC
GTTTTCTGCTCGGCAGACGTGTGAGCAGCTACCCAGAAGTCTCAAGCCAAAAGGGGAGCCTCG
CTCGCTGGCTCCTCTGCAGGTGCCTTATCGACCTGTGCTCTTCTTTTTCCCGTGTCAA
GATGTTGGACAGGATCTTGTACTTGAAACATACTACAAATGAGTTACTATGAAATAAATTC
TGACCTGTGGACCGAAAAA

FIG. 10

18 / 23

5' -CCCACGCGTCCGCACGTGACCAGTTATATTGCTATGAAAATGGTGGAGATGCCTCGTA
GAAGGCGAGTGCTGGGTGCACATGTGACATTTTCTTCAGGGAGCGACTCATGGTGAGACCA
GAGAGGGCTCTTAGCTTGCAGGACTGGCTTCTGCAGGGCATCTGTGTCCTGCTGTTAAAAG
CAGGAGGAGGTGCTTGTCTGGGAGCTTTAAGTGTGCTGGGCTCATATCGTCCCGTTTGCA
AGGAATTGGGCCACCTTGAGAGGCCATAGTTGATGGCTATGGGACACACACACACTTTTT
CCTTAAGTCCACCAAATGCCTGCCTGTACACACACACACACACACACACACACACACAC
ACACACACACTGGCTGGTTTGCTGATGGAACCCTTAGACCACCCTCCCACCCCCACCCCT
CCCCAAGCATGGCTGCAAGTGTGAGGGCACCACACCTTCCTCTTCTTGACATTTCTTTGA
ACAGACATCATTTTGTAGGATCTTAATTTATACATTTTTTTTTCAGGTCATAAAATGTGGGA
TGAACATACTTTGAACCCCAGTGCCTTCAGGGTCCATTGACTAGGGAGGCACTGTCTTAG
GGGACAGGTATGTGCAAGGCCTTACCCACCAGTGGCTTCTCGCTGCAGGTCATGTTTGTG
GCACTTGTTCCTTAAGGTGAGGGTCTTATGACCGACTGTTCTGAGACAGCCCTGTGTCAG
GCAAGCTCTTTCACAGGGTTGTAGGTATTTCCAAGACGCCATAGGAACCAGACAGTGAAT
CATAGCTATCAGTTTGCTGTGGGCAAGGAACCTCTTTTTGGCCACCTGGTAACAAAATTT
TATGTCTGTAAATTTTTTCTTGCTATTTAAAAAATAATCAATCTTACGTTTTTCTGT
AGGAAAAAAAAAACAAGTAAAAGAACAGGCCATATTTTCAGGTCAAAGGCTTCTTCCTGC
TGGTAAATGGGACTGAAGACTTTCTTACATCATTATTAAGGCTAATTGCTGAACCACT
AGAGTATATGAACTGTTTGTGAATGATATTAGCCATAGTCTCCTGAGGTGTTTCCTTGTG
GCCTGAGTGGTAACATTGTTTTGCTTATGGAGATGCTGTAACCTGACCTAGTGACTCAGCT
TATCCTATTGTGCATGGCTGTCTGGAAAGCCAGCGTACAAGTGGGGCTTTGCCTGCCCTG
TGTACAGAGGGTGGGTGGGAAAGAGTGAATTATTTAATTTTAAATGTTATAATAAGCCA
ATGTAGTTGAGACCAAGGAAATGAGCATTGAGAACACAACTTGAAGTCTGGTGCCAGGG
TTGTTGGACCTCACACCCTGTCTCTGAGCCACCCGGAAGTGACATAAAGGACGCTGTGTG
ATCAAGTTCTGGACACTTTTCTGGGATGCGTACCACTGGACTATTTATGTCACAAATCTA
GTGGGTTGACGCTGCCCTGCAAGTTTTCAATGTCCCTGCATCCTATGAAGTCATAATGTC
TGA CTGTACTGGAGGTTTTCTGCATTTTTTACTTTTCGAAAATAGAGGTTTGGGCTGAG
AATTCTAAACGCATGTGCCTGGGTGGGACGTCAAGTCAGGGTTCTCATCAAAGCTGAGAA
GTGGCTGGAATGTTCACTTGGTGTCTGGGGAGGATCCTGTGAGCTATGTAGAGAGGTGG
CTCTTCAGCCTGACTCAGTGTGGGCTGAACGAAGTACCTGCAGAACACACGGTAGCAGGC
TCCAAAATCGTCACCTCAAGCATGCGTGCAAGCAAACCTCCGAGAACTCCGTTTTCTGCT
CGGCAGACGTGTGAGCAGCTACCCAGAAGTCTCAAGCCAAAAGGGGAGCCTCGCTCGCTG
GCTCCTCTGCAGGTGCCTTATCGACCTGTGCTCTTCTCTTTTCCCGTGTCAAAGATGTTG
GACAGGATCTTGTACTTGAAACATACTACAAATGAGTTACTATGAAATAAATTCTGACCT
GTGGACCGAAAAAAAAAAAAAAAAA

FIG. 11

19 / 23

5' -CCCACGCGTCCGCGCCGAGGGACGCGGCGTCAAGTGCGTGCTGGTTCGGCGACGGCGCGGT
GGGCAAGACCAGCCTGGTGGTCAGCTACACCACTAACGGCTACCCCACCGAGTACATCCC
TACGGCCTTCGACAACCTTCTCGGCCGTGGTGTCTGTAGATGGGCGGCCTGTGAGACTCCA
GCTCTGTGACACTGCAGGACAGGATGAGTTTGACAAGCTGAGGCCCCCTCTGCTACACCAA
CACAGACATCTTCCTGCTGTGCTTCAGCGTGGTGAGCCCCACATCCTTCCAGAACGTGGG
CGAGAAGTGGGTTCAGAGATTCGACGTCCTGCCCCAAAGGCCCCCATCATCCTGGTTCGG
GACACAGTCGGACCTCAGGGAGGACGTCAAAGTGCTCATAGAACTGGACAAGTGCAAAGA
GAAGCCGGTGCCTGAAGAGGCGGCGAAGCTGTGCGCGGAGGAAGTCAAAGCTGTCTCCTA
CATCGAGTGCTCAGCGTTGACTCAGAAAAACCTCAAAGAGGTTTTTCGACGCCGCCATTGT
TGCTGGTATCCAGCACTCAGACTCCCAGCTACAGCCAAAGAAGTCTAAAAGCAGGACCCC
GGATAAGGTGCGGGACCTGTCCAAGTCTTGGTGGAGGAAGTATTGCTGCCTGGCCTGACT
CTCGCAAATAGCAGGTGTTTAAAGCTGCAACAGCTCTTTATGGACGAGGCTGTCATAGGAT
GAGCCCCAAAGCACCCCTCTTCTGCCCTTAACCTCCTGTGTGCGGGAGCTTAGGGCTGAGA
TTCATATGCAAAATACGTTTTTTTAAAAATTGAAAGTTACATTTTTTTTCTGTAAAGTCT
GGAAGCTTTGAGCTGTTAGACCTCCGGATTAATTTATATTCCATATGAAAAGGGCTCTTC
AAAAGCGGGGGTGTGAGCATGAAGTTCTGCTGGTGTGTTGTACAGGACAAAGGAGAATGAA
TGGGGAACCTTCCTCCTGAATTAAGGGGCTAACTGAAGGGCTCAATTGCAAGGGCA

FIG. 12

5' -CGCGGTGGGCAAGACCAGCCTGGTGGTCAGCTACACCACTAACGGCTACCCCACCGAGTA
CATCCCTACGGCCTTCGACAACCTTCTCGGCCGTGGTGTCTGTAGATGGGCGGCCTGTGAG
ACTCCAGCTCTGTGACACTGCAGGACAGGATGAGTTTGACAAGCTGAGGCCCCCTCTGCTA
CACCAACACAGACATCTTCCTGCTGTGCTTCAGCGTGGTGAGCCCCACATCCTTCCAGAA
CGTGGGCGAGAAGTGGGTTCAGAGATTCGACGTCCTGCCCCAAAGGCCCCCATCATCCT
GGTCGGGACACAGTCGGACCTCAGGGAGGACGTCAAAGTGCTCATAGAACTGGCTTCTGC
AGGGCATCTGTGTCCTGCTGTTAAAAGCAGGAGGAGGTGCTTGTCTGGGAGCTTTAAGTG
TGCTGGGCTCATATCGTCCCGTTTGCAAGGAATTGGGCCACCTTGAGAGGCCATAGTTGA
TGGCTATGGGACACACACACACTTTTTCCTTAAGTCCACCAAATGCCTGCCTGTACACA
CACACACACACACACACACACACACACACACTGGCTGGTTTGCTGATGGAACCC
TTAGACCACCCTCCCACCCCCACCCCTCCCCAAGCATGGCTGCAAGTGTCAGGGCACCAC
ACCTTCCTCTTCTTGACATTTCTTTGAACAGACATCATTTTGTAGGATCTTAATTTATAC
ATTTTTTTCAGGTCATAAAATGTGGGATGAACATACTTTGAACCCCAGTGCCTTCAGGGT
CCATTGACTAGGGAGGCACTGTCTTAGGGGACAGGTATGTGCAAGGCCTTACCCACCAGT
GGCTTCT

FIG. 14

20 / 23

5' -CCCACGCGTCCGGCGCGAGCTTAGCAGATCTCCACTTACCGAACATCTAGAGAGTCGCGC
CGCGCGCCGACGGAGCGGACATGGGCAGAGCGATGGTGGCCAGGCTAGGGGCTGGGGTTGC
TGCTTCTGGCACTGCTCCTACCCACGCAGATTTACTGCAACCAAACATCTGTTGCACCGT
TTCCCGGTAACCAGAATATTTCTGCTTCCCCAAATCCAAGTAACGCTACCACCAGAGGGG
GTGGCAGCTCCCTGCAGTCCACAGCTGGTCTCCTGGGCTCTCTCTCTCTCTCTTCCACAT
CTCTACTGTTAGAGACTCAGGCCAGGAAACGTCTCTACTTCCCCATCCTCTAGACCTACC
CCAAATGGCAACCACAAGTCCAATGTGATCAGGAAGAAACAGGTCCACCTCGAATTGGCT
GTTACCATATCTCAACAGAAAACACGGAGAATTCGAAATTCGACGGGATTAAAGGACGCG
TGAAAGGTTTGAGAGAAGAGAGATGCCGCTATTGAATCTGCTGGAGTTTACATCCCAAG
ATGAAGACAGCATTGAGAATTGATGTGATTTCTTGAATGTGGCTTAGGAAAAGTGGACA
CTTAAACTCTCACTTGAAATTGGGCACAGGTTTGATGTAGAGATAAGGACGGGGTGC GG
AATGGAGACCCATTTTGTGATTGATTCATCTGACCGATAAGGCCATAGTGCAGTTAGGTG
ATATTCGAAAGCTTCTTTGATGCTCTTTATGTATATGTTGGAAGGAACCTACCAGGCGTTG
CTTTAAATTCCCAATGTGTTGTTTCGTTACTACTAATTTAATACCGTAAGCTCTAGGTAA
AGTTCCATGTTGTTGAACTCTGACTGTTCTCTTTGGAATTGAACGTTTTGCATCCTCCTC
CTGTGGCTTTAGGTCTGACATTGTATTTGACCTTTACTAGTAATTAACATGTGCCAGGCA
ATGGTGGATTGGAACCCATCCCCAAGTCCAGCCACCACTGAATAAATCTGATTTCAAAG
TCAAACAGTAGACATTTCCCATTTGTCGTTTCTCACTCACCACAAGCACCAAATTCCTAG
AGTACACTGGTTCCAGAGAGCAGAATCATGTTGGCCTTGGCTAATTTCAAATGCTGTCT
TTTACTTTGGTATATGTTGAGGGCTTTTTTCATAATTTAAAGTGTGTTCTGTTAGCAAGGC
AAAAATTATGAGTCTTAATTCTACAGGCAAATATGCAAAGGAGCCAAAACCTGTAAACCCA
GCATTTGGGATGTGAAGACTGGAAGCTAACTCTCATTGAATTCACAAAGTCTTTTATACA
ATTTCTGTACATACTTTTTTTTTTTTTTAAGAGAAAAACAAACGGTGGATCAGAATAGCCA
CGTTTGGAACTTTGGTTATCCATTCATATTTTATAGATAGTTATTGGTCCTGTGCCTGA
AAGGGGGCTTGGTTCTACCGTAAGTTTTTCCAATTTCTTGATATACACATACCTTCTAA
AACCTAGACATTTCTGAAAAAATCTTTTGTTCGCATGGTCACACACTGATGCTTACCC
GTACAGTAGTCTTGATAACCAGAGTCATTTTCTCCATCTTTAGAAACCTTCTGGGAAGA
AGGAGAGCTCACAGACCCGAAGCTACTGTGTGTGTGAATGAACACTCCCCTTGCCTCACA
CCTGAATGCTGTACATCTATTTGATTGTAAATTGTGTTTGTGTATTTATGCTTTGATTCA
TAGTAACTTCTCATGTTATGGAATTGATTTGCATTGAACACAACTGTAAAAAATAAAAA
AAAAAGGGCGGCGCCGCCCCGCG
ATGGCCCCGCGAGCAAGGCCGGCGCGCTGCCCGCCCGCTGCGAGCCGCGGGCGGCGCCG
CCGGTACCGCCTCGCCGAGAGCGCGGGGGGCGCGGGGCGCGCGGGGCCGGGGTGTCCGGG
GGTCGGGGGCGCGCGGGGCGGCGCCGAGGGACGCGGCGTCAAGTGCCTGCTGGTCGGCGAC
GGCGCGGTGGGCAAGACCAGCCTGGTGGTCAGCTACACCACTAACGGCTACCCACCGAG
TACATCCCTACGGCCTTCGACAACTTCTCGGCCGTGGTGTCTGTAGATGGGCGGCCTGTG
AGACTCCAGCTCTGTGACACTGCAGGACAGGATGAGTTTGACAAGCTGAGGCCCTCTGC
TACACCAACACAGACATCTTCTGCTGTGCTTCAGCGTGGTGAGCCCCACATCCTTCCAG
AACGTGGGCGAGAAGTGGGTTCAGAGATTCGACGTCACTGCCCAAAGGCCCCCATCATC
CTGGTTCGGGACACAGTCGGACCTCAGGGAGGACGTCAAAGTGCTCATAGAACTGGACAAG
TGCAAAGAGAAGCCGGTGCCTGAAGAGGCGGCGAAGCTGTGCGCGGAGGAAGTCAAAGCT
GTCTCCTACATCGAGTGCTCAGCGTTGACTCAGAAAAACCTCAAAGAGGTTTTCGACGCC
GCCATTGTTGCTGGTATCCAGCACTCAGACTCCCAGCTACAGCCAAAGAAGTCTAAAAGC
AGGACCCCGGATAAGGTGCGGGACCTGTCCAAGTCTTGGTGGAGGAAGTATTGCTGCCTG
GCCTGACTCTCGCAAATAGCAGGTGTTTAAGCTGCAACAGCTCTTTATGGACGAGGCTGT
CATAGGATGAGCCCCAAAGCACCTCTTCTGCCCTTAACCTTCTGTGTGCGGGAGCTTAG
GGCTGAGATTCATATGCAAATACGTTTTTTTTTAAAAATTGAAAGTTACATTTTTTTTTCTG

FIG. 13A

21 / 23

TTAAGTCTGGAAGCTTTGAGCTGTAGACCTCCGGATTAATTTATATTCCATATGAAAAGG
 GCTCTTCAAAGCGGGGTGTCAGCATGAAGTTCTGCTGTGTTGTACAGGACAAAGGAGAAT
 GAATGGGACCTTCTCCTGATTAAGGGCTACTGAGGGCTCAGTGCAGGGCACGTGTGCACC
 AGGCTTGGTGAGAGTGAGCAAGCGTGAGCTTTGAAACCACACGAGCCACCCCGGTTTTG
 TAAGGGCAAAGATCTGAAACCAGCAAGGGCCTTCTGCTTACGAAACCTCGAGCCCATCCC
 TTCTGTTTACTCAGATTCTCTTAGGATTTTAAACAACCAAACATCCCACAGCCTACTGG
 CATAGTGTTGGCGAACAGTGCACCTTGCTTGTTACGGTTTTGTTTTTGTAAAAATCAC
 GTGACCAGTTATATTGCTATGAAAATGGTGGAGATGCCTCGTAGAAGGCGAGTGCTGGGT
 GCACATGTGACATTTTCTTCAGGGAGCGACTCATGGTGAGACCAGAGAGGGCTCTTAGCT
 TGCAGGACTGGCTTCTGCAGGGCATCTGTGTCCTGCTGTTAAAAGCAGGAGGAGGTGCTT
 GTCTGGGAGCTTTAAGTGTGCTGGGCTCATATCGTCCCGTTTGCAAGGAATTGGGCCACC
 TTGAGAGGCCATAGTTGATGGCTATGGGACACACACACACTTTTTCTTAAGTCCACCAA
 AATGCCTGCCTGTACACACACACACACACACACACACACACACACACTGGCT
 GGTTTGCTGATGGAACCCTTAGACCACCCTCCACCCCCACCCCTCCCCAAGCATGGCTG
 CAAGTGTCAGGGCACACACCTTCCTCTTCTTGACATTTCTTTGAACAGACATCATTTTG
 TAGGATCTTAATTTATACATTTTTTTTCAGGTCATAAAATGTGGGATGAACATACTTTGAA
 CCCCAGTGCCTTCAGGGTCCATTGACTAGGGAGGCACTGTCTTAGGGGACAGGTATGTGC
 AAGGCCTTACCCACCAGTGGCTTCTCGCTGCAGGTCATGTTTGTGGCACTTGTTCTTTAA
 GGTGAGGGTCTTATGACCGACTGTTCTGAGACAGCCCTGTGTCAGGCAAGCTCTTTCACA
 GGGTTGTAGGTATTTCCAAGACGCCATAGGAACCAGACAGTGAATCATAGCTATCAGTTT
 GCTGTGGGCAAGGAACCTCTTTTTGGCCACCTGGTAACAAAATTTTATGTCTGTAAATTT
 TTTCTTGCTATTTAAAAA

FIG. 13B

5' -CCCACGCGTCCGCGGACGCGTGGTTCAGGGTCCATTGACTAGGGAGGCACTGTCTTAGGG
 GACAGGTATGTGCAAGGCCTTACCCACCAGTGGCTTCTCGCTGCAGGTCATGTTTGTGGC
 ACTTGTTCTTTAAGGTGAGGGTCTTATGACCGACTGTTCTGAGACAGCCCTGTGTCAGGC
 AAGCTCTTTCACAGGGTTGTAGGTATTTCCAAGACGCCATAGGAACCAGACAGTGAATCA
 TAGCTATCAGTTTGCTGTGGGCAAGGAACCTCTTTTTGGCCACCTGGTAACAAAATTTTA
 TGTCTGTAAATTTTTTCTTGCTATTTAAAAAATCAATCTTACGTTTTTCTGTAGG
 AAAAAAAAAACAAGTAAAAGAACAGGCCATATTTCAAGGTCAAAGGCTTCTTCCTGCTGG
 TAAATGGGACTGAAGACTTTCTTACATCATTATTAAAAGGCTAATTGCTGAACCACTAGA
 GTATATGAACTGTTTGTGAATGATATTAGCCATAGTCTCCTGAGGTGTTTCCTTGTGGCC
 TGAGTGGTAACATTGTTTTGCTTATGGAGATGCTGTAACCTGACCTAGTGACTCAGCTTAT
 CCTATTGTGCATGGCTGTCTGGAAAGCCAGCGTACAAGTGGGGCTTTGCCTGCCCTGTGT
 ACAGAGGGTGGGTGGGAAAGAGTGAATTATTTAATTTTAAATGTTATAATAAGCCAATG
 TAGTTGAGACCAAGGAAATGAGCATTGAGAACACAACTTGAAGTCTGGTGCCAGGGTTG
 TTGGACCTCACACCCTGTCTCTGAGCCACCCGGAAGTGACATAAAGGACGCTGTGTGATC
 A

FIG. 17

22 / 23

5' -CCCACGCGTCCGTATGAAAATGGTGGAGATGCCTCGTAGAAGGCGAGTGCTGGGTGCACATG
TGACATTTTCTTCAGGGAGCGACTCATGGTGAGACCAGAGAGGGCTCTTAGCTTGACAGGAC
TGGCTTCTGCAGGGCATCTGTGTCCTGCTGTTAAAAGCAGGAGGAGGTGCTTGTCTGGGAGCTTTAA
GTGTGCTGGGCTCATATCGTCCCGTTTGCAAGGAATTGGGCCACCTTGAGAGGCCA
TAGTTGATGGCTATGGGACACACACACACTTTTTCTTAAGTCCACCAAATGCCTGCCTGTA
CACACACACACACACACACACACACACACACACACTGGCTGGTTTGCTGATGGAA
CCCTTAGACCACCCTCCCACCCCCACCCCTCCCCAAGCATGGCTGCAAGTGTCAGGGCACACAC
CTTCTCTTCTTGACATTTCTTTGAACAGACATCATTTTGTAGGATCTTAATTTATAC
ATTTTTTTCANGTCATAAAATGTGGGATGAACATACTTTGAACCCCAGTGCCTTCAGGGTC
CATTGACTAGGGAGGCACTGTCTTAGGGGACAGGTATGTGCAAGGCCTTACCCACCAGT
GGCTTCTCGCTGCAGGTCATGTTTGTGGCACTTGTTCTTTAAGGTGAGGGTCTTATGACCG
ACTGTTCTGAGACAGCCCTGTGTCAGGCAAGCTCTTTCACAGGGTTGTAGGTATTTT
CAAGACGCCATAGGAACCAGACAGTGAATCATAGCTATCAGTTTGCTGTGGGCAAGGAACC
TCTTTTTTGGCCACCTGGTAACAAAATTTTATGTCTGTAAATTTTTTCTTGCTATTTAAAA
AAAAAATCAATCTTACGTTTTTCTGTAGGAAAAAACAAGTAAAAGAACAGGCCAT
ATTTCAAGGTCAAAGGCTTCTTCCTTCTGGTAAATGGGACTGAAGACTTTCTTACATCA
TTATTAAAAGGCTAATTGCTGAACCACTAGAGTATATGAACTGTTTGTGAATGATATTAGC
CATAGTCTCCTGAGGTGTTTCCTTGTGGCCTGAGTGGTAACATTGTTTTGCTTATGGAGA
TGCTGTAACCTGACCTAGTGACTCAGCTTATCCTATTGTGCATGGCTGTCTGGAAAGCCAG
CGTACAAGTGGGGCTTTGCCTGCCCTGTGTACAGAGGGTGGGTGGGAAAGAGTGAATT
ATTTAATTTTAAATGTTATAATAAGCCAATGTAGTTGAGACCAAGGAATGAGCATTGAGA
ACACAAACTTGAAGTCTGGTGCCAGGGTTGTTGGACCTCACACCCTGTCTCTGAGCCACC
CGGAAGTGACATAAAGGACGCTGTGTGATCA

FIG. 15

23 / 23

5' -CCCACGCGTCCGGTGACCAGTTATATTGCTATGAAAATGGTGGAGATGCCTCGTAGAAGG
CGAGTGCTGGGTGCACATGTGACATTTTCTTCAGGGAGCGACTCATGGTGAGACCAGAGA
GGGCTCTTAGCTTGCAGGACTGGCTTCTGCAGGGCATCTGTGTCCTGCTGTTAAAAGCAG
GAGGAGGTGCTTGTCTGGGAGCTTTAAGTGTGCTGGGCTCATATCGTCCCGTTTGCAAGG
AATTGGGCCACCTTGAGAGGCCATAGTTGATGGCTATGGGACACACACACACTTTTTCCT
TAAGTCCACCAAATGCCTGCCTGTACACACACACACACACACACACACACACACACACA
CACACACTGGCTGGTTTGCTGATGGAACCCTTAGACCACCCTCCCACCCCCACCCCTCCC
CAAGCATGGCTGCAAGTGTGAGGGCACCACACCTTCCTCTTCTTGACATTTCTTTGAACA
GACATCATTTTGTAGGATCTAATTTATACATTTTTTTTCAGGTCATAAAATGTGGGATGAA
CATACTTTGAACCCCAGTGCCTTCAGGGTCCATTGACTAGGGAGGCACTGTCTTAGGGGA
CAGGTATGTGCAAGGCCTTACCCACCAGTGGCTTCTCGCTGCAGGTCATGTTTGTGGCAC
TTGTTCTTTAAGGTGAGGGTCTTATGACCGACTGTTCTGAGACAGCCCTGTGTCAGGCAA
GCTCTTTCACAGGGTTGTAGGTATTTCCAAGACGCCATAGGAACCAGACAGTGAATCATA
GCTATCAGTTTGCTGTGGGCAAGGAACCTCTTTTTGGCCACCTGGTAACAAAATTTTATG
TCTGTAAATTTTTTCTTGCTATTTAAAAAATAATCAATCTTACGTTTTTCTGTAGGAA
AAAAAAAACAAGTAAAAGAACAGGCCATATTTTCAGGTCAAAGGCTTCTTCCTGCTGGTA
AATGGGACTGAAGACTTTCTTACATCATTATTTAAAGGCTAATTGCTGAACCACTAGAGT
ATATGAACTGTTTGTGAATGATATTAGCCATAGTCTCCTGAGGTGTTTCCTTGTGGCCTG
AGTGGTAACATTGTTTTGCTTATGGAGATGCTGTAACCTGACCTAGTGACTCAGCTTATCC
TATTGTGCATGGCTGTCTGGAAAGCCAGCGTACAAGTGGGGCTTTGCCTGCCCTGTGTAC
AGAGGGTGGGTGGGAAAGAGTGAATTATTTAATTTTAAATGTTATAATAAGCCAATGTA
GTTGAGACCAAGGAAATGAGCATTGAGAACACAACTTGAAGTCTGGTGCCAGGGTTGTT
GGACCTCACACCCTGTCTCTGAGCCACCCGGAAGTGACATAAAGGACGCTGTGTGATCAA
GTTCTGGACACTTTTCTGGGATGCGTACCACTGGACTATTTATGTCACAAATCTAGTGGG
TTGACGCTGCCCTGCAAGTTTTCAATGTCCCTGCATCCTATGAAGTCATAATGTCTGACT
GTA CTGGAGGTTTTCTGCATTTTTTACTTTTCGAAAATAGAGGTTTGGGCTGAGAATTC
TAAACGCATGTGCCTGGGTGGGACGTCAAGTCAGGGTTCTCATCAAAGCTGAGAAGTGGC
TGGAATGTTTCAAGCTTGGTGTCTGGGGCAGGCTCCAAAATCGTCACCTCAAGCATGCGTGC
AAGCAA ACTTCCGAGAACTCCGTTTTCTGCTCGGCAGACGTGTGAGCAGCTACCCAGAAG
TCTCAAGCCAAAAGGGGAGCCTCGCTCGCTGGCTCCTCTGCAGGTGCCTTATCGACCTGT
GCTCTTCTCTTTTCCCGTGTCAAAGATGTTGGACAGGATCTTGTACTTGAAACATACTAC
AAATGAGTTACTATGAAATAAATTCTGACCTGTGGACCGAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

FIG. 16